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The aim of this thesis was to test the hypothesis that varying substituents on 
the 2-phenylaminophenylacetic acid scaffold, of which diclofenac and 
lumiracoxib were derived from, will affect bioactivation and subsequently, 
toxicity to a significant degree. We also aimed to study how these subtle 
changes to substituents on the given chemical scaffold affect the intricate link 
between toxicity and pharmacology, providing an opportunity to optimize 
drug safety and efficacy.  
 
Twenty-four 2-phenylaminophenylacetic acid derived compounds with 
varying substituents at three critical pharmacophores were synthesized. The 
compounds were subjected to in vitro cytotoxicity testing on two liver cell 
lines of contrasting metabolic competencies. We observed higher toxicity in 
the more metabolically competent cell line. We have also shown that structural 
changes on the chemical scaffold exerted pronounced effect on liver 
cytotoxicity. Thereafter, we developed a quantitative-structure-toxicity 
relationship (QSTR) model which unveils the trend of increasing lipophilicity 
in the cellular manifestation of toxicity. A concurrent determination of their 
pharmacological activity using COX inhibition assays allowed us to derive a 
safety profile, which showed that selectivity towards COX-2 negatively 
affected activity and in some cases, toxicity.  
 
In order to probe further into the toxicity caused by bioactivation, we carried 
out a series of metabolic assays. We measured the Phase I and Phase II 
metabolic stability of the compounds separately. We observed that the most 
ix 
 
toxic compound was not the least stable compound. In fact, the toxicity of the 
compounds is not intricately linked to their metabolic stabilities. Given this 
interesting observation, we decided to determine the reactivity of the Phase I 
and Phase II metabolites formed from the compounds. We observed that the 
more toxic compounds produced more reactive metabolites regardless of the 
compound’s metabolic stability, especially in the case of Phase I metabolism.  
 
Last but not least, we carried out trapping assays to elucidate possible 
structures of the reactive metabolites via LC-MS/MS and to investigate 
possible bioactivation pathways. We elucidated several possible structures of 
the Phase I and Phase II reactive metabolites and their possible bioactivation 
pathways. In addition, we observed that the varying substituents do affect the 
structures and amount of reactive metabolites formed but further experiments 
need to be carried out. On the other hand, we observed that substituents have 
no effect on the structures of Phase II reactive metabolites. 
 
In conclusion, the findings of this thesis supported our hypothesis that varying 
substituents on the 2-phenylaminophenylacetic acid scaffold, will affect 
bioactivation and subsequently, toxicity to a significant degree. In addition, we 
also elucidated a possible relationship between toxicity and pharmacology, 
which provided a better understanding in the balance between toxicity and 
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Chapter 1. Introduction 
 
1.1. Adverse drug reactions – Drug-induced liver injury (DILI) 
Adverse drug reactions (ADRs), as defined by the World Health Organization 
(WHO), are “any responses to a drug which are noxious and unintended, and 
which occur at doses used in man for prophylaxis, diagnosis or treatment”. It 
is estimated that ADRs are the sixth leading cause of death worldwide, and the 
financial cost to society can range from $75 to $180 billion each year (Hacker, 
2009). Mechanistically, there are four types of ADRs; Type A 
(pharmacological), Type B (idiosyncratic), Type C (chemical) and Type D 
(delayed) (Williams et al., 2002). Such classification of ADRs facilitates swift 
identification and intervention should a patient encounter such an episode, as 
well as a basis for re-designing a drug to achieve a better safety profile. Type 
A reactions are an extension of the desired pharmacological effect of the drug 
administered and is often predictable and preventable. Type B reactions, 
which include drug allergies, idiosyncratic responses and intolerance, are 
difficult or impossible to predict from the known pharmacology of the drug. 
Type B reactions often surface after a period of usage of newly approved 
drugs by a large population of patients. Thus, often than not, type B reactions 
are the underlying cause of withdrawals of newly approved drugs. Type C 
reactions result from the formation of certain chemical features after 
metabolism. Certain chemical features predispose the molecule to greater 
toxicity than others. Type D reactions are delayed toxicities such as 
carcinogenicity and teratogenicity that arise from long-term drug treatment. 
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These toxicities are often observed in bioassays or during preclinical trials and 
may be prevented from occurring in patients. 
	
ADRs that involve the liver are known as drug-induced liver injuries (DILIs). 
The impact of DILI on drug development is very significant, being the most 
common reason, among all forms of drug-induced toxicities, for the restriction 
or withdrawal of a drug from the market and cessation of drug testing in 
clinical trials (Tran and Lee, 2013). Most DILIs fall under type B and type C 
reactions and are classified as idiosyncratic responses. Idiosyncratic responses 
are individual-based and can be affected by several internal and external 
factors. Even though incidence rates are relatively low, with estimates at 1 per 
10 000 to 1 per 100 000 treated patients (Stirnimann et al., 2010), DILI 
accounts for 5% of hospital admissions and 50% of acute liver failures in the 
USA, with paracetamol being the lead cause of such events (Russo et al., 
2004).  
 
The liver is highly susceptible to drug-induced injury as it is the site of 
detoxification. Blood from the gastrointestinal system and spleen arrives 
directly via the portal vein and hepatic artery respectively to the liver in a 
unidirectional flow, bringing drugs and xenobiotics in concentrated forms and 
in large volumes per unit time (Giri et al., 2010). Liver injury can range from 
mild elevations in serum transaminases (alanine aminotransferase, ALT and 
aspartate aminotransferase, AST) to life-threatening fulminant hepatic failure. 
Although classified as an idiosyncratic response, DILI is not independent of 
dose. It has been shown that a number of liver transplants carried out for 
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hepatic failure due to an oral prescription drug was the lowest for patients 
assigned the lowest daily drug dosage (Stirnimann et al., 2010). Other than 
dose, DILI can also depend on both intrinsic and environmental factors, such 
as age, sex, nutritional factors, physiological changes, genotype, duration, 
drug-drug interactions, drug-enzyme induction/inhibition and metabolic 
conditions (Giri et al., 2010). 
 
 
Figure 1-1 Six mechanisms of liver injury: A) Disruption of cellular calcium 
homeostasis results in cell membrane disruption, leading to rupture and lysis; 
B) Injury to the canniliculus, the portion responsible for bile excretion; C) 
Bioactivation to reactive metabolites by cytochrome P450 system; D) 
Enzyme-drug adducts causes immune responses; E) Activation of apoptosis 
and F) Inhibition of β-oxidation of free fatty acids and respiration, resulting in 
mitochondrial injury. Reproduced with permission from Lee (2003), 
Copyright Massachusetts Medical Society. 
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At the cellular and molecular level, there are several ways a drug can induce 
injury to the liver. To date, that are six proposed mechanisms of DILI (Figure 
1-1): A) disruption of calcium homeostasis leading to cell blebbing and lysis; 
B) cannilicular injury; C) metabolic bioactivation; D) stimulation of 
autoimmunity; E) activation of apoptosis and F) inhibition of mitochondrial 
function (Lee, 2003). These six mechanisms are not mutually exclusive. The 
onset of these mechanisms of toxicity requires an initial interaction between 
the administered drug and the biological target. Oftentimes, the metabolic 
activation of the parent drug is the initiating event for these other events to 
occur. 
 
1.2. Metabolism and its role in DILI 
Biotransformation of the parent drug via metabolism is a means by the body to 
aid in excretion of the lipophilic parent drug. In this process, the lipophilic 
parent drug is converted to a more water-soluble form, which is more readily 
excreted in the bile, urine or feces. It is estimated that 70% of marketed drugs 
undergo metabolism prior to excretion, while the remaining are excreted in 
their parent form (Table 1-1).  
 
Table 1-1 Routes of elimination of marketed drugs (Williams et al., 2004). 
Route of elimination Percentage of marketed drugs 










While the goal of drug metabolism is “detoxification”, “intoxication” can 
occur as an unintended outcome. Occasionally, bioactivation of the parent 
drug can result in the formation of reactive metabolites. These reactive 
metabolites can present as either electrophiles or free radicals (Williams et al., 
2002). Electrophiles are electron deficient and they readily form covalent 
adducts with cellular nucleophiles such as proteins and DNA. Adduct 
formation, if irreversible, leads to the loss of function of the original biological 
molecules and induces cellular toxicity. For example, N-acetyl-p-
benzoquinone imine (NAPQI), a quinone imine derived from the oxidative 
metabolism of paracetamol, can form adducts with critical thiol groups in 
calcium channels in hepatic mitochondria, causing increased cytosolic calcium 
concentrations and adverse effects (Monks and Jones, 2002). Electrophiles are 
classified into two categories: hard (high positive charge density at the 
electrophilic center) and soft (lower positive charge density at the electrophilic 
center) (Srivastava et al., 2010). Hard and soft electrophiles differ in their 
selective binding to target nucleophiles in the body. Generally, hard 
electrophiles like aldehydes bind to hard nucleophiles such as DNA and amino 
groups on amino acid residues while soft electrophiles like quinone imines 
bind to soft nucleophiles such as protein thiol groups (Table 1-2). Another 
type of reactive metabolites is free radicals, such as reactive oxygen species 
(ROS) generated from redox cycling. Free radicals possess unpaired electrons 
which can self-propagate and induce oxidative stress, causing oxidative 







Table 1-2 Examples of hard and soft electrophiles and hard and soft 
nucleophiles (Attia, 2010; Srivastava et al., 2010). 
Type Electrophiles Nucleophiles 
Hard Alkyl carbonium ions Oxygen atoms of purine/ pyrimidine bases 
in DNA 
 Benzylic carbonium 
ions 
Endocyclic nitrogens of purine bases in 
DNA 
 Iminium ions Primary/ secondary amino groups 
 Aldehydes  
Soft Epoxides Protein thiol groups 
 Enones Sulfhydryl groups of glutathione (GSH) 
 Quinone imines Alkenes 
 Quinone methides Selenium groups 
 Michael acceptors  
 
Drugs carrying certain physicochemical features can be predisposed to the 
formation of reactive and toxic metabolites through specific metabolic 
pathways. Broadly, xenobiotics can undergo two phases of metabolism, 
namely Phase I and/or Phase II. Each phase is carried out by a different family 
of enzymes and results in formation of different metabolites. Phase I 
metabolism is defined by changes in functionality and involves oxidation, 
reduction, and/or hydrolysis while Phase II metabolism involves conjugate 
formation (Khojasteh et al., 2010).  
 
The major family of enzymes involved in Phase I metabolism is the 
cytochrome P450 enzymes (P450s). P450s are found in many organs, with the 
highest concentration in the liver (1.5-3% of the total microsomal protein in 
human livers) (Khojasteh et al., 2010). P450s are bound to the membrane of 
the cytoplasmic side of the endoplasmic reticulum (ER). There are several 
different P450 isoforms. Expression levels and substrates of each isoform 
differ from one another (Table 1-3). Genetic polymorphism of P450s can exist 
for each isoform. Such polymorphism has significant effects on the 
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metabolism of a drug by the P450 isoform, resulting in differences in drug 
responses and possibly a higher risk of ADRs (Zhou et al., 2009). 
 
Table 1-3 Abundance of CYP enzymes in the human liver and their possible 
substrates (Khojasteh et al., 2010). 
Isoform Mean 
abundance in 






CYP1A2 11% B, N Planar polyaromatic, one 
hydrogen bond 
donor, may contain amines or 
amides 
CYP2A6 8.6% B, N Small size, nonplanar, at least 
one aromatic ring 
CYP2B6 2.1% B, N Medium size, angular, 1–2 H-
bond donors or acceptors 
CYP2C8 5.7% A, N Large size, elongated 
CYP2C9 18% A Medium size, 1–2 H-bond 
donors, lipophilic 
CYP2C19 2.7% B 2–3 H-bond acceptors, 
moderately lipophilic 
CYP2D6 2.1% B Medium size, 5–7 Å distance 
between basic nitrogen and site 
of oxidation 
CYP2E1 15% N Small size, hydrophilic, 
relatively planar 
CYP3A4/5 40% B, A, N Large size, lipophilic 
 
P450s are mainly involved in oxidative reactions. Polar functionalities are 
introduced into the parent drug molecules. A simplified P450-catalysed 
reaction is: 
NADPH + H+ + O2 + RH                               NADP+ + H2O + ROH 
where RH represents an oxidizable drug substrate and ROH, the hydroxylated 
metabolite (Ionescu and Caira, 2005a). One oxygen atom is incorporated into 
the substrate while the other is reduced to water. P450s are also involved in N-




special form of oxidative reaction as the initial event is a hydroxylation 
followed by elimination. 
 
At times, hydroxylation can become the precursor for reactive metabolite 
formation. Some hydroxylated aromatic rings have the ability to be further 
oxidized into reactive metabolites via a further two electron oxidation to 
generate benzoquinones, quinone imines, quinone methides and imine 
methides by monooxygenase and peroxidase enzymes, metal ions and 
molecular oxygen (Figure 1-2) (Bolton et al., 2000; Leung et al., 2011). These 
reactive metabolites are electrophilic in nature and are able to form covalent 
adducts with nucleophiles. For example, benzene can be metabolized to 
benzoquinones and conjugate to nucleophiles in bone marrow, causing aplastic 


















































Figure 1-2 Hydroxylated aromatic rings can undergo a further two electron 
oxidation to reactive electrophiles such as benzoquinones, quinone imines, 




Besides the generation of electrophilic intermediates, quinones can undergo 
enzymatic or non-enzymatic redox cycling, yielding reactive free radicals such 
as ROS which causes oxidative damage to biological macromolecules (Figure 
1-3) (Bolton et al., 2000; Monks and Jones, 2002). For example, doxorubicin 
is an extensively used chemotherapy agent. However, it is known to cause 
cardiomyotoxicity due to formation of ROS via redox cycling of its quinone 
nucleus (Ganey et al., 1988). Quinone imines, due to the substitution of one 
oxygen atom with a nitrogen atom are less likely to undergo redox cycling as 
compared to benzoquinones as the redox potential of quinone imines is lower. 
Nevertheless, it is still possible for quinone imines to undergo redox cycling to 
produce free radicals (Monks and Jones, 2002), contributing to their 
significance in drug toxicology. One example is primaquine, an anti-malarial 
drug known to cause hemolysis. The hydroxylated metabolites are 
aminophenols, which can undergo redox cycling to produce ROS that 
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Figure 1-3 Redox cycling of benzoquinones produces ROS which causes 
oxidative damage (Bolton et al., 2000). 
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Metabolites formed after Phase I metabolism or the parent drug can undergo 
Phase II conjugation reactions to form more hydrophilic molecules that are 
more readily excreted (Ionescu and Caira, 2005a; Khojasteh et al., 2010). 
Major Phase II conjugation reactions include glucuronidation, sulfation and 
acetylation (Ionescu and Caira, 2005b). Of all the Phase II reactions, 
glucuronidation, which involves conjugation of the parent aglycone to a α-D-
glucuronic acid sugar moiety, is the major route of conjugation and mainly 
occurs in the liver (Ionescu and Caira, 2005b). Glucuronidation is catalyzed by 
the enzyme uridine disphosphate glucuronosyltransferases (UGTs) and 
requires the presence of cofactor, uridine diphosphoglucuronic acid (UDPGA) 
(Khojasteh et al., 2010).  
 
While most glucuronides are readily excreted from the system, some toxicity 
of glucuronides can arise from the formation of 1-β-O-acyl glucuronides (1-β-
O-AGs). 1-β-O-AGs are formed from glucuronidation of a carboxylic acid 
moiety. Covalent modification of proteins may occur through transacylation, 
whereby the glucuronic acid moiety is displaced and the parent drug 
conjugates to the protein (Figure 1-4). 1-β-O-AGs have the ability to undergo 
a process known as acyl migration, which is the intramolecular migration of 
the acyl group. The pyranose ring of the acyl migration products (2-β-O-, 3-β-
O-, 4-β-O-) can open up to form an aldehyde (Figure 1-4). Aldehydes are 
reactive in nature and will bind to amine groups in proteins or DNA via an 
imine (Schiff base) linkage through a process known as glycation (Regan et al., 
2010). Imines are hydrolyzable and the bound protein can be released from the 
aldehyde. In the case of 3-β-O- and 4-β-O-AGs, imine adducts can undergo 
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acid-catalyzed Amadori rearrangement whereby a more stable 1-amino-keto 
product is formed, rendering the glycation irreversible (Figure 1-4) (Smith et 
al., 1990). A classic example of transacylation and acyl migration of Phase II 






























































Figure 1-4 AGs can undergo transacylation or acyl migration (2-β-O-, 3-β-O-, 
4-β-O-) followed by glycation. A 3-β-O-AG is shown here as an example 
whereby the resulting aldehyde from ring opening can undergo glycation to 
form an imine. Acid-catalyzed Amadori rearrangement of the imine can occur 
to give the more stable 1-amino-keto product. 
 
Clearly, Phase I and Phase II metabolism are important contributors to DILI 
via the possible generation of reactive metabolites.  A better understanding of 
the drug property that alters this tendency will go a long way towards 
addressing this problem. One such class of drugs with a highly manifested 
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DILI due to metabolism that might benefit from an improved understanding is 
the non-steroidal anti-inflammatory drugs (NSAIDs). 
 
1.3. NSAIDs - Mechanism of action and induced liver injury 
NSAIDs are drugs with analgesic, antipyretic and anti-inflammatory 
properties. They act by blocking cyclooxygenase (COX) enzymes, which 
inhibit the production of prostanoids, thereby giving rise to their therapeutic 
properties (Vonkeman and van de Laar, 2010). Prostanoids are a collective 
group of bioactive lipids that consist of prostaglandins, prostacyclins and 
thromboxanes which play an important role in inflammatory and resolution 
responses. Prostanoids are produced by COX from arachidonic acid when 
trauma or tissue damage occurs, giving rise to inflammatory responses (Figure 
1-5) (FitzGerald and Patrono, 2001). There are two isoforms of COX, the 
constitutive COX-1 and the inducible COX-2, of which COX-2 had been 
indicated as the COX isoform responsible for the main production of 





Figure 1-5 Production of prostanoids by COX-1 and COX-2 from arachidonic 
acid and their respective target tissue/organ. Reproduced with permission from 
FitzGerald and Patrono (2001), Copyright Massachusetts Medical Society. 
 
In recent years, the focus of NSAIDs have been on the development of COX-2 
selective inhibitors to reduce the side-effects such as gastrointestinal toxicity 
associated with inhibition of COX-1 by non-selective COX inhibitors 
(Chakraborti et al., 2010). The ability of COX-2 inhibitors to selectively 
inhibit COX-2 arises from the presence of a hydrophobic pocket in COX-2 
which allows accommodation of side chains. The same pocket is not available 
in COX-1 due to bulky amino acid residues which restrict the insertion of a 
side chain on the drug molecule and thus lowering the binding affinity of the 




Besides toxicity arising from COX-1 inhibition, liver toxicity continues to 
remain as the bane of NSAID therapeutics. It is estimated that roughly 10% of 
total DILI is NSAIDs-related and 50% of fulminant hepatic failure is due to 
DILI (Bessone, 2010). This is a significant clinical challenge that has sidelined 
many of the promising drugs in this class. The most common route of 
elimination for NSAIDs is via hepatic biotransformation by Phase I and Phase 
II metabolism (Davies and Skjodt, 2000). It has been proposed that NSAID-
induced hepatotoxicity is a result of drug bioactivation by Phase I and Phase II 
metabolic enzymes (Agundez et al., 2011; Lee et al., 2011). Many NSAIDs, 
for example, nimesulide and ibuprofen, possess aromatic structures and 
carboxylic acid moieties that can potentially be metabolized to reactive 
metabolites and contribute to the onset of liver injury.  
 
1.4. Comparison of non-selective NSAID (Diclofenac) and COX-2 selective 
NSAID (Lumiracoxib) 
One commonly used NSAID, diclofenac (Voltaren®, Norvatis) is a reversible 
non-selective COX inhibitor. The established mechanism of action of 
diclofenac has been attributed to its extremely good ability to block the 
synthesis of prostaglandin E2 (PGE2) in COX (Gan, 2010). However, a potent 
effect on COX-1 besides COX-2, resulted in gastrointestinal toxicity. 
Diclofenac has also been attributed to cause approximately 34.1% of NSAID-
induced hepatotoxicity via bioactivation by metabolism (Agundez et al., 2011). 
The bioactivation process of diclofenac has been extensively studied and its 
hepatotoxicity could be attributed to the formation of reactive quinone imines, 
arene oxides and 1-β-O-AGs. Diclofenac can be hydroxylated at two positions: 
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5-position to form 5-hydroxy (OH) diclofenac by CYP3A4 (Shen et al., 1999) 
and 4’-position to form 4’-OH-diclofenac by CYP2C9 (Figure 1-6) (Leemann 
et al., 1993). In vivo studies involving rats and humans have found two 
different hydroxyl-diclofenac conjugates in urine samples; 5-OH-4-N-
acetylcysteine (NAC) diclofenac and 4’-OH-3’-NAC-diclofenac (Poon et al., 
2001). These conjugates were proposed to be N-acetylated degradation 
products of S-glutathionyl (GS) adducts derived from both 5-OH and 4’-OH-
diclofenac. Additional in vivo studies involving bile samples from rats and in 
vitro studies involving human hepatocytes and human liver microsomes 
identified two additional conjugates; 5-OH-6-GS-diclofenac (Tang et al., 

























































































Figure 1-6 Phase I metabolic pathway of diclofenac by CYP2C9 and 
CYP3A4 and subsequent possible bioactivation and conjugation of cellular 




Diclofenac possesses an acetic acid moiety that can undergo Phase II 
metabolism to form 1-β-O-AG. Both in vivo studies in rats and in vitro studies 
utilizing hepatocytes and liver microsomes have detected GSH or protein 
adducts of diclofenac-1-β-O-AG and have shown that such adduct formation 
induces toxicity (Kretzrommel and Boelsterli, 1993; Kretzrommel and 
Boelsterli, 1994b; Kretzrommel and Boelsterli, 1994a; Grillo et al., 2003). As 
shown in Figure 1-7, diclofenac-1-β-O-AG can undergo two conjugation 
pathways; direct transacylation whereby the glucuronic acid moiety is lost 
(Grillo et al., 2003), or by acyl migration followed by glycation whereby the 
glucuronic acid moiety is retained (Kretzrommel and Boelsterli, 1994a). 
Despite its ability to form reactive metabolites and its high percentage 
contribution to NSAID-induced hepatotoxicity, only a very small percentage 
had fatal outcomes or required hospitalizations and liver transplants (Bessone, 





































Figure 1-7 Formation of covalent adducts by diclofenac-1-β-O-AG through 




A drug with a similar structure, lumiracoxib (Prexige®), was developed by 
Norvatis as a reversible COX-2 selective inhibitor to counteract the 
undesirable gastrointestinal effects associated with non-COX selective 
NSAIDs and was first approved in 2006. Instead of having two chlorine atoms 
at the positions 2’ and 6’ as with diclofenac, a chlorine atom was substituted 




















Figure 1-8 Numbering of aromatic rings of lumiracoxib. A methyl group is 
substituted at position 5 and a fluorine replaces chlorine at position 6’. 
 
A structure-activity relationship (SAR) study done on analogs of lumiracoxib 
has shown that the methyl group at position 5 confers COX-2 selectivity to the 
drug (Blobaum and Marnett, 2007). However, within a year of approval in 
Canada, Oceanic and European countries, lumiracoxib was withdrawn from 
the market due to eight cases of severe hepatotoxicity, resulting in two deaths 
and two liver transplants in Australia in the span of 2006 to 2007 (Li et al., 
2008). An in vivo study in human subjects has identified that lumiracoxib is 
extensively metabolized by CYP2C9 to form 4’-OH-lumiracoxib, a metabolite 
that can possibly undergo further oxidation to a reactive quinone imine 
(Mangold et al., 2004). Additional in vitro bioactivation studies were done 
using human and rat liver microsomes. These studies utilized GSH and NAC 
as trapping agents to trap reactive metabolites formed. Similar to the in vivo 
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study, 4’-OH-lumiracoxib was detected and was shown to further oxidize to a 
quinone imine, which was trapped with NAC to form 4’-OH-3’-NAC-
lumiracoxib (Li et al., 2008). It should be noted with interest that the 
conjugation occurred at the position ortho to chlorine and not at the position 
ortho to fluorine. 4’-OH-6’-NAC-lumiracoxib and 4’-OH-6’-GS-lumiracoxib 
were identified in two studies, whereby a selective displacement of fluorine 
occurred (Li et al., 2008; Kang et al., 2009). Lumiracoxib was also proposed 
to be able to form an imine methide, 5-methyl-GS-lumiracoxib, which was 
detected in a trapping study with GSH (Kang et al., 2009). In addition to 
mono-conjugated adducts, di-, tri- and tetra-GSH adducts were identified, 
which indicates that re-oxidation of the mono-GSH adduct is possible (Kang 



















































4'-OH-3'-GSH-lumiracoxib Lumiracoxib-1',4'-quinone imine  
Figure 1-9 Phase I metabolism pathway and subsequent bioactivation and 




1.5. Statement of purpose 
Individual bioactivation studies of drugs give mechanistic insights into how 
drugs induce toxicity through formation of reactive metabolites. In the case of 
diclofenac and lumiracoxib, which are structurally-similar NSAIDs possessing 
the 2-phenylaminophenylacetic acid backbone, individual studies have noted 
that both drugs form reactive metabolites that are highly reactive electrophiles. 
However, there are few studies to compare the toxic effects due to 
bioactivation of such structurally similar drugs. Given that diclofenac and 
lumiracoxib are so similar structurally yet so different in their toxic effects and 
pharmacological properties, we propose to study how subtle changes to 
substituents on the 2-phenylaminophenylacetic acid backbone affect 1) the 
toxicity induced through bioactivation and 2) their pharmacological properties 
in order to elucidate the structure-toxicity relationship for a given chemical 
backbone. This study could provide better mechanistic insights on how 
substituents on a given chemical backbone affect its bioactivation to reactive 
metabolites and their subsequent reactivity and toxicity. It will also provide 
better understanding in the balance between toxicity and activity for further 
drug design.  
 
In order to investigate the effects of substituents on toxicity and pharmacology, 
we designed and synthesized 2-phenylaminophenylacetic acid analogs that 
were structurally similar to diclofenac and lumiracoxib with varying 
substituents at three positions on the said backbone. The in vitro toxicity of the 
synthesized compounds was determined on two liver cell-lines with different 
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metabolic capabilities using MTT assay. With the data obtained, further 
comparative structure-toxicity relationships could be elucidated. 
 
However, with only the in vitro cell toxicity data in hand, we could not 
determine if toxicity was caused by formation of reactive metabolites or via 
other mechanisms. Thus, we carried out in vitro bioactivation assays such as 
GSH depletion assay, AG reactivity determination, metabolic stability assays 
and reactive metabolite identification. These investigations provide an insight 
into the role of metabolism and bioactivation in affecting the toxicity of the 
compounds. Furthermore, the effect of subtle changes on the chemical 
backbone on metabolic stability, metabolite reactivity and the structures of 
reactive metabolites formed could be elucidated. 
 
In addition to the toxicity and metabolic studies, pharmacological studies 
involving cell-based COX inhibition assays were carried out to determine the 
efficacy and selectivity of the synthesized compounds. These assays allowed 
elucidation of SARs for the compounds. In addition, with the combined 
pharmacology and toxicity data, activity-selectivity-toxicity relationships 
could be deduced for the synthesized compounds. 
 
In summary, this thesis is organized into five experimental chapters. Chapter 2 
illustrates the chemical structures and synthetic schemes of the compounds. 
With the synthesized compounds available, Chapter 3 compiles the in vitro 
toxicity data together with subsequently generated structure-toxicity 
relationship models. Chapter 4 looks into the pharmacological properties and 
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the activity-selectivity-toxicity relationships of the synthesized compounds. 
Moving on, we looked into the role of metabolism in the toxicity of the 
compounds. Chapter 5 involves investigating the metabolic stability and 
reactivity of the compounds for both Phase I and Phase II metabolism. Last 
but not least, the identification and proposal of mechanistic pathways involved 
in the formation of Phase I and Phase II reactive metabolites of the compounds 








Twenty-four compounds, including diclofenac and lumiracoxib were proposed 
for this study. The basis of analog design was to change the substitutions at R1, 
R2 and R3 so as to evaluate the influence of these positions to the observed 
toxicities (Figure 2-1). Lumiracoxib differs from diclofenac in having a 
methyl group at R1 on ring A and a fluorine at R2 on ring B. Thus, the focus 






     R1     R2     R3 
1   H       F      Cl
2   H       F      F
3   H       Cl     Cl
4   H       Br     Br
5   Me     F      Cl
6   Me     F      F
7   Me     Cl     Cl
8   Me     Br     Br
       R1     R2     R3 
17   i-Pr    F      Cl
18   i-Pr    F      F
19   i-Pr    Cl     Cl
20   i-Pr    Br     Br
21   t-Bu   F      Cl
22   t-Bu   F      F
23   t-Bu   Cl     Cl
24   t-Bu   Br     Br
       R1     R2     R3 
9    Et      F      Cl 
10   Et      F      F
11   Et      Cl     Cl
12   Et      Br     Br
13   n-Pr   F      Cl
14   n-Pr   F      F
15   n-Pr   Cl     Cl
16   n-Pr   Br     Br
A
B
Figure 2-1 Structures of target compounds synthesized with position R1 on 
ring A and positions R2 and R3 on ring B. Diclofenac and lumiracoxib are 
compounds 3 and 5 respectively. Full structures are listed in Appendix 2-1. 
 
The selectivity of lumiracoxib for COX-2 arises from the addition of a methyl 
group at R1. It was observed that the addition of the methyl group reduces 
potency in addition to conferring selectivity (Blobaum and Marnett, 2007). 
Thus far, SAR studies of 2-phenylaminophenylacetic acids were carried out 
only for and up to methyl substitution at R1 (Blobaum and Marnett, 2007). 
Further increase in alkyl group size was not determined. Thus, a change in 
alkyl groups at position R1 was proposed to investigate if the size of the 
substituent will affect the toxicity and pharmacology of the compound. 
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Hydrogen, methyl, ethyl, n-propyl, iso-propyl and tert-butyl were chosen as 
the substituents at R1. 
 
R2 and R3 were proposed as changes in halogen substituents. A SAR-study on 
2-phenylaminophenylacetic acids observed that substituting chlorine for 
fluorine increased potency of the analog. It was proposed that larger halogens 
contribute to an increased angle of twist between the two phenyl rings, which 
affects the potency of the compound (Moser et al., 1990).  
 
The selection of substituents at these positions allow us to probe specific 
physicochemical contributors to toxicity because homologous alkyl groups on 
ring A differ in size, lipophilicity and extent of branching, while the halogens 
on ring B differ in size, lipophilicity and electronegativity. These 
physicochemical parameters can in turn affect the metabolism and disposition 
to effect varying biological responses. 
 
2.2. Experimental methods 
Merck silica 60 F254 sheets and Merck silica gel (0.040-0.063 mm) (Merck 
KGaA, Darmstadt, Germany) were used for thin layer chromatography (TLC) 
and flash chromatography respectively. HPLC/spectro grade acetonitrile and 
methanol were purchased from Tedia (Fairfield, OH). All other chemicals and 
reagents were obtained from Sigma Aldrich (St. Louis, MO) or Alfa Aesar 
(Ward Hill, MA) unless otherwise mentioned. Final compounds characterized 
by 1H and 13C nuclear magnetic resonance (NMR) spectra were recorded on a 
Bruker DPX 300 or Bruker ADVIII 400 spectrometer (Billerica, MA). 
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Chemical shifts were reported in parts per million (ppm, ) and referenced to 
residual solvents, deuterated chloroform (CDCl3) (7.260) or deuterated 
dimethyl sulfoxide (DMSO-d6) (δ 2.500) for 1H spectra and DMSO-d6 (δ 
39.43) for proton decoupled 13C NMR.  Coupling constants (J) were reported 
in Hertz (Hz). Proton coupling patterns were described as singlet (s), doublet 
(d), triplet (t), quartet (q), sextet (sext), septet (sept), doublet of doublets (dd), 
doublet of doublet of doublets (ddd), doublet of triplets (dt), triplet of doublets 
(td), triplet of triplets (tt) and multiplet (m). Mass spectra were captured on a 
Sciex API 3000 Qtrap (AB Sciex, Framingham, MA) equipped with an 
electrospray ionization (ESI) probe. Accurate mass was determined on a 
Bruker MicroOTOF-QII (Billerica, MA) equipped with an ESI probe. Masses 
of the compounds were reported in m/z values for the molecular ion detected. 
Melting point was acquired on a Gallenkamp melting point apparatus (Weiss 
Technik UK, United Kingdom). All characterization data of intermediates and 
final compounds are listed in Appendix 2-2. 
 
2.2.1. Extraction of diclofenac (3) from Voltaren tablets 
The enteric coating of six Voltaren® tablets (50 mg diclofenac per tablet, 
Norvatis, Switzerland) was removed. The tablets were then powdered with a 
pestle and mortar. To the powdered tablets (1.66 g), methanol (30 mL) and 
glacial acetic acid (1 mL) were added and the mixture sonicated for 5 min. 
The mixture was then shaken gently for 1 min and filtered. Water (30 mL) was 
added to the filtrate and the residue was removed by filtration under reduced 
pressure, after which it was washed with cold water (5 mL x 4). The residue 



























       R2   R3
26   F     Cl
27   F     F
28   Br    Br
     R2   R3
1   F     Cl
2   F     F
4   Br    Br
25
Scheme 2-1 Synthetic scheme for synthesis of 1, 2 and 4: (a) SOCl2, 
NH(CH3)2, DCM, 0°C; (b) Anhydrous K2CO3, CuI, Cu, toluene, reflux, 96 h; 
(c) Ethanolic KOH, reflux, overnight. 
 
2.2.2.1. Synthesis of 2-iodophenyl-N, N-dimethylacetamide (25) 
The method reported by Kenny, et al. (Kenny et al., 2004) was followed with 
some modifications. 2-Iodophenylacetic acid (0.53 g, 1.98 mmol) was 
dissolved in 12 mL of dichloromethane (DCM). To this solution, thionyl 
chloride (0.5 mL, 6.88 mmol) was added drop-wise with stirring at 0°C. DMF 
(1 drop) was added and the solution stirred at room temperature for 2 h, then 
evaporated to dryness. DCM was added, the mixture evaporated and the 
evaporating procedure was repeated again. The product was re-dissolved in 
DCM (5 mL) and added drop-wise to a two-phase system of 40% w/w 
aqueous dimethylamine (12 mL) in water (35 mL) and DCM (50 mL), which 
was stirred vigorously at 0°C. After 1 h, the organic layer was separated, 
washed with 1 M HCl, 10% aqueous Na2CO3, and water, and dried over 
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anhydrous Na2SO4 before evaporating to dryness. Purification by 
chromatography (eluting with ethyl acetate (EtOAc):hexane, 1:3) afforded 25 
as a colorless oil. 
 
2.2.2.2. General procedure for the synthesis of 2-[(2,6-disubstituted 
phenyl)amino)phenyl-N,N,-diethylacetamides (26 - 28)  
A mixture of 25 (0.24 g, 0.83 mmol), 2,6-disubstituted aniline (1.90 mmol), 
anhydrous K2CO3 (0.11 g, 0.76 mmol), CuI (0.011 g, 0.052 mmol) and freshly 
activated Cu(Vogel, 1989) (0.035 g) in toluene (5 mL) in a Dean-Stark 
apparatus filled with 4 Å molecular sieves was stirred and refluxed for 96 h. 
The mixture was filtered while still warm over celite, concentrated, and re-
dissolved in EtOAc, then washed with water, dried over anhydrous Na2SO4 
and evaporated. Purification by chromatography (eluting with EtOAc:hexane, 
1:4 followed by 2:3) afforded the product as crystals. 
 
2.2.2.3. General procedure for hydrolysis of acetamide to free acid (1, 2 and 4) 
The 2-[(2,6-disubstituted phenyl)amino)phenyl-N,N,-diethylacetamide (26 - 
28) (0.16 M) was dissolved in ethanolic KOH (0.67 M) and refluxed overnight 
in an inert N2 atmosphere. The solution was cooled to room temperature, 
concentrated and then re-dissolved in water (10 mL). The aqueous solution 
was extracted with EtOAc (2 x 30 mL) and the organic layer discarded. The 
aqueous solution was acidified with 1 M HCl to pH 3 and extracted with 
EtOAc (2 x 30 mL), washed with water, dried over Na2SO4 and evaporated to 
dryness. Purification by chromatography (eluting with EtOAc:hexane/1% 
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acetic acid, 1:4 to 2:3), followed by recrystallization from EtOAc/hexane 
afforded the product as powder. 
 



























       R2   R3
29   F      Cl
30   F      F
31   Cl     Cl
32   Br     Br
       R2   R3
49   F      Cl
50   F      F
51   Cl     Cl
52   Br     Br
       R2   R3
53   F      Cl
54   F      F
55   Cl     Cl
56   Br     Br
     R2   R3 
5   F      Cl
6   F      F
7   Cl     Cl
8   Br     Br
 
Scheme 2-2 Synthetic scheme for synthesis of 5 - 8: (a) Pd(OAc)2, (±) BINAP, 
NaOC(CH3)3, toluene, reflux, 24-48 h; (b) BrCH2COBr, 80°C, neat; (c) AlCl3, 
chlorobenzene, 155-160°C, 5 h; (d) NaOH, ethanol, reflux, 4-5 h. 
 
 
2.2.3.1. General procedure for the syntheses of 2,6-disubstituted-N-(p-
alkyl)anilines (29 - 48) 
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The reaction was carried out as previously reported (Wolfe and Buchwald, 
2000). Toluene (2 mL) and (±)-2,2’-bis(diphenylphosphino)-1,1’-
binaphthalene ((±)-BINAP) (9.3 mg, 1.5 mol%) were stirred under argon at 
80°C for 1 min. Pd(OAc)2 (2.2 mg, 1 mol%) was added to the mixture, purged 
with argon for approximately 30 s and stirred at room temperature for 1 min. 
1-Bromo-4-alkylbenzene or 1-iodo-4-alkylbenzene (2 mmol) and the 2,6-
disubstituted aniline (2 mmol) were added to the mixture, followed by addition 
of NaOC(CH3)3 (0.270 g, 2.8 mmol) and toluene (1.6 mL). The mixture was 
stirred and refluxed under argon for 24-48 h (reaction progress was checked 
by TLC and halted when aniline spot was faint or not visible). The mixture 
was cooled to room temperature, 5 M HCl (4 mL) and activated charcoal (0.5 
g) was added and stirred for an additional 1 h. The organic layer was separated, 
washed with water, dried over Na2SO4 and evaporated. The product was used 
with minimal purification (filtration through silica gel to reduce color) or 
removal of remaining aniline (by, chromatography, eluting with hexane) for 
the next step. It should be noted that the product obtained and used for the next 
step is not pure as the only concern here is the removal of color and aniline. 
 
2.2.3.2. General procedure for the syntheses of N-acetylated 2,6-disubstituted-
N-(p-tolyl)anilines (49 – 52) 
The 2,6-disubstituted-N-(p-tolyl)aniline (29 – 32) (~1 mmol) was heated, neat, 
to 80°C and bromoacetyl bromide (1.2 mmol, 0.1 mL) was added drop-wise 
with stirring. The mixture was heated at 80°C for 2-3 h. After the mixture was 
cooled to room temperature, water (5 mL) and toluene (5 mL) was added. The 
organic layer was separated, washed with water, dried over anhydrous Na2SO4 
29 
 
and evaporated. Purification by chromatography (eluting with EtOAc:hexane, 
1:3) afforded the N-acetylated 2,6-disubstituted-N-(p-tolyl)anilines (49 - 52). 
 
2.2.3.3. General procedure for the syntheses of 1-(2,6-disubstituted)-5-
methylindolin-2-ones (53 - 56)  
The reaction was carried out as previously reported (Acemoglu et al., 2004). A 
mixture of the N-acetylated 2,6-disubstituted-N-(p-tolyl)aniline (1 mmol), 
AlCl3 (1.5 mmol) and chlorobenzene (2 mL) was stirred and heated to 155-
160°C and maintained at this temperature for 5 h. The reaction mixture was 
then cooled to room temperature and water (5 mL) and toluene (5 mL) were 
added. The organic layer was separated, washed with 2 M HCl and water, 
dried over anhydrous Na2SO4 and evaporated. The residue was re-dissolved in 
ethanol, stirred with activated charcoal (0.2 g) for 30 min, filtered over celite 
and evaporated. Purification by recrystallization from 2-propanol afforded the 
product as crystals. 
 
2.2.3.4. General procedure for the syntheses of 2-(2-(2,6-
disubstitutedphenyl)amino)-5-methylphenyl)acetic acid (5 - 8)  
A solution of the indolinone (53 - 56) (1 mmol), in ethanol (3.7 mL) and water 
(0.2 mL) was heated to reflux under nitrogen. NaOH solution (0.39 g of a 30% 
w/w solution) was slowly added and refluxing was continued for 4-5 h. The 
solution was cooled, evaporated to remove ethanol, re-dissolved in water, 
acidified with 5 M HCl to pH 3, extracted with EtOAc, washed with water and 
dried over anhydrous Na2SO4. The residue was dissolved in ethanol, stirred 
30 
 
with activated charcoal (0.2 g) for 30 min, filtered over celite and evaporated. 
Recrystallization from DCM/hexane twice gave the product as crystals. 
 


































X = Br or I
       R1     R2     R3 
9     Et      F      Cl
10   Et      F      F
11   Et      Cl     Cl
12   Et      Br     Br
13   n-Pr   F      Cl
14   n-Pr   F      F
15   n-Pr   Cl     Cl
16   n-Pr   Br     Br
       R1     R2     R3 
17   i-Pr    F      Cl
18   i-Pr    F      F
19   i-Pr    Cl     Cl
20   i-Pr    Br     Br
21   t-Bu   F      Cl
22   t-Bu   F      F
23   t-Bu   Cl     Cl
24   t-Bu   Br     Br
       R1     R2     R3 
57   Et      F      Cl
58   Et      F      F
59   Et      Cl     Cl
60   Et      Br     Br
61   n-Pr   F      Cl
62   n-Pr   F      F
63   n-Pr   Cl     Cl
64   n-Pr   Br     Br
       R1     R2     R3 
65   i-Pr    F      Cl
66   i-Pr    F      F
67   i-Pr    Cl     Cl
68   i-Pr    Br     Br
69   t-Bu   F      Cl
70   t-Bu   F      F
71   t-Bu   Cl     Cl
72   t-Bu   Br     Br
       R1     R2     R3 
33   Et      F      Cl
34   Et      F      F
35   Et      Cl     Cl
36   Et      Br     Br
37   n-Pr   F      Cl
38   n-Pr   F      F
39   n-Pr   Cl     Cl
40   n-Pr   Br     Br
       R1     R2     R3 
41   i-Pr    F      Cl
42   i-Pr    F      F
43   i-Pr    Cl     Cl
44   i-Pr    Br     Br
45   t-Bu   F      Cl
46   t-Bu   F      F
47   t-Bu   Cl     Cl
48   t-Bu   Br     Br
Scheme 2-3 Synthetic scheme for synthesis of 9 - 24: (a) Pd(OAc)2, (±) 
BINAP, NaOC(CH3)3, toluene, reflux, 24-48 h; (b) Oxalyl chloride, DCM, 2h, 
rt.; (c) AlCl3, DCM, 2h, rt.; (d) NaOH, ethanol, reflux, 10-15 min; (e) 
H2NNH2•H2O, NaOCH3, 2-methoxyethanol, 150°C, 2 h. 
 
2.2.4.1. General method for the synthesis of 1-(2,6-disubstituted phenyl)-5-
ethylindoline-2,3-diones  (57 - 72) 
To a mixture of the 2,6-disubstituted-N-(4-alkyl)aniline (33 - 48) (2 mmol) in 
DCM (2 mL), oxalyl chloride (0.5 mL, 4 mmol) was added drop-wise with 
stirring at 0°C. The mixture was stirred for 2 h at room temperature, 
evaporated to dryness and twice evaporated from DCM. The resulting oxoacid 
chloride was re-dissolved in DCM (4 mL), cooled to 0°C and anhydrous AlCl3 
(0.54 g, 4 mmol) was added portion wise with stirring. The mixture was 
flushed with argon, allowed to stir at room temperature for 2 h and poured 
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over crushed ice and 2 M HCl (5 mL). The mixture was extracted with DCM 
and the organic layer separated, washed with 2 M HCl and water, dried over 
anhydrous Na2SO4 and evaporated. Purification by chromatography (eluting 
with EtOAc:hexane, 1:9 to 1:4) afforded the product as a semi-crystalline 
residue. 
 
2.2.4.2. General method for the syntheses of 2-(2-(2,6-
disubstitutedphenyl)amino)-5-alkylphenyl)acetic acid (9 - 24)  
The reaction was carried out as previously reported (Moser et al., 1990). A 
mixture of the indoline-diones (57 - 72) (1 mmol) and NaOH solution (0.39 g 
of a 30% w/w solution) (0.39 g) in ethanol (4.3 mL) was refluxed for 10-15 
min, cooled and evaporated. The residue was re-dissolved in water and 
acidified with 5 M HCl to pH 3 to form a fine suspension. The acidified 
mixture was extracted with EtOAc, the organic layer washed with water, dried 
over anhydrous Na2SO4 and evaporated. The resulting oxoacetic acid, without 
purification, was re-dissolved in 2-methoxyethanol (4.3 mL) and hydrazine 
hydrate (0.28 mL, 5 mmol) was added. The mixture was warmed to 60°C with 
stirring and NaOCH3 (0.53 g, 10 mmol) was added portion-wise. The mixture 
was slowly heated to 150°C, held at that temperature for 2 h, cooled to room 
temperature and poured over crushed ice. The mixture was acidified with 5 M 
HCl to pH 3 and extracted with EtOAc. The organic layer was separated, 
washed with water, dried over anhydrous Na2SO4 and evaporated. Purification 
by chromatography (eluting with EtOAc:hexane/0.5% acetic acid, 1:9 to 1:4) 
followed by recrystallization from DCM/hexane twice to afford the product as 




2.2.5. Purity determination by HPLC 
Purities of final compounds were verified by high performance liquid 
chromatography (HPLC) using an Agilent 1100 series system (Santa Clara, 
CA) coupled with a diode array detector using a reverse phase Phenomenex 
Luna® 5 µm C18(2) 100 Å 250 × 4.6 mm column (Torrance, CA). The 
solvents used were acetonitrile (A), methanol (B) and water with 0.1% 
trifluoroacetic acid (C). For 1 - 4, gradient A was run from 5:95 A:C to 95:5 
A:C over 10 min and held at 95:5 A:C for 3 min. Gradient B was run from 
5:95 B:C to 95:5 B:C over 10 min and held at 95:5 B:C for 3 min. For 5 - 8, 
gradient A was run from 5:95 A:C to 95:5 A:C over 10 min and held at 95:5 
A:C for 3 min. Gradient B was run from 15:95 B:C to 95:5 B:C over 8 min 
and held at 95:5 B:C for 5 min. For 9 - 24, gradient A was run from 15:95 A:C 
to 95:5 A:C over 8 min and held at 95:5 A:C for 5 min. Gradient B was run 
from 15:95 B:C to 95:5 B:C over 8 min and held at 95:5 B:C for 5 min. The 
compounds were analyzed at a wavelength of 280 nm. Purities of all twenty-
four compounds are listed in Appendix 2-3. 
 
2.3. Discussion 
The structures of the test compounds are presented in Figure 2-1. The 
compounds possess a common 2-phenylamino-phenylacetic acid scaffold but 
with varying alkyl substituents (methyl, ethyl, n-propyl, iso-propyl, tert-butyl) 
at position R1 on ring A and different halogens (fluoro, bromo, chloro and 
combinations thereof) at positions R2 and R3 on ring B. Compounds 3 and 5 




Compounds 1, 2 and 4 are structurally related to diclofenac (3), differing only 
in the halogens substituted on ring B. Their reaction scheme is shown in 
Scheme 2-1. The carboxylic acid present in 2-iodophenylacetic acid was first 
converted to the tertiary amide by reaction with thionyl chloride and 
dimethylamine via a nucleophilic acyl substitution pathway.  Amide formation 
via acid chlorides is faster and requires milder conditions as compared to 
direct synthesis from the carboxylic acid. The acid chloride reacts with 
dimethylamine by a nucleophilic acyl substitution process to form the 2-(2-
iodophenyl)-N,N-dimethylacetamide (Figure 2-2). The acid to amide 
conversion was necessary to ensure that the Ullman condensation between the 
ortho-disubstituted aniline and the iodo functionality in phenylacetamide 25 






















































































Figure 2-2 Mechanism of the formation of an amide via formation of an acid 
chloride (Li, 2009).  
 
Ullman condensation was carried out by between the ortho-disubstituted 
aniline and the iodo functionality in phenylacetamide 25. Ullmann 
condensation occurs by the formation of a copper (III) complex. The aniline 
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first forms a complex with the copper (I) iodide (CuI) catalyst. 2-(2-
iodophenyl)-N,N-dimethylacetamide adds to the complex via oxidative 
addition. The copper (III) complex then undergoes reductive elimination to 
form the 2-phenylaminophenylacetic acid product (Figure 2-3). The CuI 
























Figure 2-3 Mechanism of Ullmann condensation (Li, 2009). 
 
On completion of the reaction, the amide (26, 27 or 28) was hydrolyzed to 
regenerate the free acid. The size of the halogens on ring B did not affect the 
rate of the Ullman condensation reaction but it was observed that the yield 
decreased for the dibromo-substituted compund (4) after hydrolysis. For this 
compound, the aqueous solution after hydrolysis was washed with EtOAc in 
order to facilitate the purification process after acidification. It is possible that 
the dibromo-substituted compound (4), although present in its ionized anionic 





Compounds 6 - 8 are analogs of lumiracoxib (5), differing only in the ortho-
halogens present on ring B.  Scheme 2-2 illustrates the reaction sequences 
involved in their syntheses. The first step in the synthesis involves formation 
of a diarylamine via Buchwald-Hartwig coupling from the respective aniline 
and halo-alkylbenzene. For bromo-substituted analogs at R2 and R3 positions, 
iodo-alkylbenzene is required instead of bromo-alkylbenzne as the reaction 
could not proceed with a bromo-alkylbenzene. Palladium (II) acetate 
(Pd(OAc)2) was used as the catalyst and can be reduced to the required 
palladium (0) upon contact with the hindered base sodium tert-butoxide  
(NaOtBu) used (Wolfe and Buchwald, 2000). The mechanism behind 
Buchwald-Hartwig coupling starts with addition of 13a to the Pd(0)-ligand 
complex via oxidative addition. This is followed by displacement of the halide 
by NaOtBu, which is in turn displaced by the aniline. Finally, the diarylamine 
is formed by reductive elimination and the catalyst is regenerated (Figure 2-4). 
 











































The aniline nitrogen of the product (29 - 32) was acetylated by reacting with 
bromoacetylbromide to give N,N-disubstituted  bromoacetamide (49 – 52). 
The next step involved an intramolecular Friedal-Crafts alkylation to give the 
oxindole (53 – 56).  Friedal-Crafts alkylation occurs by formation of a 
carbocation, which acts as the electrophile in an electrophilic aromatic 
substitution, forming an oxindole (Figure 2-5). Hydrolysis of the oxindole 







































Figure 2-5 Mechanism for intramolecular Friedel-Crafts alkylation (Li, 2009). 
 
Compounds 9 - 24 have ethyl, n-propyl, iso-propyl or tert-butyl at R1 on ring 
A. The syntheses of these compounds are similar to the ring A methyl analogs 
5 - 8. Scheme 2-3 illustrates the reactions involved in the synthesis. The 
Buchwald-Hartwig reaction was employed to give the diarylamine (33 – 48). 
The removal of any remaining disubstituted aniline was crucial as the acid 
chloride obtained in the next step cannot be purified. However, it was found 
that the diarylamine could be used in spite of impurities as long as the 
disubstituted aniline was not present. Thus, disubstituted aniline was the only 
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impurity removed as elution with hexane made separation of other impurities 
difficult. The aniline nitrogen was then acylated with oxalyl chloride to form 
an acyl chloride. An acyl cation is generated from the reaction between the 
acyl chloride and AlCl3, which attacks the upper aromatic ring (Figure 2-6). 



















































Figure 2-6 Mechanism of Friedel-Crafts acylation (Li, 2009). 
 
A Friedel-Crafts acylation was required as previous attempts at Friedel-Crafts 
alkylation resulted in the loss of the alkyl group on ring A. As seen from 
Figure 2-7a, an ethyl group (δ ppm 2.66 (q, J = 7.6 Hz, 2H), 1.25 (t, J = 7.6 
Hz, 3H)) is present in the NMR spectrum of 2-bromo-N-(2,6-difluorophenyl)-
N-(4-ethylphenyl)acetamide. After Friedel-Crafts alkylation, the peaks 
corresponding to an ethyl group is absent from the NMR spectrum of the 
reaction product (Figure 2-7b). Determination of mass by mass spectroscopy 
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(MS) further confirmed the absence of an ethyl group in the product after 






Figure 2-7 (a) H1 NMR spectrum of compound 10 acetamide showing the 
presence of the triplet and quadruplet at chemical shift range of 1.0 – 3.0 
corresponding to an ethyl group; (b) H1 NMR spectrum of compound 10 
oxindole showing the absence of the triplet and quadruplet previously seen for 
the acetamide; (c) [M+H]+ of compound 10 oxindole is 246.0 m/z, which is 28 










The loss of the ethyl group was most probably due to reverse Friedel-Crafts 
reaction. This reaction is actually Friedel-Crafts reaction occurring backwards 
and occurs in the presence of an acid and a Lewis acid. The acid in this 
instance was the hydrobromic acid (HBr) formed from the forward Friedel-
Crafts alkylation. The acid forms a complex with aluminum (III) chloride 
(AlCl3), allowing the proton to protonate the aromatic ring of the oxindole to 
form an aromatic carbocation. The alkyl group is then expelled and is trapped 





























Figure 2-8 Mechanism of reverse Friedel-Crafts (Li, 2009). 
 
Ring opening was effected by alkaline hydrolysis to give the oxoacetic acid. 
The oxoacetic acid was not purified before use as it degraded rapidly to the 
starting N-substituted isatin. The ketone carbonyl was reduced in a Wolff-
Kishner reaction with hydrazine hydrate and sodium methoxide as base. The 
oxoacetic acid reacts with hydrazine (H2NNH2) at the ketone oxygen to form a 
hydrazone which is subsequently deprotonated, with the release of nitrogen 
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gas (Figure 2-9). The ketone is reduced to an alkane, forming the 2-














































Figure 2-9 Mechanism of a modified Wolff-Kishner reduction (Li, 2009). 
 
2.4. Conclusion 
In conclusion, twenty-four analogs were synthesized via three schemes. The 
obtained yields of the analogs ranged from 25% to 89%. They were 
characterized via NMR, mass spectroscopy and melting point (Appendix 2-2). 
Their purities were determined via HPLC and were ascertained to be 




Chapter 3. In vitro toxicity of 2-Phenylaminophenylacetic Acid derived 
Compounds in Liver Cell Lines: Effect of Substituents on Toxicity and 
Derivation of Quantitative Structure-Toxicity Relationships (QSTR) 
 
3.1. Introduction 
Diclofenac and lumiracoxib toxicities are mainly associated with the liver. 
Extensive research has revealed that their liver toxicities were primarily due to 
the formation of reactive metabolites via Phase I and Phase II metabolism in 
the liver (Kretzrommel and Boelsterli, 1994a; Tang et al., 1999b; Tang, 2003; 
Li et al., 2008; Kang et al., 2009). Thus, in order to determine the effect of 
substituents on the 2-phenylaminophenylacetic acid chemical scaffold on its 
toxicity, we have decided to test the twenty-four synthesized compounds on 
liver cell lines. To further ascertain the role of bioactivation in such toxicities, 
we intentionally selected liver cell lines of contrasting metabolic capacity for 
toxicity profiling of the compounds. HuH-7 and TAMH were used to carry out 
the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay in order to determine the effect of the compounds on cell viability. In 
addition, we carried out an enzyme functionality test on the two key 
cytochrome P450 enzymes involved in the metabolism of diclofenac and 
lumiracoxib to validate the contrasting metabolic potential of our experimental 
models. 
 
We decided to look at the possible relationships between physicochemical 
properties of the compounds and their in vitro cytotoxicity. In addition to a 
qualitative analysis, we performed a quantitative structure-toxicity relationship 
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(QSTR) modelling which led to the creation of regression models depicting 
the relationship between physicochemical properties in terms of molecular 
descriptors and experimental data.  
 
3.2. Experimental methods 
Dulbecco’s modified Eagle’s medium/Ham’s F12 (DMEM/F12) and soybean 
trypsin inhibitor were obtained from Gibco® (Life Technologies, Carlsbad, 
CA). ITS Universal Culture Supplement Premix containing 5 mg/mL insulin, 
5 mg/mL transferrin and 5 ng/mL selenium was obtained from BD Bioscience 
(Belford, MA). Fetal bovine serum (FBS) was obtained from Hyclone 
(Thermo Scientific, Waltharm, MA). MTT was obtained from Duchefa 
Biochemie (Haarlem, Netherlands). Luciferin-H and Luciferin-PFBE P450-
Glo assay kits were obtained from Promega (Fitchburg, WI). All other 
chemicals and reagents were obtained from Sigma Aldrich (St. Louis, MO) 
unless otherwise mentioned. 
 
3.2.1. Cell culture 
All cultures were maintained in a humidified incubator with 5% carbon 
dioxide at 37°C unless otherwise stated. TAMH cells were a gift from 
Professor Nelson Fausto (University of Washington, USA). The cells were 
grown in serum free DMEM/F12 supplemented with ITS Universal Culture 
Supplement Premix, 100 nM dexamethasone, 10 mM nicotinamide and 0.01% 
(v/v) gentamicin (Pierce et al., 2002). Trypsin was used to passage cells at 80-
90% confluence, and was inhibited with 0.5 mg/mL soybean trypsin inhibitor. 
HuH-7 cells were obtained from Health Science Research Resources Bank 
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(HSRRB, Japan). The cells were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% FBS. Trypsin was used to passage 
cells at 80-90% confluence, and was inhibited with 10% FBS supplemented 
DMEM. Cultures were maintained in a humidified incubator with 5% carbon 
dioxide at 37 °C. 
 
3.2.2. Determination of key cytochrome P450 enzyme activities  
TAMH and HuH-7 cells seeded at a density of 5.0 × 104 cells/ well. The 
activity of two classes of cytochrome P450s, CYP2C9 and CYP3As, were 
determined using the Luciferin-H and Luciferin-PFBE P450-Glo assay 
respectively. The P450-Glo assay was carried out in accordance to 
manufacturer’s instruction.  Briefly, medium was aspirated 48 h after seeding 
of cells. Luciferin substrates were dissolved in the respective growth medium 
and 50 μL was added to each well. The plates were incubated for 4 h in the 
dark at 37°C. The medium in each well were then transferred to a 96-well 
opaque white plate and 50 μL of Luciferin Detection Reagent was added. The 
plate was incubated at room temperature for 20 min. Luminescence was read 
on a Tecan M200 Pro plate reader (Männedorf, Switzerland) and the readout 
was expressed in relative luminescence units (RLU). Net signals were 
calculated by subtracting away the background luminescence values. MTT 
assay was carried out on the same cells to normalize the net luminescence 






3.2.3. MTT assay to determine cytotoxicity 
MTT assay was carried out as reported elsewhere (Plumb et al., 1989). Briefly, 
TAMH cells were seeded at a density of 1.2 × 104 cells/ well. HuH-7 cells 
were seeded at a density of 1 × 104 cells/ well. Test compounds were dissolved 
in DMSO and the final DMSO concentration for all treatments was 
synchronized at 0.5% v/v in the growth medium. The treatment duration was 
24 h, after which the medium was aspirated from the wells. MTT dye (50 μL 
of 2 mg/mL in PBS) and growth medium (200 μL) were added per well and 
incubated at 37°C in the dark for 3 h. The MTT containing medium was then 
aspirated and Sorenson’s buffer (25 μL of 0.1 M glycine and 0.1 M sodium 
chloride equilibrated to pH 10.5 with 0.1 M sodium hydroxide) and DMSO 
(200 μL) were added to each well. The plates were read at 560 nm using a 
Tecan M200 plate reader. Cell viability was expressed as the percentage ratio 
of treated cells normalized over DMSO controls. Median lethal concentrations 
(LC50) values were obtained from the dose-response curve using Graphpad 
Prism 5 (Graphpad Software Inc., San Diego, CA).  
 
3.2.4. Calculation of molecular descriptors 
The chemical structures of the twenty-four compounds were drawn and 
energy-minimized using the MMFF94x force field in the Molecular Operating 
Environment (MOE) 2008.10 software (Chemical Computing Group, 
Montreal, Canada) with the root-mean-square (RMS) gradient set to 0.00001. 
All available 327 molecular descriptors were calculated with MOE. In 
addition, log D(o/w) values were calculated using the online ACD/I-Lab 
prediction engine (ACD/Labs, Canada). These descriptors were put through a 
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descriptor selection procedure in order to remove unsuitable descriptors (as 
described in the next section).  
 
3.2.5. Selection of relevant molecular descriptors 
Molecular descriptors with constant values were eliminated. The respective 
LC50 values were converted to pLC50 or −log(LC50) values. Thereafter, all the 
remaining descriptors were first sorted in descending order based on the 
Pearson’s correlation coefficients between TAMH pLC50 values and the 
individual descriptors. In the next step, the descriptor possessing the highest 
correlation coefficient to the TAMH pLC50 values was retained. All other 
descriptors with correlation coefficients of more than or equal to 0.60 to the 
retained descriptor were discarded. This was carried out to ensure the absence 
of collinearity in the selected set of descriptors. Of the remaining descriptors, 
the descriptor with the next highest correlation coefficient to TAMH pLC50 
was retained. Similarly, as mentioned above, the descriptors found to be 
correlated to the second retained descriptor were discarded. This procedure 
was repeated until all the descriptors were processed. The same procedure was 
repeated using the HuH-7 pLC50 values. 
 
3.2.6. QSTR models: Multiple linear regression and validation 
For each set of the assay data from the TAMH and HuH-7 cell lines, a QSTR 
model was built using multiple linear regression based on the remaining 
molecular descriptors that were passed through the descriptor selection step. 
Prior to building the QSTR models, the respective LC50 values were converted 
to pLC50 or −log(LC50) values so as to facilitate the regression process. The 
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step-wise multiple linear regression was carried out using the IBM SPSS 
Statistics for Windows, Version 21.0 (IBM, Armonk, NY). In order to ensure 
statistical rigor, the ratio of the number of compounds to the number of 
descriptors is recommended to be ≥ 5. Therefore, with twenty-four compounds 
in this study, the maximum number of descriptors that can be included in each 
of the QSAR regression models is 4.  
 
In order to validate the QSAR models generated, leave-one-out cross-
validation and 100 rounds of y-scrambling were conducted for each of the 
models (Wold et al., 1995). In leave-one-out cross-validation, each compound 
was left out of the inputs during the regression model building stage and the 
model obtained was used to predict the corresponding pLC50 value for that 
left-out compound. The predicted pLC50 values were then compared to the 
experimental pLC50 and the cross-validated R2 or q2 value was calculated. 
Furthermore, in order to eliminate the possibility that the regression models 
were generated by chance, the y-scrambling procedure was carried out. In this 
procedure, models are fitted for randomly re-ordered pLC50 values and 
compared with the model obtained for the actual pLC50 values. This was 
conducted for 100 iterations. 
 
3.2.7. Partial order ranking 
In order to get an overview of the toxicity of the compounds in this study, one 
of the possible ways is to rank them according to the LC50 values obtained 
using the two cell lines. However, the LC50 values from each of the cell lines 
are not in total agreement for some of the compounds. In other words, if the 
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compounds are ranked according to each of the cell line LC50 values, then the 
rankings obtained will be different. This is because the separate rankings are 
not able to reconcile contradictions in the assay results. Therefore, in order to 
take those contradictions from both cell lines into account, the compounds 
need to be ranked using a method known as partial order ranking. Partial order 
ranking is a vectorial approach that not only ranks elements but also identifies 
contradictions in the criteria used for ranking (Lerche et al., 2002; Carlsen, 
2008). It helps to circumvent the lack of comparability with some compounds. 
Such incomparability is due to contradictory attributes; for each incomparable 
pair of compounds there must be LC50 values from different cell lines that are 
counteracting. In order to visualize the partial order rankings, the Hasse 
diagram technique can be applied. 
 
3.2.8. Hasse diagram technique 
In the Hasse diagram, the compound that is at the apex is called the maximal 
(Halfon and Reggiani, 1986; Bruggemann and Bartel, 1999; Bruggemann et 
al., 1999). On the other hand, the compound at the bottom of the diagram 
without any compounds below it is called the minimal.   
 
When the Hasse diagram technique was first applied, the criteria describe the 
elements in terms of environmental hazard. The main assumption is that the 
lower the numerical value the lower the hazard. Since a high numerical value 
of cell line LC50 values corresponds to low toxicity, the values must be 
multiplied by -1 to invert their order. Based on this convention, the maximal 
elements are the most toxic and top priority should be assigned to them. In this 
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study, the partial order ranking and the Hass diagram were generated using the 
Data Analysis by Ranking Techniques (DART) version 2.0.5 software.  
 
3.2.9. Statistical Analysis 
Unpaired t-test (one-tailed) was used to analyze the expression of P450 
enzymes in the cell-lines using GraphPad Prism 5. LC50 values were 
calculated from triplicates and expressed as mean and standard deviation. 
One-way analysis of variance (ANOVA) was used to determine the statistical 
significant difference between the MTT results using GraphPad Prism 5. 
 
3.3. Results 
3.3.1. Determination of key cytochrome P450 activities 
To determine if the difference in toxicity could be due to the contrasting 
metabolic capacity between the two cell lines, TAMH and HuH-7, cytochrome 
P450 activities were evaluated. Two key enzymes important in the metabolism 
of phenylaminophenylacetic acid were considered, namely CYP2C9 and 
CYP3As (CYP3A4, CYP3A5 and CYP3A7). These P450 enzymes were 
previously shown to be involved in the metabolism of diclofenac and 
lumiracoxib (Leemann et al., 1993; Shen et al., 1999; Mangold et al., 2004). 
The activity was evaluated using luminogenic P450 substrates incubated in the 
respective cell lines. Unpaired one-tailed t-tests showed that the differences in 
CYP activity between the two cell lines are significant (Figure 3-1). The 
activity of CYP2C9 and CYP3As in TAMH are approximately 5.7 and 6.2 
fold respectively of that of HuH-7. Based on the RLU measured, both cell 
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lines have more CYP3As activity as compared to CYP2C9, consistent with the 
predominance of CYP3A4/5 also seen in humans. 
 
 
Figure 3-1 Comparison between the relative luminescence units (RLU) 
obtained for HuH-7 and TAMH for (a) CYP2C9 and (b) CYP3As. Values 
were generated from three biological replicates. Unpaired t-test (one-tailed) of 
results with calculated P values. Statistically significant only when P < 0.05. 
 
3.3.2. Effect of structural changes on toxicity 
The cytotoxicity of synthesized compounds were evaluated on two liver cell 
lines, namely TAMH, which is a TGF-α overexpressing mouse hepatocyte cell 
line derived from transgenic MT42 male mice (Wu et al., 1994) and HuH-7, a 
human hepatocellular carcinoma cell line. Test compounds were tested up to a 
concentration of 1000 µM, which is close to the limit of solubility. The 
calculated LC50 values range from approximately 3 µM to 500 µM for TAMH 























that the most cytotoxic compound on both cell lines was compound 24 while 
compound 2 was identified as the least. 
 








Compound R1 R2 R3 
Calculated Descriptors LC50 (μM)a 
Log 
P(o/w)f 
FASA_Hg TAMHb,c HuH-7d,e 
1 H  F  Cl 3.913 0.835 232.7 ± 9.2 639.6 ± 77.5 
2 H  F  F  3.474 0.826 513.1 ± 34.2 1959 ± 477.8h 
3 (Diclofenac) H  Cl  Cl 4.352 0.851 94.2 ± 2.9 341.1 ± 23.8 
4 H  Br  Br 4.764 0.860 36.7 ± 3.7 231.7 ± 9.8 
5 (Lumiracoxib) Me  F  Cl 4.248 0.842 111.1 ± 6.1 424.6 ± 39.3 
6 Me  F  F  3.809 0.836 323.9 ± 7.9 659.9 ± 88.3 
7 Me  Cl  Cl 4.687 0.861 48.7 ± 4.0 311.6 ± 50.0 
8 Me Br  Br 5.099 0.874 15.9 ± 1.6 213.8 ± 10.7 
9 Et  F  Cl 4.723 0.849 46.8 ± 5.1 323.3 ± 19.9 
10 Et  F  F  4.284 0.844 106.6 ± 11.3 472.4 ± 50.5 
11 Et  Cl  Cl 5.162 0.866 21.1 ± 1.3 235.5 ± 11.4 
12 Et  Br  Br 5.574 0.874 11.3 ± 0.7 247.6 + 2.2 
13 n-Pr  F  Cl 5.165 0.859 17.0 ± 1.4 241.1 ± 22.1 
14 n-Pr  F  F  4.726 0.854 32.8 ± 1.0 310.2 ± 12.6 
15 n-Pr  Cl  Cl 5.604 0.876 8.0 ± 1.1 195.2 ± 19.6 
16 n-Pr  Br  Br 6.016 0.871 4.0 ± 0.4 192.1 ± 5.2 
17 i-Pr  F  Cl 5.093 0.856 22.2 ± 1.8 261.3 ± 9.0 
18 i-Pr F  F  4.654 0.854 36.9 ± 0.6 360.8 ± 33.8 
19 i-Pr Cl  Cl 5.532 0.870 8.9 ± 0.7 207.0 ± 12.8 
20 i-Pr Br  Br 5.944 0.880 5.8 ± 0.5 171.1 ± 16.7 
21 t-Bu  F  Cl 5.449 0.860 10.4 ± 0.4 213.2 ± 12.8 
22 t-Bu F  F  5.010 0.857 23.3 ± 1.1 260.8 ± 15.1 
23 t-Bu Cl  Cl 5.888 0.877 5.5 ± 0.8 173.0 ± 12.7 
24 t-Bu Br  Br 6.300 0.883 3.7 ± 0.4 143.4 ± 5.6 
a LC50 values were determined after an incubation period of 24 h, 37°C from three biological 
replicates and expressed as mean ± standard error. 
b TGF-α transfected mouse hepatocyte cell line. 
c One-way ANOVA: P < 0.05, indicating average IC50 values for TAMH are statistically 
different. 
d Human hepatocellular carcinoma cell line. 
e One-way ANOVA: P < 0.05, indicating average IC50 values for HuH-7 are statistically 
different. 
f Calculated partition coefficient in water/octanol. 
g Fractional accessible surface area_hydrophobic (FASA_H) is calculated as ASA_H / ASA. 
ASA_H is the water accessible surface area of all hydrophobic atoms. ASA is the water 
accessible surface area calculated using a radius of 1.4 Å for the water molecule. 




There was however some variability in the toxicity ranking of the other 
compounds. To obtain a comprehensive overview of the standing of the series 
on both cell lines, and thus the structure toxicity relationship, we employed the 
approach described in the Hasse diagram (Halfon and Reggiani, 1986; 
Bruggemann and Bartel, 1999; Bruggemann et al., 1999). In the Hasse 
diagram (Figure 3-2), the compounds are arranged into 16 levels based on the 
cytotoxicity results from both cell lines. Accordingly, the levels in the Hasse 
diagram indicates the level of toxicity in descending order, i.e. compounds 
assigned to Level 16 are the most toxic and those at Level 1 are the least toxic. 
As mentioned earlier, these were compounds 24 and 2 respectively. By 
convention, compounds that were not comparable are placed on the same level. 
At level 15, compounds 16, 20 and 23 can be said to be incomparable 
according to the partial order concept (Lerche et al., 2002; Carlsen, 2008). 
Incomparability is due to contradictory attributes: for each incomparable pair 
of compounds there must be LC50 values that are counteracting. For example, 
the LC50 of compound 16, 20 and 23 were ranked as level 23, 21 and 22 
respectively in TAMH but level 21, 23 and 22 respectively in HuH-7. In short, 
compounds with similar LC50 values were ranked at the same level due to 
incomparability and cannot be said to be more toxic than the other. The levels 





Figure 3-2 The Hasse diagram of the twenty-four compounds investigated in 
this study. The numbers in the circles are the compound numbers. The 
numbers in the left margin are the levels that the compounds are assigned to 
according to partial order ranking based on both cell lines. The toxicity is 
ranked in ascending order, with level 1 being the least toxic. 
 
Broadly, the LC50 values obtained for the twenty-four compounds decreased 
with respect to both increase in size of alkyl group at R1 of ring A and the size 
of the halogens at R2 and R3 on ring B. In general, the contribution to toxicity 
by the alkyl substituents are H < methyl < ethyl < iso-propyl ≤ n-propyl < tert-
butyl, of which H contributing the least to toxicity. For halogen substituents, 
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the contributions are fluorine < chlorine < bromine, with fluorine contributing 
the least to toxicity. We examined the effect of alkyl substituents for a given 
set of halogen substituents on ring B. As an example, we compared 
compounds 1, 5, 9, 13, 17 and 21 where substitutions at R2 and R3 are fluorine 
and chlorine and with alkyl substitution increasing from H to tert-butyl at R1. 
Here, the LC50 values decreased from compounds 1 to 21. This decrease is 
clearly shown in the Hasse diagram (Figure 3-2) whereby each subsequent 
compound is ranked at higher levels. The LC50 values of compounds with n-
propyl substitution at R1 were slightly lower than that of a branched iso-propyl 
substitution but were ranked at a higher level (except in the case of 16 and 20). 
This indicates that branching of the alkyl side chain affected the toxicity of the 
compounds, albeit to a small degree. 
 
On the other hand, with respect to the influence of halogen on toxicity, we 
examined the halogen series while keeping the alkyl substituents constant. For 
example, compounds 5 to 8 possess a methyl group at R1 but the halogen 
substituents at R2 and R3 were varied. The LC50 values within this group of 
four compounds decreased as the substitutions changed from fluorine to 
bromine (6 > 5 > 7 > 8), in agreement to the rankings proposed in the Hasse 
diagram. A replacement of fluorine with either chlorine or bromine caused a 
more dramatic change in LC50 values as compared to a substitution of chlorine 
with bromine or vice versa. To further illustrate the potential benefit of 
fluorine, compounds 5 and 10 (Figure 3-2, Level 4) were compared. It is 
shown that a change in R1 from methyl (compound 5) to ethyl (compound 9) 
caused a dramatic drop in LC50 value. However, substituting fluorine at R2 or 
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R3, with R1 as ethyl (compound 10) gave a LC50 value similar to that of 
compound 5, indicating that fluorine substitutions decreases toxicity. 
 
Another observation made was that for bigger halogen groups, the effect of 
increasing the size of the alkyl group is less significant. As seen in Table 3-2, 
the ratio between LC50 values of the H-substituted compound and the tert-
butyl-substituted compound at R1 is the greatest for difluoro-substituted 
compounds (1 : 21) and the least for dibromo-substituted compounds (4 : 24).  
 
Table 3-2 Ratios of LC50 values between substitutions at R1: H and R1: tert-
butyl. Compound names are bracketed. 
 HuH-7 TAMH 
R2: F, R3:Cl 






R2: F, R3: F 






R2: Cl, R3: Cl 






R2: Br, R3: Br 






3.3.3. Effect of cell lines with varying metabolic competencies 
Toxicity profiles of the compounds were compared across two liver cell lines: 
TAMH and HuH-7. Consistent between them, the least toxic compound is 
observed to be 2 and the most toxic compound is 24. Compound 2 possesses 
the combination of the least toxic substituents observed, which are hydrogen at 
R1 and fluorine at R2 and R3. On the other hand, compound 24 possesses the 




However, the LC50 values obtained for TAMH are consistently lower than that 
for HuH-7 (Figure 3-3). The LC50 of the most toxic compound (24) for TAMH 
(3.7 μM) is very much lower than that of HuH-7 (143.4 μM). Furthermore, as 
the size of the alkyl and halogen substituents increases, the decrease in LC50 
values for HuH-7 is less pronounced as compared to the corresponding values 
for TAMH. The LC50 of the least toxic compound (2) is approximately 139 
times higher than that of the most toxic compound (24) for TAMH, while for 
HuH-7, the difference between the extremes is only 14 times.  
 
 
Figure 3-3 Plot of LC50 values of HuH-7 against TAMH for all compounds. 
Point lying above the intersection line indicates that LC50 value is higher for 
HuH-7 for that compound. 
 
3.3.4. QSTR models: Multiple linear regression and validation 
To define the relationship between structural changes and toxicity more 
explicitly to support subsequent structural modifications, a QSTR model was 
generated using cytotoxicity results from each cell line. The QSTR regression 
model obtained for the TAMH cell line using −log(TAMH LC50) and log 
P(o/w) (partition coefficient) was: 
















R = 0.991, q2 = 0.978, F = 1161.020, S = 0.083, N = 24, where R is the 
correlation coefficient, q2 is the cross-validated R2, F is the Fisher test for 
significance of the equation, S denotes the standard error, and N is the number 
of compounds. The predicted −log(TAMH LC50) and experimental 
−log(TAMH LC50) are listed in Table 3-3. Log P(o/w) is the calculated 
partition coefficient in water/octanol, which indicates the lipophilicity of the 
compounds. 
 
Correspondingly, the QSTR regression model obtained for the HuH-7 cell line 
using −log(HuH-7 LC50) and FASA_H was: 
-log(HuH-7 LC50) = 14.485  FASA_H − 8.913 (Eq. 2) 
R = 0.910, q2 = 0.770, F = 106.636, S = 0.103, N = 24. 
The predicted −log(HuH-7 LC50) and experimental −log(HuH-7 LC50) are 
listed in Table 3-3. FASA_H is calculated as ASA_H / ASA. ASA_H is the 
water accessible surface area of all hydrophobic (|qi| < 0.2) atoms. The qi value 
denotes the partial charge of atom i. ASA is the water accessible surface area 
calculated using a radius of 1.4 Å for the water molecule. A polyhedral 
representation is used for each atom in calculating the surface area. FASA_H 
is an indicator of the total hydrophobic area in a molecule of the compound, 








Table 3-3 The predicted and the experimental -log(TAMH LC50) and -











1 4.05 3.63 3.41 3.19 
2 3.70 3.29 3.18 2.71 
3 (Diclofenac) 3.62 4.03 3.55 3.47 
4 4.00 4.44 3.71 3.64 
5 (Lumiracoxib) 4.38 3.95 3.28 3.37 
6 3.35 3.49 3.05 3.18 
7 4.32 4.31 3.38 3.51 
8 5.39 4.80 3.49 3.67 
9 4.65 4.33 3.75 3.49 
10 3.97 3.97 3.54 3.33 
11 4.35 4.68 3.77 3.63 
12 4.65 4.95 3.53 3.61 
13 5.06 4.77 3.46 3.62 
14 4.70 4.48 3.31 3.51 
15 5.33 5.10 3.84 3.71 
16 5.28 5.40 3.55 3.72 
17 4.70 4.65 3.63 3.58 
18 4.35 4.43 3.20 3.44 
19 5.00 5.05 3.68 3.68 
20 4.93 5.24 3.80 3.77 
21 4.29 4.98 3.45 3.67 
22 5.03 4.63 3.75 3.58 
23 4.58 5.26 3.49 3.76 
24 5.61 5.43 3.88 3.84 
 
In the y-scrambling procedure, the average correlation coefficient (R) values 
obtained for TAMH and HuH-7 were 0.368 and 0.333 respectively. The values 
obtained were low, indicating that the derived regression models did not arise 
by chance. The QSTR model for TAMH gave better predicted LC50 values 
compared to experimental LC50 values than the model for HuH-7 as seen from 
Figure 3-4. Interestingly, both the QSTR models obtained were single-
descriptor (log P(o/w) and FASA_H respectively) models. The high 
correlation coefficients obtained for both models indicate that the toxicity of 
the twenty-four compounds investigated in this study were strongly dependent 
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on the lipophilicity of the compounds, which is consistent and affirms our 
qualitative analysis. It was also observed that the relationship between log 
P(o/w) or FASA_H and log LC50 values is linear in both the QSTR model and 
plots of the two descriptors (Figures 3-5a and 3-5b). 
 
 
Figure 3-4 Predicted −log(LC50) versus experimental −log(LC50) for (a) TAMH 
(R2 = 0.6641) and (b) HuH-7 (R2 = 0.458). TAMH is observed to give better 














































Figure 3-5 (a) Plot of –log(LC50) against log P(o/w) for TAMH. A linear 
relationship was observed with an R2 = 0.9816; (b) Plot of –log(LC50) against 
FASA_H for HuH-7. A linear relationship was observed with an R2 = 0.8331. 
 
3.4. Discussion 
The subtle structural difference between diclofenac and lumiracoxib and the 
dramatic differences in both their pharmacology and toxicity alluded to a 
profound influence of chemical contributors that remains incompletely 
understood.  In this study, we aimed to define a structure-toxicity relationship 
by exploiting the three positions where analogs of diclofenac are often 
investigated. Twenty-four compounds were synthesized; their cytotoxicity 
tested in vitro and a QSTR model was generated to investigate structure-
toxicity relationship of the compounds. In addition, the activity and selectivity 
of the compounds were determined in vitro and a cross-comparison between 



































3.4.1. Comparison of cell lines 
We performed the cytotoxicity assays of the synthesized compounds on two 
cell-lines for two reasons: first, to eliminate cell-line specific phenomena, and 
second, to qualitatively determine the impact of the hosts’ metabolic capacities 
on the onset of toxicity. Two liver cell lines, TAMH and HuH-7 were chosen 
as cell models for the cytotoxicity studies. TAMH is an immortalized murine 
hepatocyte cell line derived from transgenic MT42 male mice. Due to the 
over-expression of TGF-α, TAMH is able to proliferate continuously as a 
stable monolayer culture (Wu et al., 1994). In addition, TAMH is able to 
express adult differentiated hepatocytic markers (Wu et al., 1994), unlike liver 
cancer cell lines. There have been studies which have successfully used 
TAMH as an in vitro model to investigate drug-induced liver toxicity and have 
shown that this cell line expresses considerable levels of CYP2e1 and 
CYP3a11 enzymes, which are homologous to human CYP2E1 and CYP3A4 
respectively (Pierce et al., 2002; Coe et al., 2007). The Phase I P450s of 
interest in this study is CYP2C9 and CYP3A4. The mice orthologs to 
CYP2C9 and CYP3A4 are Cyp2c29 and Cyp3a11 respectively. These 
orthologs have been shown to carry approximately 80% similarity in both 
protein sequence and function (McLaughlin et al., 2008).  
 
HuH-7, a representative liver cell line, is widely used. It is a human hepatoma 
cell line derived from a liver tumor in a Japanese male. Metabolic enzyme 
profiling of HuH-7 has shown that this cell line expresses considerably low 
levels of Phase I and Phase II enzymes as compared to primary hepatocytes 
(Sivertsson et al., 2010; Guo et al., 2011). In addition, the ability of HuH-7 to 
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metabolize P450s specific substrates was shown to be lower as compared to 
primary hepatocytes. Given that this cell line has significantly lower metabolic 
capability, HuH-7 can be used as a comparison to a metabolically active cell 
line to determine the role of metabolism and reactive metabolite formation in 
inducing toxicity. 
 
TAMH was utilized as the liver cell line exhibiting greater metabolic 
capacities. This difference in metabolic capacities was shown in our results 
obtained whereby key enzymatic activities in TAMH are 5 to 6 folds higher 
than in HuH-7 (Figure 3-1). Despite a huge difference in metabolic capacities, 
toxicity of the compounds in TAMH and HuH-7 displayed similar trends. Yet, 
LC50 values are consistently much lower in TAMH than HuH-7 (Figure 3-3). 
It was hypothesized that metabolism to reactive metabolites is one of main 
reasons behind the toxicity induced by 2-phenylaminophenylacetic acid 
derivatives. The lower metabolic capability of HuH-7 reduces the propensity 
of forming reactive metabolites responsible for cytotoxicity. The lower 
metabolic capability of HuH-7 could mean that the amount of metabolic 
enzyme sites present in the cells is lower and thus, the highest rate of 
metabolism in HuH-7 is fixed at a lower level as compared to TAMH at any 
given time. The results suggest a greater susceptibility of TAMH to the 







3.4.2. Effect of substituents on toxicity – relationship with lipophilicity 
The substituents on the three positions on both rings A and B affected the 
lipophilicity of the compounds, with increase in size of alkyl substituents at R1 
and halogen substituents on R2 and R3 leading to an increase in cytotoxicity. 
Increase in toxicity with increase in alkyl substituent size was also observed in 
other studies on substituted anilines and phenols (Schultz et al., 1989; Cronin 
and Schultz, 1996). The Hansch (π) values of alkyl substituents show an 
increase from hydrogen (0.00) to methyl (0.56), ethyl (1.02), n-propyl (1.55), 
iso-propyl (1.53) and finally to tert-butyl (1.98) (Selassie, 2003), indicating an 
increase in lipophilicity of the substituent. Similarly for halogen substituents, 
π values increase from fluorine (0.14) to chlorine (0.71) and to bromine (0.86) 
(Selassie, 2003). iso-Propyl has a slightly lower π value as compared to n-
propyl but the effect of that difference on toxicity can be seen clearly from the 
Hasse diagram. iso-Propyl compounds are ranked lower in toxicity as 
compared to n-propyl compounds (Figure 3-2). Looking more broadly at the 
overall lipophilicity of the compounds, the increase in lipophilicity coupled 
with increase in toxicity is observed in our study as seen from the linear 
relationship between log P(o/w) or FASA_H and log LC50 values (Figures 3-
5a and 3-5b). Both log P(o/w) and FASA_H are molecular descriptors related 
to lipophilicity. However, FASA_H depended on the partial charge and 
conformation of the molecules while log P(o/w) did not take that into account 
during calculation. It was also observed that the gradient of the plot for TAMH 
is steeper than for HuH-7. This could indicate that lipophilicity has a greater 
effect on toxicity of the compounds in TAMH than in HuH-7. From the QSTR 
model, TAMH gave better predicted values as compared to HuH-7 (Figure 3-
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4). This could be due to the better metabolic capabilities of TAMH. HuH-7 is 
less sensitive towards the toxicity induced by the compounds as mentioned in 
section 3.3.3 whereby the difference between the least and most toxic 
compounds in HuH-7 is much lower than in TAMH.  The QSTR model of 
HuH-7 will thus give a less accurate prediction as the experimental values 
used to create the model did not truly reflect the actual toxicity of the 
compounds due to low metabolic capabilities. 
 
Lipophilicity is an important physicochemical property that can affect 
pharmacological and toxicological effects of drugs in many ways. Lipophilic 
compounds are generally metabolized to a larger extent in order to increase 
their hydrophilicity to aid in excretion. The more lipophilic the compound, the 
rate of metabolism of the compound will be higher. For example, studies done 
to investigate the relationship between lipophilicity and metabolism rates 
showed that metabolism rates generally increase with increase in lipophilicity 
for both Phase I and Phase II (Siraki et al., 2005; Smith et al., 2006). This is 
because lipophilic compounds are more likely to interact with Phase I and 
Phase II metabolic enzymes such as cytochrome P450s and UGTs (Little and 
Ryan, 1982; Lewis et al., 1995; Vashishtha et al., 2001). A possible 
consequence of increased metabolism would be the generation of reactive 
metabolites, if such a structural predisposition exists for the given compound. 
Independent groups found that log P(o/w) was an important descriptor in the 
QSAR models generated from data obtained from in vitro cell assays for 
halogenated benzene ring series and observed that an increase in log P(o/w) 
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lead to increased cytotoxicity (Fratello et al., 1997; Chan et al., 2007). This 
trend was similarly observed in our study.  
 
More lipophilic compounds may have greater binding affinities or higher 
abilities to disrupt cellular sites, thus causing a direct toxic effect. Absorption 
also plays a part in effecting toxicity as the compound needs to be absorbed by 
the cells to exert any toxic effects or to be metabolized. It is interesting to note 
that while the relationship between toxicity and log P(o/w) values usually 
follows a bell-shaped trend, we observed a linear proportionality between the 
two parameters. In situations where cell permeation is a limiting factor for 
drug accumulation, lipophilicity can alter the extent of toxicity in significant 
ways.  In an in vitro cell setting, permeability is chiefly represented by 
compounds diffusing through the lipid bilayer of the cell membrane. 
Compounds of greater lipophilicity can diffuse through the lipid bilayer more 
easily as compared to compounds of lower lipophilicity. The log P(o/w) values 
of the compounds tested range from 3.5 to 6.3. Presumably, compounds with 
log P(o/w) values closer to the upper range will be able to cross the lipid 
bilayer of the cells more easily as compared with those at the lower range. 
This causes greater accumulation of compounds in the cells, which will 
increase the magnitude of toxicity induced by the compounds. It is anticipated 
that at even higher log P(o/w) values, we may be able to observe a trend 
reversal where solubility and the sequestration of the drugs within the 
membrane will limit toxicity, hence re-establishing a bell-shaped relationship. 
Alternatively, it is possible that the proportional increase in toxicity with 
lipophilicity could be due to a direct toxicant effect. The toxicity caused by the 
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compounds could be a physical association with off-target cellular sites such 
as receptors, disruption of cellular sites such as the cell membrane or 
accumulation within the cells.  
 
3.4.3. Halogen substituents and their role in drug design 
Compounds with fluorine substituents at R2 and R3 were observed to be the 
least toxic among the series of compounds in this study. Using the Hasse 
diagram (Figure 3-2), it was shown that fluorine has the greatest effect on 
toxicity, namely its ability to decrease toxicity. Not surprisingly, fluorinated 
drugs (57%) form a huge proportion of drugs approved by the U.S. Food and 
Drug administration (FDA) as compared to chlorinated (38%) or brominated 
drugs (4%) (Hernandes et al., 2010). The high proportion of fluorinated drugs 
may underscore their contribution to better efficacy and absorption, or lowered 
toxicities as exemplified by the relationship between the halogen groups and 
toxicity seen in this study. Fluorinated compounds are generally metabolically 
more stable than the larger sized halogens. Prior studies suggested that 
fluorine substitution can block metabolic sites or decrease the susceptibility of 
neighboring moieties to cytochrome P450 enzyme metabolism, which in turn 
could lead to reduced formation of reactive metabolites (Park et al., 2001). It 
was found that introduction of fluorine substitutions into the aromatic ring of 
paracetamol increased the oxidative potential of the parent molecule and 
subsequently decreased the chances of the metabolite being oxidized to a 
cytotoxic quinone imine (Barnard et al., 1993). Another classic example of 
fluorine improving metabolic stability is the addition of a fluorine at the 4-
position of the aminophenol ring to block the metabolic site of amodiaquine, 
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which resulted in the abolishment of bioactivation with said compound (Oneill 
et al., 1994). 
 
The low proportion of brominated drugs could be due to the common 
occurrence of elevated toxicity. Brominated compounds were often 
susceptible to P450-mediated metabolism. Several studies have shown that 
aromatic compounds carrying bromine substitution were metabolized into 
reactive species and these were proposed as the mechanisms involved in their 
toxicities (Monks et al., 1982; McDonald and Rettie, 2007). For example, the 
hepatotoxicity of benzbromarone was linked to the formation of reactive 
species via metabolic hydroxylation to catechols (McDonald and Rettie, 2007). 
Anecdotally, the usage of several brominated drugs such as zimelidine, 
bromfenac and benzbromarone were curtailed (United-Nations, 2005b; 
United-Nations, 2005a), thus causing this substituent to be flagged out as a 
potential toxicophoric group (Nelson, 2001). Mechanistically, this tendency 
could also have arisen from an intrinsic chemical inactivity due to a shorter 
and stronger C-F bond as compared to either C-Cl or C-Br. In addition, Cl- and 
Br- are weaker bases than F-, which make chlorine and bromine better leaving 
groups as compared to fluorine. Defluorination is thus much less likely to 
occur than dechlorination and debromination. The relationship reflected in this 
study is also consistent with several structure-toxicity relationship 
investigations of halogenated compounds in different biological systems 
(Schultz et al., 1989; Cronin and Schultz, 1996; Fratello et al., 1997; Warne et 
al., 1999; Chan et al., 2007). For example, in a study on the toxicity of 
substituted phenols, it was found that fluoro-substitution generally had the 
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lowest toxicity and bromo-substitution had the highest toxicity (Cronin and 
Schultz, 1996). However, it is important to note that the effect of halogen 
substitution and toxicity is dependent on the overall molecular structure and 
the substitution positions. Yet, it is interesting to note that in some studies 
such as structure-toxicity relationships of (bis)aziridinyl-benzoquinones (Prins 
et al., 1994) and paracetamol analogs (Bessems et al., 1995), the reverse was 
observed whereby fluoro-substituted compounds are the most toxic. Hence, 
the exact influence of halogens to toxicity must be contextualized and 
investigated separately in the light of different chemical scaffolds being used 
for drug design.  
 
3.5. Conclusion 
In summary, from the cytotoxicity profile of the synthesized twenty-four 2-
phenylaminophenylacetic acid compounds, metabolism could be postulated as 
an important factor in the toxic effects of the compounds. These compounds 
were subjected to cytotoxicity studies using MTT assay to determine their 
cytotoxicity on liver cells. Two liver cell lines, TAMH and HuH-7, were used 
as a comparison to determine the role of metabolism in the toxicity induced by 
the compounds. Metabolic enzyme activities were determined for both cell 
lines and TAMH was shown to be the more metabolically competent one. 
From experimental results, it was shown that metabolism could be an 
important factor in the toxic effects of the compounds as the toxic effects were 
more prominent in TAMH as compared to HuH-7. However, metabolism to 
reactive metabolites cannot be attributed as the sole cause as direct toxicant 
effects of the compounds could also be a contributor. Further studies are 
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required to determine whether metabolism or direct toxicant effects is the 
more important contributor to the toxicity induced by the compounds. 
 
Substituents on both phenyl rings are crucial in affecting the toxicity of the 
compounds. As seen from the results obtained, increasing the alkyl group size 
at R1 resulted in an increase in toxicity (indicated by a decrease in LC50 
values). Increasing the halogen group size at R2 and R3 increased the toxicity. 
Taken together, difluoro-substituted compounds are the least toxic while 
dibromo-substituted compounds are the most toxic. The contribution of the 
changes in substituents to toxicity could be an increase in lipophilic properties 
of the parent compounds. A QSTR model generated with experimental data 
clearly showed a linear relationship between lipophilicity and toxicity. 




Chapter 4. Inhibitory Effects of Synthesized Compounds on COX 




Diclofenac and lumiracoxib are NSAIDs that inhibit the prostaglandin 
synthesis in COX enzymes. Diclofenac is a non-selective COX inhibitor. On 
the other hand, lumiracoxib is selective towards COX-2. The twenty-four 
compounds synthesized vary in their alkyl and halogen substituents where 
many of which were not previously investigated for pharmacological activity. 
These include those with alkyl groups such as n-propyl, iso-propyl and tert-
butyl and bromine. Thus, we would like to investigate the potency and the 
selectivity towards COX-2, and how the pharmacophore may differ from the 
toxicophore. 
 
In order to investigate the potency of the compounds, a cell-based assay 
involving two cell lines that expresses either exclusively COX-1 or COX-2 
was used. Enzyme-linked immunosorbent assay (ELISA) was carried out to 
detect the eicosanoids produced by the cells as a surrogate for COX activities. 
In the previous chapter, we have evaluated the toxicity of the compounds in 
liver cell lines. A safety profile was then generated using the toxicity and 
pharmacological data obtained in order to determine the relationship between 





4.2. Experimental methods 
COX-1 antibody, rabbit polyclonal IgG and COX-2 antibody, rabbit 
polyclonal IgG were purchased from Santa Cruz Biotechnology (Dallas, TX). 
β-actin antibody, mouse monoclonal IgG was purchased from Abcam 
(Cambridge, UK). Bicinchoninic acid (BCA) Protein Assay Kit and 
SuperSignal West Chemiluminescent Substrate were purchased from Thermo 
Scientific Pierce (Waltham, MA). Thromboxane-B2 (TXB2) and 
prostaglandin-E2 (PGE2) ELISA kits were purchased from Cayman Chemical 
Company (Ann Arbor, MI). All other chemicals and reagents were obtained 
from Sigma Aldrich (St. Louis, MO) unless otherwise mentioned. 
 
4.2.1. Cell culture 
All cultures were maintained in a humidified incubator with 5% carbon 
dioxide at 37°C unless otherwise stated. COX-1 expressing HEL92.1.7 cells 
and COX-2 inducible RAW264.7 were obtained from ATCC (Manassas, VA). 
HEL92.1.7 cells were grown in Roswell Park Memorial Institute Medium 
1640 (RPMI 1640) supplemented with 10% FBS, 2 mM glutamine and 1 mM 
sodium pyruvate. Cells were maintained between 1 x 105 and 1 x 106 cells/mL. 
RAW264.7 cells were grown in DMEM supplemented with 10% FBS, 2 mM 
glutamine and 1 mM sodium pyruvate. Cells were passaged at 80-90% 







4.2.2. Western blot to determine expression of COX enzymes in cell lines 
4.2.2.1. Cell harvesting and lysis 
Five million RAW264.7 cells were seeded onto petri dishes and incubated at 
37˚C, 5% CO2 for 24 h. Following which, the culture medium was aspirated 
from each petri dish and replaced with 10 mL medium containing 500 ng/mL 
or no lipopolysaccharides (LPS) respectively. The cells were incubated at 
37˚C, 5% CO2 for 20 h. Likewise, 5 x 106 HEL92.1.7 cells were seeded onto 
petri dishes and incubated at 37˚C, 5% CO2 for 24 h. The cells were harvested 
and washed with cold 1X PBS, centrifuged at 5000 rpm for 1 min and the 
supernatant removed. 80 μL of complete cell lysis buffer was added to each 
cell pellet and incubated in ice for 30 min. The lysates were centrifuged at 
4°C, 13,000 rpm for 20 min. The supernatant was collected and protein 
concentration of each supernatant was determined using BCA Protein Assay 
Kit. Readouts of sample absorbance in the assay were measured at 560nm by a 
Tecan M200 Pro plate reader (Männedorf, Switzerland). 
 
4.2.2.2. SDS-PAGE and Transfer  
6X Laemmli SDS protein sample buffer (Appendix 4-1) with 6% beta-
mercaptoethanol was added to each sample to achieve a final concentration of 
1X Laemmli SDS protein sample buffer. Samples were then vortexed and 
heated at 95°C for 15 min. Samples were subjected to electrophoresis on 5% 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
stacking and 10% SDS-PAGE resolving gels for 3 h at 60V. Proteins were 
transferred from gels onto nitrocellulose membranes by electroblotting at 40V 
and 4°C overnight. 
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4.2.2.3. Detection  
Membranes were blocked with 5% milk in 1X phosphate buffered saline 
Tween-20 (PBS-T) (Appendix 4-1) for 1 h at room temperature. The 
membranes were incubated in their respective primary antibodies diluted in 10 
mL of 5% milk overnight at 4°C. The membranes were then washed with 1X 
PBS-T and were subsequently incubated in their respective secondary 
antibodies diluted in 10 mL of 5% milk at room temperature for 1 h. The 
membranes were washed with 1X PBS-T, incubated in SuperSignal West 
Chemiluminescent Substrate and exposed to film in a dark room for 
development. 
 
4.2.3. Cell-based COX-1 inhibition assay 
The assay was carried out as reported elsewhere (Berg et al., 1997). Briefly, 
HEL92.1.7 cells were seeded at 1 × 105 cells/ well in a 96-well plate. Test 
compounds were dissolved in DMSO and the final DMSO concentration was 
0.5% in medium. The cells were incubated for 30 min at 37°C, 5% CO2 with 
varying concentrations of test compounds. Arachidonic acid was added to a 
final concentration of 30 μM and further incubated for 15 min at 37°C, 5% 
CO2. The reaction was stopped by centrifugation (4000 rpm) for 5 min at 4°C. 
The levels of TXB2 were measured using the ELISA method. 
 
4.2.4. Cell-based COX-2 inhibition assay 
RAW264.7 cells were seeded at a density of 1 × 105 cells/ well a 96-well plate 
and incubated at 37˚C, 5% CO2 for 24 h. The culture medium from each well 
was then aspirated and replaced with 200 μL of medium containing 500 
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ng/mL LPS. The cells were incubated at 37˚C, 5% CO2 for a further 20 h. 
Thereafter, the assaying procedures are similar to the COX-1 inhibition assay. 
The levels of PGE2 were measured using the ELISA method. 
 
4.2.5. In silico docking of compounds to crystallized COX-isoforms 
AutoDock Vina version 1.1.2 (Trott and Olson, 2010) was used to conduct the 
docking of the compounds into the respective ligand sites of the Protein Data 
Bank (PDB) structures 1HT8 (COX-1) and 1PXX (COX-2). 
 
For the COX-1 docking, the PDB structure 1HT8 (Chain A) was protonated 
using the Protonate3D module of the Molecular Operating Environment 
(MOE) version 2008.10.  Thereafter, the coordinates of the geometric center 
of the co-crystalized ligand acclofenac was determined using MOE. This 
served as the center of the docking box in AutoDock Vina version 1.1.2. The 
box was defined by the space within 22 Å in the x-y-z directions from the 
previously mentioned center. After the docking was completed, the docking 
scores for each compound were sorted and the best-scoring pose was taken as 
the putative pose for the compound. The spatial orientation of the docked pose 
was then compared visually to that of the co-crystallized ligand in order to 
appreciate any similarities in the interactions with the binding pocket. 
 
The PDB structure 1PXX (Chain A) was used for the COX-2 docking. The 
protein structure was similarly protonated as previously mentioned. The 
coordinates of the geometric center of the co-crystallized ligand diclofenac 
was also determined using MOE. However, the docking box was defined by 
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the space within 20 Å in the x-y-z directions from the geometric center. 
AutoDock Vina was also used for the docking of the compounds into COX-2 
protein. The best-scoring pose of each compound was also taken as the 
putative pose in COX-2. Visual inspection against the co-crystallized ligand 
was also conducted for the docked poses. 
 
4.3. Results 











Figure 4-1 Western blot of HEL92.1.7 and RAW264.7. HEL92.1.7 was 
shown to express only COX-1 and RAW264.7 was shown to only express 
COX-2 when induced with LPS. 
 
In literature, HEL92.1.7 was shown to only express COX-1 constitutively and 
RAW264.7 was shown to only express COX-2 when induced with LPS (Berg 
et al., 1997; Patel et al., 1999). As seen from Figure 4-1, HEL92.1.7 cells were 
shown to only express COX-1 under normal conditions. RAW264.7 cells did 
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with LPS, RAW264.7 was shown to express only COX-2. Therefore, we have 
confirmed and optimized the conditions needed to utilize these cells 
effectively for the determination of cell-based COX-1 and COX-2 activities. 
 
4.3.2. Activity and selectivity of synthesized compounds 
Cell-based COX inhibition assay was used to determine the inhibitory effects 
of the compounds on the two enzyme isoforms. From Table 4-1, it can be 
observed that adding an alkyl group at R1 seemed to have a negative effect on 
the inhibition potency of the compounds. In general, the larger the alkyl group, 
the higher the IC50 vales of the compounds in COX-2. For COX-1, the effect 

















Table 4-1 COX median inhibitory concentrations (IC50), selectivity index and 








Compound R1 R2 R3 







1 H  F  Cl  222.2 34.2 6.5 6804 
2 H  F  F  3311 152.1 21.8 3373 
3 (Diclofenac) H  Cl  Cl  2.279 10.4 0.2 9058 
4 H  Br  Br  9558a 247.8 38.6 148 
5 (Lumiracoxib) Me  F  Cl  2034 46.1 44.1 2410 
6 Me  F  F  5172a 432.5 12.0 749 
7 Me  Cl  Cl  1364 177.9 7.7 274 
8 Me Br  Br  7414a 2214 3.4 7 
9 Et  F  Cl  1945 220.5 8.8 212 
10 Et  F  F  13720a 635.5 21.6 168 
11 Et  Cl  Cl  91.4 36.8 2.5 573 
12 Et  Br  Br  469.8 149.8 3.1 75 
13 n-Pr  F  Cl  439.2 238.5 1.8 71 
14 n-Pr  F  F  324.9 36860b 0.01 1 
15 n-Pr  Cl  Cl  443.7 5041 0.1 2 
16 n-Pr  Br  Br  1980 4171 0.5 1 
17 i-Pr  F  Cl  1963 2581 0.8 9 
18 i-Pr F  F  815 16290a 0.1 2 
19 i-Pr Cl  Cl  643.4 329.9 2.0 27 
20 i-Pr Br  Br  1234 1056 1.2 5 
21 t-Bu  F  Cl  336 3473 0.1 3 
22 t-Bu F  F  148.5 15850 0.01 1 
23 t-Bu Cl  Cl  1495 542.2 2.8 10 
24 t-Bu Br  Br  3002 1863 1.6 2 
a Each IC50 value was generated from dose response curve using three 
technical replicates.  
b IC50 value extrapolated from dose response curve using Graphpad Prism 5. 
c Selectivity Index calculated by ratio of IC50 value of COX-1 to IC50 value of 
COX-2 for each compound. 
d Safety Index is calculated by toxicity/activity ratio using LC50 of TAMH and 









Figure 4-2 Comparison plots for IC50 values for COX-1 and COX-2 obtained 
from cell-based COX inhibition assays for (a) F-Cl series; (b) F-F series; (c) 
Cl-Cl series and (d) Br-Br series. 
 
Comparing each halogen series, some observations can be made. For the F-Cl 
series (Figure 4-2a), IC50 values were observed to increase when alkyl chain 



























































R1 (for example, a methyl group) was much more pronounced in COX-1 
(approximately 10 times increment) than in COX-2 (approximately 1.3 times 
increment) as seen from Table 4-1. For the F-F series (Figure 4-2b), IC50 for 
COX-1 inhibition increased initially followed by a decrement with increase in 
alkyl chain. A more consistent trend was observed for COX-2, whereby 
increases in alkyl chain size increased the IC50 values. For the Cl-Cl series 
(Figure 4-2c), a dramatic increase in IC50 values for both COX isoforms was 
observed with increase in alkyl chain size. The only exception was compound 
11 whereby a decrease in IC50 values was observed for both COX isoforms as 
compared to other alkyl chain lengths. For Br-Br series (Figure 4-2d), increase 
in alkyl chain size overall decreased IC50 values for COX-1 while an increase 
in IC50 values was observed for COX-2. The ethyl substituted compound 12 
(COX-1: 469.8 nM and COX-2: 149.8 nM) was observed to be the most 
potent among the Br-Br series. Overall, we observed that the potency of these 
series was very poor as compared to diclofenac or lumiracoxib. 
 
Besides the influence of alkyl substitution to the COX inhibiting 
pharmacophore, the halogen substituents had profound effect on the activity 
too. It was observed that chlorine substituent at R2 or R3 improved the 
inhibitory effects of the compounds in both COX enzymes. Having at least 
one chlorine substituent on ring B gave better inhibitory effects on both COX 
isoforms. Cl-Cl compounds in general possess the highest inhibitory effect in 
each alkyl series. Fluorine and bromine substituents dramatically decrease the 
inhibitory effect of the compounds on both COX isoforms. It was noted that 
replacement of a fluorine substituent with a chlorine substituent improved the 
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inhibitory effects as seen from hydrogen series compounds 1 and 3 and ethyl 
series compounds 9 and 11 (Table 4-1). In terms of absolute inhibitory effect, 
diclofenac (3) is the most potent compound out of all the synthesized 
compounds for both COX isoforms and our reported IC50 is consistent with 
literature findings (Moser et al., 1990; Blobaum and Marnett, 2007).  
 
Selectivity was calculated based on the ratio of the activities of the compounds 
in COX-1 to that in COX-2. A selectivity ratio of 6.5 (Table 4-1, compound 1) 
indicates the compound is 6.5 times more selective towards COX-2 than 
COX-1. From Table 4-1, lumiracoxib (5) was the most selective towards 
COX-2 as compared to other compounds. Adding an alkyl substituent at R1 
did not improve selectivity towards COX-2 by much except in the case of 
lumiracoxib. For most of the compounds, the improvement in selectivity was 
only marginal and in some cases, no selectivity was observed. Thus, improved 
selectivity may arise from the optimal combination of substituents at all three 
pharmacophoric positions. 
 
Table 4-2 Comparison of potency ranking of compounds with literature data. 
Ranking COX-1 (Compounds) COX-2 (Compounds) Our study Literature Our study Literature 
Most potent 1a 7 1 7 
 7c 1 5 5 
Least potent 5b 5 7 1 
a Literature values of compound 1 IC50: 30% inhibition at 4 µM (COX-1) and 
25% inhibition at 4 µM (COX-2). 
b Literature values of compound 5 IC50: < 20% inhibition at 4 µM (COX-1) 
and 107 nM (COX-2). 
c Literature values of compound 7 IC50: 40% inhibition at 4 µM (COX-1) and 




Comparisons between literature findings and our data revealed some 
discrepancies (Table 4-2). Compounds 1, 5 and 7 were reported in literature 
and were tested for both COX-1 and COX-2. Against COX-2, our data showed 
that Compound 1 (34.2 nM) was the most potent compound of the F-Cl series, 
followed by compound 5 (46.1 nM). Our data also showed that compound 5 
was more potent than compound 7 (177.9nM). In contrast, literature data 
showed that compound 5 was more potent than compound 1. Also, compound 
7 was shown to be superior to compound 5 (Blobaum and Marnett, 2007). In 
COX-1, our results showed that compound 1 was more potent than both 
compounds 5 and 7. In literature, it was shown that compound 7 was more 
potent than both compounds 5 and 1 in COX-1 (Blobaum and Marnett, 2007). 
 
A safety index was calculated by dividing the LC50 of the compound in 
TAMH by the IC50 of the compound for COX-2. The safety index indicated 
that diclofenac (3) is the compound with the highest activity and least toxic 
effects. Interestingly, lumiracoxib (5), which has been withdrawn from the 
market, has a safety index that is approximately 3.8 times lower than 
diclofenac (3). The non-alkylated compounds 1, 2 and 3 with the exception of 
compounds 4 were observed to give the highest safety indices. Compounds 
with ethyl, n-propyl, iso-propyl or tert-butyl substituents at R1 have very low 
safety indices. It would seem that inclusion of an alkyl substituent on R1 added 
some selectivity but decreased the safety index as shown in Table 4-1. 
Compounds with bromine or fluorine at both R1 and R2 also exhibited low 
safety indices. It can be concluded that both alkyl substituent at R1 and 
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halogen substituents at R2 and R3 exert significant impact on the safety of the 
compounds. 
 
4.3.3. In silico docking scores 
Docking was carried out to determine the affinity of each compound to each of 
the two COX isoforms. Crystallized COX-1 bound to an acclofenac ligand and 
crystallized COX-2 bound to diclofenac were used for the docking studies. 
The results obtained are summarized in Table 4-3. Docking score is an 
arbitrary parameter generated by the model where a more negative score 
indicates greater affinity to the enzyme. It was observed that the compounds in 
general have higher affinities to COX-2 as compared to COX-1, especially 
compounds with alkyl substituents at R1. While there was general agreement 
between the in silico and in vitro data, there were some contradiction between 
our experimental data and docking scores. Specifically, this occurred with 
compounds with propyl and butyl substituents at R1. For example, 15 – 18, 21 
and 22 were observed to have lower IC50 values for COX-1 but were shown to 











Table 4-3 In silico docking scores for the synthesized twenty-four compounds. 
Compound Docking Scores (Affinity) 
COX-1 COX-2 
1 -8.0 -8.4 
2 -8.0 -8.3 
3 (Diclofenac) -7.4 -8.5 
4 -7.4 -8.2 
5 (Lumiracoxib) -8.2 -8.7 
6 -8.3 -8.8 
7 -8.2 -8.6 
8 -7.3 -8.1 
9 -7.6 -8.6 
10 -8.7 -8.5 
11 -7.8 -8.4 
12 -7.1 -8.1 
13 -8.3 -8.9 
14 -8.0 -9 
15 -7.8 -8.5 
16 -7.1 -7.9 
17 -8.5 -9.1 
18 -8.3 -9.0 
19 -8.0 -8.8 
20 -7.4 -7.8 
21 -7.3 -8.8 
22 -7.5 -9.1 
23 -6.9 -8.3 
24 -6.4 -8.2 
 
The docking poses of diclofenac in both crystallized COX isoforms showed 
that the carboxylic acid moiety on ring A interacts with Try-385 and Ser-530. 
We also observed that the chlorine substituent on the compounds shown in 
Figures 4-3 and 4-4 interacts with four amino acid residues, Ala-527, Ser-530, 
Val-349 and Leu-531 in COX-1 (Figure 4-3) and two amino acid residues Ser-





Figure 4-3 Docking pose of diclofenac (orange, top) and compound 7 (orange, 





Figure 4-4 Docking pose of diclofenac (orange, left) and compound 7 (orange, 









4.3.4. Lipophilicity and effect on inhibitory potency of the compounds 
 
Figure 4-5 Plot of Log IC50 (nM) against log P(o/w) of the compounds for 
COX-1 (blue) and COX-2 (red) for compound series (a) F-Cl; (b) F-F; (c) Cl-
Cl and (d) Br-Br. 
 
In Chapter 3, we observed that lipophilicity and toxicity had a positive 
relationship. Thus, there was interest to evaluate the influence of lipophilicity 
on the pharmacological activity. We compared the log P(o/w) of the 
compounds to their COX IC50 values for each of the halogen series. From 
Figure 4-5, it was observed that lipophilicity played a role in the inhibitory 
effect of the compounds for COX-2. As whole cell assay was carried, the 
penetration of the compounds into the cells will be affected by the size and 
lipophilicity of the compounds. In this instance, lipophilicity of the 
compounds were measured in terms of log P(o/w). It can be observed that for 





































































series. For the F-Cl series, the increase in log P(o/w) across the compounds 
had little effect on IC50 values. On the other hand, F-F and Br-Br series 
showed an opposite trend whereby increase in log P(o/w) decreased IC50 
values and improved inhibitory effects of the compounds. The F-F and Cl-Cl 
series were observed to give more linear relationships between lipophilicity 
and inhibitory effect. 
 
As observed from Figure 4-5, a much more consistent trend was observed 
between lipophilicity and COX-2, especially for F-Cl and Cl-Cl compounds. 
For all the series, a consistent increase in IC50 values was observed with 
increase in log P(o/w) values of the compounds. A more linear relationship 
was observed for F-Cl and F-F series as seen from Figures 4-5a and 4-5b (R2 = 
0.8401 and 0.7909 respectively). The Br-Br series gave the least linear 
relationship between inhibitory effect and lipophilicity as seen from Figure 4-
5d (R2 = 0.2689). This indicated that the correlation between lipophilicity and 
COX-2 inhibitory activities is weak for Cl-Cl and Br-Br compounds. 
 
4.4. Discussion 
4.4.1. Effect of substituents on inhibitory effect and safety of the compounds 
The pharmacological properties of the compounds were evaluated using a cell-
based assay. A cell-based assay was chosen over conventional enzyme-based 
assays as whole cells will mimic an environment where absorption and 
intracellular metabolism occur. The substituents on R1, R2 and R3 were shown 
to affect the selectivity and activity of the synthesized compounds in this study 
as mentioned earlier in section 4.3.2. This is in line with literature whereby it 
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was found that the methyl group at R1 was postulated to give rise to the 
selectivity of the lumiracoxib towards COX-2 (Blobaum and Marnett, 2007). 
It was hypothesized that an amino acid residue, Leu-384 in the COX isoforms 
determines the selectivity of lumiracoxib. COX-2 possesses a more flexible 
Leu-384 due to less steric hindrance between the amino acid residues as 
compared to COX-1 which allows the methyl group to insert into the small 
groove created by movement of Leu-384. Our study gave an insight into the 
possibility of larger alkyl chain lengths to selectively inhibit COX-2.  
However, with that said, the most selective compound seen in this study was 
lumiracoxib (Selectivity Index of 44.1). As the alkyl group size at R1 increased, 
selectivity was seen to decrease. This could be a restriction on the size on the 
groove created by movement of Leu-384. It was observed that any alkyl group 
size bigger than an ethyl group (n-propyl, iso-propyl and tert-butyl) was 
detrimental to the selectivity towards COX-2.  
 
Compounds that contain at least one chlorine substituent on ring B in general 
were more potent in the series as compared to other halogen substituents. Both 
COX isoforms have a hydrophobic pocket made up by four amino acid 
residues; Ala-527, Val-349, Ser-530 and Leu-531. It was postulated in 
literature that the substituents on ring B make important binding interactions 
with this hydrophobic pocket and is crucial in the interaction between 
compound and enzyme (Blobaum and Marnett, 2007). Chlorine was found to 
be the best substituent to interact with this hydrophobic pocket via halogen 
bonds. Fluorine is unable to make halogen bonds which disallow it to form 
any substantial interactions with the hydrophobic pocket (Wilcken et al., 
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2013). Although bromine is able to form stronger halogen bonds as compared 
to chlorine, it may be too big in size to fit into this hydrophobic pocket.  
 
In addition to interaction with the hydrophobic pocket in COX, the angle of 
twist between the two phenyl rings can affect the potency of the compounds. It 
was reported that the substituent at R2 and R3 affected the angle of twist 
between the two phenyl rings of the compound and larger substituents 
contributed to a larger angle of twist, which in turn increased the activity 
(Moser et al., 1990). Moser et al. also indicated that compounds with 
increasing substituent size at R2 and R3 (F-F < Cl-F < Cl-Cl < Cl-Br < Cl-I) 
improved the potency of the compounds. Given that Cl-Br compound gave 
better potency than the Cl-Cl compound, we expected the Br-Br compound in 
our series to have improved potency. However, this was not the case with Br-
Br compounds often having lower potency on the COX isoforms. Chlorine is 
perhaps the best sized substituent to constrain the angle of twist to achieve an 
optimum spatial relationship between the two rings for interaction with the 
active site and at least one is needed for potency.  The fluorine and bromine 
may be too small or too large respectively to exert the correct angle of twist 
between the two phenyl rings. In addition, the need for at least one chlorine 
substituent to be present could be due to the important interaction with the 
hydrophobic pocket in the COX enzymes as mentioned in the previous 
paragraph. It was also reported in literature that potency also arises from the 
carboxylate group on diclofenac interacting with amino acid residues Ser-530 
and Tyr-385 via hydrogen bonding at the top of the active site of both COX 
isoforms (Rowlinson et al., 2003). The angle of twist of the two phenyl rings 
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could be necessary to rotate the carboxylate group on ring A to the right 
conformation to interact with Ser-530 and Try-385. In addition, interaction of 
chlorine with the hydrophobic pocket mentioned could also be crucial to 
anchor down the molecule to the right conformation for optimal interactions of 
the carboxylate group to interact with the two amino acid residues.  
 
The inhibitory effect of the compounds with alkyl substituents at R1 (5 – 24) 
are lower than of the compounds without substituents at R1 (1 – 4) in both 
COX isoforms. It was reported in literature that inclusion of the methyl group 
at R1 in lumiracoxib decreased the potency of the compound in COX-2 
(Blobaum and Marnett, 2007). From our docking results, we observed that the 
addition of an alkyl substituent at R1 improved affinity of the compound 
towards COX-2 as compared to COX-1. This indicates that the compounds 
should in general be more potent towards COX-2 than COX-1 and thus be 
selective. However, the docking results showed some contradictions, 
particularly for compounds with propyl and butyl substituents at R1 in terms of 
selectivity. It should be noted that the activity assay used in this study was a 
cell-based assay while docking is a direct compound-enzyme interaction. Cell-
based assays involve other factors such cell penetration, possibility of 
metabolism and effect on cell viability by the compounds which could affect 
the activity of the compound towards the COX enzymes. Taking diclofenac (3) 
as an example, in a cell-based assay, diclofenac was shown to be more active 
towards COX-1 (0.6 nM) than COX-2 (20 nM) (Berg et al., 1997). However, 
in an enzyme-based assay, the reverse was observed whereby diclofenac is 
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more active towards COX-2 (28 nM) than COX-1 (67 nM) (Blobaum and 
Marnett, 2007). 
 
The interactions with the hydrophobic pocket and two amino acid residues at 
the top of the active site and angle of twist between the two phenyl rings of the 
compound could be essential in determining the potency of the compound. 
Adding an alkyl group to R1 could essentially change the conformation of the 
compound in the COX active site from an optimal conformation that gives the 
highest binding interaction to one that is less optimal, thus decreasing the 
potency of the compound. As seen from Figures 4-3 and 4-4, the docking pose 
of diclofenac and compound 7 showed the interaction between the chlorine 
substituent on ring B with the hydrophobic pocket consisting of Ala-527, Val-
349, Ser-530 and Leu-531. Also, it can be seen from both figures that the 
carboxylate group of the two compounds interacted with the two amino acid 
residues Ser-530 and Tyr-385 at the top of the active site. However, not all of 
the compounds conform to this binding confirmation. Several compounds 
have very different docking poses (Appendix 4-2), which could be due to the 
inflexibility of the crystallized protein structure or the inability of the 
compounds to conform to the binding conformation of diclofenac due to size 
issues. This could have affected the docking scores and gave rise to 
experimental-in silico contradictions.  
 
We mentioned previously that with increase in alkyl chain length, we noted a 
decrease in potency. The exception was compound 11 and 12 whereby the 
increase of the alkyl chain size at R1 from methyl to ethyl improved the 
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potency of the compounds in both COX isoforms. The improvement in 
potency with the presence of an ethyl group at R1 towards COX-2 inhibitory 
potency could be due to the further insertion of the longer ethyl group into the 
small pocket exposed by the movement of Leu-384. For COX-1, it could 
simply be due to a larger molecule being fit into the active size. The 
conformation of the molecule could have changed by further pushing the 
chlorine or bromine substituent on ring B closer to the hydrophobic pocket 
consisting of Ala-527, Val-349, Ser-530 and Leu-531. The carboxylate group 
on ring A could also be pushed closer to Ser-530 and Tyr-385. The increased 
proximity could translate to stronger halogen or hydrogen bonding to the 
amino acid residues, which increases the inhibitory potency of compounds 11 
and 12 over compounds 7 and 8. 
 
While some of our findings may not entirely agree with literature findings for 
a few of the similar compounds, this discrepancy could be due to the 
differences in experimental methods used. Literature findings were based on a 
purified enzyme inhibitory assay using purified COX-1 and COX-2 enzymes. 
On the other hand, we carried out a whole cell assay using cell-lines that 
expresses one isoform of COX. Additional factors such as cell permeation and 
cell metabolism can come into play. Thus, differences in the inhibitory effects 
of the compounds can be expected due to methodology differences. We 
reasoned that using a cell-based assay over an enzyme-based assay could 
factor in the effect of cell permeation and metabolism to obtain more broad 




A safety index was calculated using the ratio of LC50 values in TAMH to the 
IC50 values of COX-2 inhibition assay. Diclofenac (compound 3) possesses 
the highest safety index out of the twenty-four compounds. It is interesting to 
note that the other non-alkylated compounds 1 and 2 also possess high safety 
indices than alkylated compounds. The exception is compound 4, a di-
brominated analog. The safety index is affected by both changes in IC50 and 
LC50 values. The decrease of the safety indices of the compound across the 
series was due to a significant decrease in LC50 values due to elevated toxicity 
(Chapter 3) and a notable increase in IC50 values due to reduced potency. The 
ethyl substituent was shown to be favorable towards compound potency for 
compounds 11 and 12 previously. However, compounds 11 and 12 have rather 
low LC50 values (Chapter 3), which indicates that they are rather toxic in 
nature. Thus, even though they exhibit good inhibition potency towards COX-
2, their toxicity negates all beneficial potency effects which resulted in low 
safety indices. On the other hand, F-F compounds general have low toxicity as 
seen from their high LC50 values (Chapter 3). However, the low potency of F-
F compounds negates any beneficial effect of their low toxicity, resulting in 
their low safety indices. It can be concluded that increasing the size of the 
compound either via addition of alkyl groups on R1 or swapping out smaller 
halogens for larger ones at R2 and R3 (fluorine to chlorine to bromine) can 
adversely affect the safety of the compounds in vitro. 
 
It is interesting to note that in terms of absolute toxicity, diclofenac (3) is 
shown to be slightly more toxic than lumiracoxib (5) (Chapter 3, Table 3-1). 
This is surprising considering that lumiracoxib was withdrawn from the 
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market but diclofenac is still widely available. However, taking into account 
the dose required to achieve the desired pharmacological activity and the 
safety index calculated for both drugs, lumiracoxib was demonstrated to be 
less safe than diclofenac. From our findings, diclofenac is only 1.2 times more 
toxic than lumiracoxib but is 4.4 times more active to achieve the intended 
COX inhibition. Clinically, lumiracoxib was dosed at high dosages (100 mg to 
400 mg) in one sitting while diclofenac is usually dosed at lower dosages (50 
mg to 100 mg) two to three times a day or with an extended release 
formulation (Bannwarth and Berenbaum, 2007; Gan, 2010). This heightened 
exposure could have been a contributing factor to lumiracoxib’s severe 
toxicity observed in patients (Stepan et al., 2011).  
 
4.4.2. Lipophilicity and its effect on inhibitory potency 
It was reported previously that the penetration of the cell membrane by 
NSAIDs plays a significant role in their activity (Mitchell et al., 1993). Since a 
cell-based assay was used in our study, lipophilicity can affect the potency via 
affecting the rate of permeation across the cell membrane into the whole cells. 
In general, a lipophilic compound of a certain degree can diffuse more easily 
across the cell membrane. From Figure 4-5, it can be observed that 
lipophilicity and potency have a linear relationship in COX-2. Consistent 
across all the series, it was observed that increasing log P(o/w) negatively 
affects the potency of the compounds. This can be attributed to Lipinski’s 
“Rule of 5” whereby there is a higher probability of poor permeation 
associated with compounds with log P(o/w) more than 5 (Lipinski, 2000; 
Lipinski et al., 2001). Poor permeation results in decreased concentration of 
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compounds within the cell and could potentially affect the inhibition of the 
compounds on COX enzymes.  
 
On the other hand, the trend for COX-1 was not as consistent as COX-2. In 
fact opposite trends were observed for the F-F and Br-Br series. It is rather 
puzzling as in the case of these two series, an increase in log P(o/w) increased 
the potency of the compounds in COX-1. It was previously reported in a 
QSAR study of acidic NSAIDs that membrane affinity was only a prerequisite 
required for COX-2 inhibition and no such relationship was observed for 
COX-1 (Barbato et al., 1997). The inconsistent trend between lipophilicity and 
COX-1 observed in our study could thus be explained by the absence of a 
membrane affinity-COX-1 relationship. Also, the substituents on the 
compound itself could have exerted more effect on the pharmacology of the 
compound in COX-1 than the lipophilicity of the compound. F-F and Br-Br 
may not be favorable substituents for binding into the COX-1 active site; thus, 
an increase in lipophilicity may not confer significant gains beyond the weak 
interactions possibly associated with these two series of compounds.  
 
The compounds have an ionizable carboxylic acid. Diclofenac possess a pKa 
of 4.15 (Sangster, 2006) and will exist in its ionizable form at physiological 
pH. Given the high degree of similarity across the compounds, their pKa are 
not expected to differ dramatically and they should also be significantly 
ionized under our experimental conditions. Thus, log D(o/w) at pH 7.4 will be 
a better measurement of the lipophilicity of the compounds. The log D(o/w) at 
pH 7.4 of the compounds ranges from 0.46 to 3.03 (Appendix 4-3), which is 
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lower than the Lipinski’s “Rule of 5”. However, since the compounds are 
charged, permeation through the cell membrane is often hindered. Thus, 
overall lipophilicity of the compound could have a less important role in 
affecting the potency of the compounds. On the other hand, the substituent 
combinations on the molecule could have a greater effect on the potency of the 
compounds. We mentioned earlier in section 4.4.1 that interaction of 
substituents with the hydrophobic pocket in COX enzymes was important in 
determining the potency of the compound. Previous QSAR studies have 
further proposed that the lipophilicity of the individual substituents on the 
chemical backbone of the compound played significant roles in the 
determining the potency of the compounds (Wilkerson et al., 1995; Prasanna 
et al., 2005). Thus, the interplay of these factors (for example, overall 
lipophilicity, substituent lipophilicity, substituent positioning) on overall 
efficacy would be a better estimate than relying only on a single factor. 
 
4.5. Conclusion 
The pharmacological aspect of the compounds in terms of their inhibitory 
effects on COX-1 and COX-2 was determined using whole cell assay. Two 
cell lines, HEL92.1.7 and RAW264.7, which expresses COX-1 constitutively 
and COX-2 when induced respectively were used in the study. In terms of 
absolute activity, diclofenac (compound 3) was found to be the most potent in 
both COX isoforms. In general, the addition of an alkyl group at R1 on ring A 
of the compound was observed to decrease potency. The increase in the alkyl 
group size was also observed to decrease the potency of the compounds. The 
halogen substituents at R2 and R3 on ring B were found to affect the activity in 
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addition to the alkyl group at R1. It was observed that the presence of at least 
one chlorine substituent improved the potency of the compounds. In general, 
fluorine or bromine substituents decreased the potency of the compounds. 
The selectivity of the compounds was determined by the ratio of the IC50 
values obtained for COX-1 inhibition to the IC50 values obtained for COX-2 
inhibition. Lumiracoxib (compound 5) was found to be the most selective of 
all the compounds. The selectivity arises from the addition of the methyl 
group at R1. It was observed that further increase in alkyl chain length 
decreased selectivity in general. Changes in halogen substituents also affected 
selectivity for some compounds. An increase in selectivity was observed to 
occur with a decrease in absolute potency. Thus, it can be concluded that the 
right combination of substituents at R1, R2 and R3 are required for good 
selectivity and potency. 
 
With the pharmacology data obtained, we generated a safety index to link 
toxicity to pharmacology. Diclofenac (compound 3) was found to be the safest 
among all the compounds but is not selective towards COX-2. Lumiracoxib 
(compounds 5), which is selective towards COX-2 had a 3.8 times lower 
safety index as compared to diclofenac. For many of the other compounds, 
safety indices were low due to increased toxicity and lowered potency. From 
this we can conclude that selectivity may come at the expense of compound 
safety when a larger dose is required due to decreased activity that 




We also carried out in silico docking in order to better understand the 
interaction of the compounds with both COX isoforms. However, in 
reconciling these biological findings with in silico docking experiments, we 
experienced contradictions particularly for compounds with propyl and butyl 
substituents at R1 in terms of selectivity. It was postulated that the 
contradictions could be due to the cell-based experimental methodology we 
used, whereby docking is a direct enzyme-compound interaction. Also, the 
contradictions could be due to receptor or ligand inflexibility during docking. 
 
Another source of variability we have yet to consider is whether the 
compounds themselves are biotransformed to generate metabolites of varying 
affinity to COX enzymes and potential for toxicity. This important property 




Chapter 5. Investigations of the Role of Metabolism in the Toxicity of the 
synthesized compounds: Effect of Substituents on Metabolic Stability 
Metabolite Reactivity, and Potential Implications on Toxicity 
 
5.1. Introduction 
In Chapter 3, we explored the in vitro toxicity of the twenty-four compounds 
in two cell-lines; HuH-7 and TAMH, which exhibit contrasting metabolic 
capabilities. The outcome led us to postulate that metabolism to reactive 
metabolites could be a factor that contributes to the toxicity of the compounds. 
This chapter will expound on the mechanistic details of such metabolism.  
 
In order for reactive metabolites to be formed, the compounds requires a 
bioactivation process mediated by cellular metabolism. An in vitro metabolic 
stability assessment is a preliminary determination of susceptibility for 
metabolism. Thus, we carried out metabolic stability assays to determine the 
metabolic half-lives (t1/2) of the compounds in presence of metabolic enzymes. 
A microsomal incubation system was used to mimic the metabolic system and 
analysis was carried via liquid chromatography-tandem mass spectroscopy 
(LC-MS/MS). Both Phase I and Phase II metabolic t1/2 were determined 
separately.  
 
The metabolites formed can exhibit different reactivity and toxicity. Therefore, 
a necessary follow-up would be to evaluate the reactivity of the metabolites. 
The reactive metabolites of toxicological significance are often electrophiles 
that can conjugate to cellular nucleophiles (Williams et al., 2002). Thus, 
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depletion of cellular nucleophiles can be a surrogate marker of the reactivity of 
the reactive metabolites formed from the compounds. In this work, we 
consider the use of GSH, a tri-peptide consisting of glutamic acid, glycine and 
cysteine. The sulfhydryl group on the cysteine moiety presents a soft 
nucleophilic site for attack by soft electrophiles such as quinone imines 
generated via Phase I metabolism. Thus, the depletion of GSH is often used as 
an indicator of cellular toxicity. We performed a cell-based GSH depletion 
assay in TAMH cells and used the GSH-binding fluorescence probe, 
monochlorobimane (MCB), to detect GSH remaining in the cells after 
exposure to the compounds (Rice et al., 1986). 
 
Acyl glucuronides (AGs) generated by Phase II metabolism of diclofenac had 
been linked to the hepatotoxicity caused by the drug via formation of reactive 
metabolites from transacylation and acyl migration (Kretzrommel and 
Boelsterli, 1994a; Grillo et al., 2003). Since our synthesized analogues 
preserve the carboxylic acid moiety which is required for the formation of 
AGs by UGTs, we cannot occlude the possibility that AGs can contribute to 
the toxicity of the compounds. Yet, the effect of different substituents on the 
change in metabolism and reactivity of the glucuronides has not been studied. 
Thus, we investigated the reactivity of AGs by biosynthesizing said AGs in a 
microsomal incubation system. As opposed to Phase I reactive metabolites, 
AGs are hard electrophiles, they require hard nucleophiles to trap (Srivastava 
et al., 2010). Hence, we used a dipeptide consisting of phenylalanine and 
lysine (Phe-Lys) as the nucleophilic trap. The un-trapped and trapped AGs 
were quantified by LC-MS/MS to determine their reactivity.  
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The studies done in this chapter will allow us to improve our understanding of 
the role of metabolism and bioactivation in the toxicity observed with the 
compounds. Given the changes in toxicity associated with changes in 
substituents, we hypothesize that metabolic stability and metabolite reactivity 
will change with different substituents. In addition, highly toxic compounds 
were expected to be metabolically unstable and form highly reactive 
metabolites.  
 
5.2. Experimental methods 
Pooled human liver microsomes (HLM) (20 mg/mL) were purchased from 
XenoTech (Lenexa, KS). Nicotinamide adenine dinucleotide phosphate 
(NADP+) was from ENZO (Farmingdale, NY). UDPGA was from Nacalai 
Tesque (Kyoto, Japan). Phe-Lys hydrochloride and 3-phenylpropionic acid 
were from MP Biomedicals (Santa Ana, CA). Bio-Rad Protein Assay Kit was 
purchased from Bio-Rad Laboratories (Hercules, CA). HPLC/spectro grade 
acetonitrile and methanol were from Tedia Company (Fairfield, OH). All other 
reagents and chemicals were form Sigma-Aldrich (St. Louis, MO) unless 
otherwise stated. 
 
5.2.1. Microsomal incubation for Phase I metabolic stability assay 
Stock solutions of compounds in acetonitrile were prepared individually. Each 
compound (1 µM) was incubated with shaking at 37°C in an incubation 
system consisting of 100 mM potassium phosphate buffer (pH 7.4), 0.5 
mg/mL HLM, 1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 0.4 U/mL 
glucose-6-phosphate dehydrogenase, 3.3 mM magnesium chloride and 0.05 
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mM sodium citrate. The final organic solvent concentration was 0.25% v/v. 
Aliquots of the incubation mixture were transferred out and quenched in ice 
cold acetonitrile containing an internal standard (indomethacin or compound 
23) at time points of 0, 5, 10, 15, 20, 30 and 60 min. Each aliquot was 
vortexed for 30 s and centrifuged down at 13,000 rpm for 20 min at 4°C. The 
supernatant was collected and injected into LC-MS/MS for analysis. 
 
5.2.2. Microsomal incubation for Phase II metabolic stability assay 
Stock solutions of compounds in acetonitrile were prepared individually. HLM 
(0.5 mg/mL) and alamethicin (25 ug/mg protein) in 100 mM potassium 
phosphate buffer were incubated in ice for 15 min. After which, each 
compound (1 µM), 1 mM magnesium chloride and 4 mM UDPGA were added 
and the mixture incubated with shaking at 37°C. The final organic solvent 
concentration was 0.25% v/v. Aliquots of the incubation mixture were 
transferred out and quenched in ice cold acetonitrile containing an internal 
standard (indomethacin or compound 23) at time points of 0, 5, 15, 30, 45 and 
60 min. Each aliquot was vortexed for 30 s and centrifuged down at 13,000 
rpm for 20 min at 4°C. The supernatant was collected and injected into LC-
MS/MS for analysis. 
 
5.2.3. Microsomal incubation for AG reactivity 
5.2.3.1. Incubation for AG formation 
The incubation method from elsewhere was carried out with modifications 
(Wang et al., 2004). Stock solutions of compounds were prepared in DMSO 
individually. HLM (1.0 mg/mL) and alamethicin (25 ug/mg protein) in 100 
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mM potassium phosphate buffer were incubated in ice for 15 min. After which, 
each compound (300 µM), 1 mM magnesium chloride and 4 mM UDPGA 
were added and the mixture incubated with shaking at 37°C for 1.5 h. The 
final organic solvent concentration was 0.5% v/v. A half aliquot of 
microsomal incubation mixture was transferred to an equal volume of 50/50 
water/acetonitrile (v/v). The pH was adjusted to 3.5 using 10% acetic acid. An 
equal volume of acetonitrile containing 10 µg/mL 3-phenylpropionic acid was 
added to the incubation mixture, followed by vortexing for 1 min. The mixture 
was centrifuged at 13,000 rpm for 20 min at 4°C. The supernatant was 
collected and injected into LC-MS/MS for analysis. 
 
5.2.3.2. AG-Phe-Lys formation with biosynthesized AGs 
A half aliquot of microsomal incubation mixture from section 5.2.3.1 was 
centrifuged at 13,000 rpm and 4°C for 15 min. The supernatant was 
transferred to an equal volume of 20 mM Phe-Lys in 100 mM potassium 
phosphate buffer. The mixture was incubated with shaking at 37°C for 24 h. 
An equal volume of acetonitrile containing 10 µg/mL 3-phenylproponoic acid 
was added to the incubation mixture, followed by vortexing for 1 min. The 
mixture was centrifuged at 13,000 rpm for 20 min at 4°C. The supernatant was 
collected and injected into LC-MS/MS for analysis. 
 
5.2.4. LC-MS/MS analysis 
5.2.4.1. LC-MS/MS analysis for metabolic stability assays 
Samples generated in incubation experiments were analyzed using LC-MS/MS. 
Quantitative LC-MS/MS was performed on either an Agilent 1290 Infinity LC 
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system (Agilent Technologies, Santa Clara, CA) connected to an Agilent 6430 
Triple Quadrupole MS (Agilent Technologies, Santa Clara, CA) or an Agilent 
1290 Infinity LC system connected to a AB Sciex Qtrap® 5500 (AB Sciex, 
Framingham, MA). The column used was a Waters AQUITY UPLC BEH C18 
120Å, 1.7 µm, 2.1 mm × 100 mm column (Waters Corporation, Milford, MA). 
The flow rate used was 400 uL/min and the column temperature was set at 
40°C. Gradient elution was used to separate the compounds and internal 
standards. Total run time was 5.1 min and 5.5 min for each sample for Agilent 
6430 Triple Quadrupole MS and AB Sciex Qtrap® 5500 respectively. The LC 
conditions are summarized in Table 5-1.  
 
Table 5-1 LC conditions for Agilent 1290 Infinity LC system + Agilent 6430 
Triple Quadrupole MS (left) and Agilent 1290 Infinity LC system + AB Sciex 
Qtrap ® 5500 (right). 
Agilent 1290 Infinity LC system + 
Agilent 6430 Triple Quadrupole 
MS 
 Agilent 1290 Infinity LC system +  AB Sciex Qtrap® 5500 
Mobile 
Phase 
A: 0.2% formic acid, 
aqueous  Mobile Phase 
A: 0.1% formic acid, 5 
mM ammonium 
formate, aqueous 
B: Acetonitrile  B: Acetonitrile 
Time 
(min) % B 
Flow 
(µL/min)  Time % B 
Flow 
(µL/min) 
0.0 20.0 500  0.0 20.0 400 
0.2 20.0 500  0.2 20.0 400 
3.2 95.0 500  3.2 95.0 400 
3.9 95.0 500  3.9 95.0 400 
4.1 20.0 500  4.1 20.0 400 
5.1 20.0 500  5.5 20.0 400 
 
Negative ion ESI LC-MS/MS was carried out to quantify the amount of 
compound in each sample. The LC effluent was introduced directly into the 
MS. The multiple reaction monitoring (MRM) mode was applied to each 
sample analysis. Compound dependent parameters such as declustering 
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potential (DP), entrance potential (EP), collision energy (CE) and collision cell 
exit potential (CXP) were optimized for each individual compound. Operation 
parameters for each LC-MS/MS system are summarized in Table 5-2. 
Precursor and product ions utilized for MRM analysis are listed in Appendix 
5-1. Evaluation of loss of parent compound with time against internal standard 
was carried out using MassHunter Workstation Quantitative Analysis (Agilent 
Technologies, Santa Clara, CA) or Analyst® Software version 1.5.2 (AB 
Sciex, Framingham, MA). Linear regression models for calculation of 
metabolic t1/2 are listed in Appendix 5-3. 
 
Table 5-2 MS source parameters for Agilent 6430 Triple Quadrupole MS (left) 
and AB Sciex Qtrap® 5500 (right). 
Agilent 6430 Triple Quadrupole 
MS 
 AB Sciex Qtrap® 5500 
Source parameters  Source parameters 
Temperature (°C) 325  Temperature (°C) 500 
Gas flow (L/min) 10.0  Curtain gas (psi) 25.0 
Nebulizer pressure (psi) 40.0  Gas 1 (psi) 50.0 
Capillary voltage (V) -3500  Gas 2 (psi) 60.0 
   Collision gas (psi) Medium 
   IonSpray voltage (V) -4500 
 
5.2.4.2. LC-MS/MS analysis for AG reactivity 
Samples generated in incubations experiments were analyzed using LC-
MS/MS. Quantitative LC-MS/MS was performed on an Agilent 1290 Infinity 
LC system connected to a AB Sciex Qtrap® 5500. The column used was a 
Waters AQUITY UPLC BEH C18 120Å, 1.7 µm, 2.1 mm × 100 mm column. 
The flow rate used was 400 uL/min and the column temperature was set at 
35°C. The mobile phase consisted of 5 mM aqueous ammonium formate, pH 
5.0 (A) and acetonitrile (B). Gradient elution was used to separate the 
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compounds and internal standards. Total run time was 15 min for each sample. 
The LC conditions are summarized in Table 5-3. 
 
Table 5-3 LC conditions for AG reactivity analysis. 
Mobile 
Phase 
A: 5 mM ammonium formate, pH 5.0 
B: Acetonitrile 
Time (min) % B Flow (µL/min) 
0.0 20.0 500 
2.0 20.0 500 
10.0 95.0 500 
12.0 95.0 500 
13.0 20.0 500 
15.0 20.0 500 
 
Negative ion ESI LC-MS/MS was carried out to analyze the analyte in each 
sample. The LC effluent was introduced directly into the MS. Single ion mode 
(SIM) mode was applied to individual sample analysis. Operation parameters 
for the LC-MS/MS system are summarized in Table 5-4. Masses used for SIM 
analysis are listed in Appendix 5-2. Evaluation of analytes relative to internal 
standard was carried out using Analyst® Software version 1.5.2. 
 
Table 5-4 MS source parameters for AG reactivity analysis. 
Source parameters 
Temperature (°C) 400 
Curtain gas (psi) 25.0 
Gas 1 (psi) 50.0 
Gas 2 (psi) 60.0 
IonSpray voltage (V) -3500 
DP (V) -90.0 
EP (V) -10.0 
 
5.2.5. Cell-based GSH depletion assay using TAMH cells 
TAMH cells were cultured as described in Chapter 3. TAMH cells were 
seeded at 3.5 × 104 cells per well in a 12-well plate. Test compounds were 
dissolved in DMSO and the final DMSO concentration was 0.5% v/v in 
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medium. The cells were treated with compounds at a concentration of 20 µM 
or 10 µM. Diethyl maleate was used as a positive control at concentrations of 
0.5 µM and 1.0 µM. The exposure period was 6 h at 37°C, 5% CO2. 100 µM 
of MCB in medium was added and further incubated in the dark at 37°C, 5% 
CO2 for 3 h. The cells were harvested by scraping and centrifuged at 5000 rpm 
and 4°C for 1 min. The cell pellet was washed with 1X PBS and lysed in 0.1% 
Triton-X in 1M Tris-HCL, pH 7.4. The lysate was sonicated in a water 
sonicator for 1 min, incubated in ice for 30 min, followed by centrifugation at 
13,000 rpm for 20 min. The fluorescence signal of the supernatant was read at 
an excitation wavelength of 380 nm and emission wavelength of 485 nm using 
a Tecan M200 Pro plate reader (Männedorf, Switzerland). To prepare a 
standard calibration curve, GSH at varying concentrations were incubated with 
1 U/mL glutathione-S-transferase, 100 µM of MCB and 1X PBS with shaking 
in the dark at 37°C.  Protein quantification was carried out using the Bio-Rad 
Protein Assay. 
 
5.2.6. Linear regression for relationship investigation of metabolic stability, 
reactivity and toxicity 
Linear regression was carried out for the following three relationships: 
metabolic stability and metabolic reactivity; metabolic stability and toxicity; 
metabolic reactivity and toxicity using Graphpad Prism 5 (Graphpad Software 







5.3.1. Metabolic stability of compounds towards Phase I and Phase II 
metabolism 
The metabolic stability of the compounds for both Phase I and Phase II 
metabolism was investigated by microsomal incubation assays followed by 
LC-MS/MS analysis. Both phases of metabolism were carried out separately 
by using the appropriate co-factors required by the metabolic enzymes. 
 
















1 H  F  Cl  9.9 ± 2.4 22.9 ± 3.3 
2 H  F  F  10.9 ± 1.6 43.1 ± 9.6 
3 (Diclofenac) H  Cl  Cl  10.7 ± 1.5 16.9 ± 2.3 
4 H  Br  Br  25.7 ± 3.1 10.5 ± 1.1 
5 (Lumiracoxib) Me  F  Cl  13.8 ± 2.1 38.4 ± 6.4 
6 Me  F  F  9.8 ± 1.8 60.6 ± 9.7 
7 Me  Cl  Cl  27.1 ± 1.5 9.2 ± 0.7 
8 Me Br  Br  39.6 ± 1.1 7.9 ± 2.1 
9 Et  F  Cl  44.6 ± 3.2 12.9 ± 3.0 
10 Et  F  F  50.7 ± 3.9 16.8 ± 3.7 
11 Et  Cl  Cl  35.6 ± 7.5 9.9 ± 4.0 
12 Et  Br  Br  47.1 ± 9.1 6.9 ± 2.6 
13 n-Pr  F  Cl  11.1 ± 1.4 12.0 ± 2.6 
14 n-Pr  F  F  19.6 ± 1.4 24.7 ± 4.8 
15 n-Pr  Cl  Cl  8.2 ± 0.7 19.6 ± 6.3 
16 n-Pr  Br  Br  4.6 ± 1.1 11.9 ± 4.1 
17 i-Pr  F  Cl  22.4 ± 1.6 15.8 ± 1.8 
18 i-Pr F  F  43.5 ± 5.7 24.3 ± 5.0 
19 i-Pr Cl  Cl  20.0 ± 1.7 12.3 ± 4.4 
20 i-Pr Br  Br  15.5 ± 1.0 16.5 ± 4.9 
21 t-Bu  F  Cl  20.3 ± 2.6 33.0 ± 6.3 
22 t-Bu F  F  59.4 ± 6.3 47.9 ± 1.8 
23 t-Bu Cl  Cl  14.9 ± 1.7 28.4 ± 7.5 
24 t-Bu Br  Br  25.7 ± 3.1 18.4 ± 1.1 
a Metabolic t1/2 was determined from triplicates and is expressed as mean ± standard deviation. 
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Metabolic t1/2 was calculated as 50% decrease in peak area ratio of compound 
relative to internal standard over time against the peak area ratio of compound 
relative to internal standard at the 0 min time point.  The metabolic t1/2 of the 
compounds are listed in Table 5-5. For Phase I metabolic t1/2, the values 
ranged from 4.6 min (lowest) to 59.4 min (highest). For Phase II metabolic t1/2, 
the values ranged from 6.9 min (lowest) to 60.6 min (highest). The Phase I 
metabolic t1/2 value obtained for diclofenac in our experiment (10.7 ± 1.5 min, 
0.5 mg/mL HLM) was similar to previous literature findings (11 ± 3 min, 0.3 
mg/mL HLM) despite having used a higher concentration of HLM (Obach, 
1999). On the other hand, the Phase II metabolic t1/2 value obtained for 
diclofenac (16.9 ± 2.3 min, 0.5 mg/mL HLM) was much shorter as compared 
to literature findings (32 min, 1.0 mg/mL HLM) (Perloft et al., 2006). 
 
5.3.1.1. Effect of changes in substituents on Phase I metabolic stability 
 
Figure 5-1 Comparison plot for Phase I metabolic stability between halogen 
substituents at R2 and R3 grouped by R1 substituents. 
 
Figure 5-1 shows a comparison between halogen substituents at R2 and R3 
grouped by alkyl group at R1. The comparison plot showed that for Phase I 
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metabolic stability of the compounds. The Cl-Cl compounds in general 
possess relatively shorter t1/2 values as compared to other halogen substituents 
when alkyl group is kept constant. The only exception was when R1 was 
substituted with a methyl group (compound 7) whereby a longer t1/2 value was 
observed as compared to F-Cl or F-F compounds. F-F compounds were 
observed to have relatively longer t1/2 than other halogens when alkyl group 
sizes are bigger than methyl. Similar to F-F compounds, F-Cl compounds 
were observed to have longer t1/2 values as compared to Cl-Cl compounds but 
not Br-Br compounds when alkyl group size at R1 increases beyond methyl. 
For Br-Br compounds, we observed that the compounds were generally more 
stable as compared to other halogen substituents except in the case where R1 
was a propyl substituent (n-propyl or iso-propyl). 
 
 
Figure 5-2 Comparison plot for Phase I metabolic stability between alkyl 
substituents at R1 and grouped by R2 and R3 substituents. 
 
In addition to the effect of halogen substituents, the alkyl substituent at R1 had 
an effect on the metabolic stability of the compounds. Notably, the compounds 
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combinations at R2 and R3, a trend not seen in other alkyl series (Figure 5-2).  
We observed that with no alkyl group substituent at R1, t1/2 values were 
generally short except in the case of Br-Br compounds where a notable 
increase in t1/2 was observed. For methyl substituents, compounds with at least 
one fluorine substituent were observed to have low t1/2 values while the 
notable increase in t1/2 were observed for Cl-Cl and Br-Br compounds. The 
branched alkyl substituents, iso-propyl and tert-butyl were observed to have 
similar trends. F-F compounds of these alkyl series were observed to have 
much longer t1/2 values as compared to other halogen substituents at R2 and R3. 
The alkyl substituent that was constantly observed to result in relatively short 
t1/2 values was n-propyl. Compound 16 (n-propyl, Br-Br) was observed to 
possess the shortest t1/2 value of all compounds. On the other hand, compound 
22 (tert-butyl, F-F) was observed to the most stable compound with the 
longest t1/2 value. 
 
5.3.1.2. Effect of changes in substituents on Phase II metabolic stability 
 
Figure 5-3 Comparison plot for Phase II metabolic stability between halogen 
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Figure 5-3 shows the comparison between halogen substituents while keeping 
alkyl substituent at R1 constant for Phase II metabolic stability. We observed 
that for Phase II metabolic stability, regardless of the substituent at R1, F-F 
compounds were the most metabolically stable with longer t1/2 values as 
compared to other halogen combinations. On the other hand, Br-Br 
compounds were observed to have relatively shorter t1/2 values as compared to 
other halogen combinations. The only exception was compound 20 (iso-propyl, 
Br-Br) where the t1/2 value was slightly longer than compound 19 (iso-propyl, 
Cl-Cl) and compound 17 (iso-propyl, F-Cl). Similar to Br-Br compounds, Cl-
Cl compounds were observed to have short t1/2 values as compared to other 
halogen combinations but not to Br-Br compounds when alkyl substituent was 
kept constant. F-Cl compounds were observed to be less metabolically stable 
as compared to F-F compounds but were mostly found to be significantly 
more stable than Cl-Cl and Br-Br compounds, especially when alkyl 
substituent at R1 is small in size. 
 
 
Figure 5-4 Comparison plot for Phase II metabolic stability between alkyl 
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Figure 5-4 shows the comparison between different alkyl substituents at R1 
while keeping halogen substituents at R2 and R3 constant. We observed that 
ethyl substituent at R1 resulted in reduced metabolic stability across all 
halogen combinations. This observation was reverse of what was observed in 
Phase I metabolic stability whereby ethyl substituted compounds were 
observed to be more metabolically stable as compared to other alkyl 
substituted or un-substituted compounds (section 5.3.1.1.). The propyl 
substituents, n-propyl and iso-propyl were observed to be similar in t1/2 values 
across halogen combinations. Their t1/2 values were relatively shorter as 
compared to other alkyl substituents (with the exception of ethyl substituents) 
for F-F and F-Cl compounds but were observed to be relatively longer for Cl-
Cl and Br-Br compounds. The reverse was observed for non-alkylated (H) and 
methyl substituted compounds where F-Cl and F-F compounds had 
comparably much longer t1/2 values as compared to other alkyl substituents, 
especially in the case of methyl substitution. On the other hand, the non-
alkylated or methyl substituted Cl-Cl and Br-Br compounds were shown to 
have comparably shorter t1/2 values. tert-Butyl substituted compounds were 
observed to have long t1/2 values as compared to other alkyl substituents 
regardless of halogen combinations at R2 and R3. Compound 12 (tert-butyl, 
Br-Br) was found to be the least metabolically stable for Phase II metabolism 






5.3.1.3. Inter-comparison between Phase I and Phase II metabolic stability and 
their relationship with lipophilicity 
 
 
Figure 5-5 Comparison of Phase I (orange) and Phase II (blue) metabolic t1/2. 
Comparison with log P(o/w) (green) with metabolic t1/2 of both metabolic 
phases. 
 
Comparing between the two phases of metabolism, some interesting 
observations can be made. As seen from Figure 5-5, some compounds that are 
more susceptible to Phase I metabolism were less prone to Phase II 
metabolism, vice versa. A good example will be compound 6, which was the 
least stable for Phase I metabolism but is the most stable for Phase II 
metabolism. Compounds 7 to 12 were observed to be very metabolically stable 
for Phase I metabolism but were observed to be metabolically unstable for 
Phase II metabolism. On the other hand, the reverse was seen for compounds 1 
to 6 (exception of compound 4) where the compounds were metabolically 
unstable for Phase I but metabolically stable for Phase II. 
 
A comparison of the metabolic stability to the lipophilicity of the compounds 

































were less lipophilic can possess either low or high metabolic stability for both 
phases of metabolism. Even with increase in the lipophilicity of the 
compounds as indicated by the increase in log P(o/w), the metabolic stability 
of the compounds for both phases fluctuated up and down. It would seem that 
the actual substituents on the compound scaffold affect the metabolic stability 
more than the resulting physicochemical properties that arose from the 
changes in substituent. 
 
5.3.2. In vitro GSH depletion of the compounds in TAMH 
GSH is a cellular nucleophile that is often used as an indicator of cellular 
toxicity and is usually depleted via conjugation to reactive metabolites and 
oxidative stress. We performed a cell-based GSH depletion assay in TAMH 
cells to investigate the extent by which the compounds deplete cellular GSH as 
a measurement of the reactivity of Phase I metabolites formed from the 
compounds. Phase I metabolism tend to generate reactive metabolites that are 
amenable to conjugate soft nucleophiles like GSH, whereas Phase II 
metabolites preferably conjugate to hard nucleophiles. MCB was used as the 
probe for cellular GSH. MCB when conjugated to GSH, forms a MCB-GSH 
adduct which is fluorescent in nature and can be easily detected with a 
fluorescence detector.  
 
From Table 5-6, the percentage GSH depletion ranged from 6.8% to 71.4%. 
Compounds 13 to 24, with the exception of compounds 14, 18 and 22, were 
tested at a lowered concentration of 10 µM instead of 20 µM. This was due to 
the extensive cell death caused by the compounds when tested at 20 µM, 
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Table 5-6 In vitro GSH depletion (%) for the twenty compounds in TAMH 
cells. 
Compound R1 R2 R3 GSH Depletion (%)a 
1 H F Cl 12.5 ± 4.7 
2 H F F 12.2 ± 2.7 
3 (Diclofenac) H Cl Cl 20.7 ± 9.6 
4 H Br Br 20.1 ± 9.2 
5 (Lumiracoxib) Me F Cl 15.8 ± 6.4 
6 Me F F 11.8 ± 3.6 
7 Me Cl Cl 10.2 ± 4.5 
8 Me Br Br 9.6 ± 5.6 
9 Et F Cl 14.6 ± 4.5 
10 Et F F 10.8 ± 6.1 
11 Et Cl Cl 8.1 ± 5.7 
12 Et Br Br 71.4 ± 12.2 
13 n-Pr F Cl 10.2 ± 4.4b 
14 n-Pr F F 6.8 ± 3.8 
15 n-Pr Cl Cl 11.7 ± 3.9b 
16 n-Pr Br Br 44.4 ± 9.0b 
17 i-Pr F Cl 16.4 ± 6.4b 
18 i-Pr F F 7.8 ± 3.8 
19 i-Pr Cl Cl 12.7 ± 4.1b 
20 i-Pr Br Br 48.6 ± 9.7b 
21 t-Bu F Cl 10.5 ± 4.1b 
22 t-Bu F F 17.1 ± 4.9 
23 t-Bu Cl Cl 45.8 ± 11.1b 
24 t-Bu Br Br 64.9 ± 19.1b 
a GSH depletion (%) was determined from biological triplicates and is 
expressed as mean ± standard error. 
b Test compound concentration used was 10 µM instead of 20 µM. 
 
Compound 24 showed the highest percentage GSH depletion. Although 
compound 12 displayed higher apparent percentage depletion as compared to 
compound 24, it should be noted that compound 12 was tested at a higher 
concentration. When tested at 20 µM, compound 24 caused complete cell 





Figure 5-6 Comparison plot for GSH depletion between halogen substituents 
at R2 and R3 grouped by R1 substituents. “*” indicates that test compound 
concentration used was 10 µM instead of 20 µM. 
 
The halogen substituents at R2 and R3 had an apparent effect on the GSH 
depletion exhibited by the compounds. A comparison plot (Figure 5-6) across 
the halogen combinations while keeping alkyl substituents constant showed 
that Br-Br compounds in general showed more depletion as compared to other 
halogen combinations, especially when coupled with larger alkyl substituents 
at R1 (ethyl, propyls and tert-butyl). F-F compounds were observed to have 
lower GSH depletion as compared to other halogen combinations, especially 
when coupled with larger alkyl substituents (propyls and tert-butyl). F-Cl and 
Cl-Cl compounds have almost similar trends across all alkyl substituents, with 
comparable GSH depletion values except in the case of tert-butyl substitution 

























Figure 5-7 Comparison plot for GSH depletion between alkyl substituents at 
R1 and grouped by R2 and R3 substituents. “*” indicates that test compound 
concentration used was 10 µM instead of 20 µM 
 
Figure 5-7 shows the comparison between alkyl substituents while keeping the 
halogen combinations constant for GSH depletion. The n-propyl, iso-propyl 
and tert-butyl substituted compounds of F-Cl, Cl-Cl and Br-Br combinations 
were tested at a lower concentration due to excessive cell death especially in 
the case of tert-butyl substituted compounds. tert-Butyl substituted 
compounds were observed to be have higher GSH depletion as compared to 
other alkyl substituents. The only exception is compound 21 (tert-butyl, F-Cl), 
where the GSH depletion percentage was observed to be lower than the iso-
propyl substituted counterpart. For Br-Br compounds, the measured viability 
of tert-butyl substitution was lower than that of ethyl substitution but this is 
because a lower concentration of 10 µM was used for tert-butyl substituted 
compounds due to excessive cell death at 6 h. n-Propyl and iso-propyl 
substituted compounds have similar trends across all halogen combinations. It 
was observed that the propyl substituted compounds had comparably higher 
GSH depletion as compared to smaller alkyl substituted or non-alkylated 
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were tested at a lower concentration. The only exception was the F-F 
combination for propyl substituted compounds where GSH depletion was 
observed to be lower than other alkyl substituted compounds. iso-Propyl 
substituted compounds was shown to have slightly higher GSH depletion as 
compared to n-propyl substituted compounds across all halogen combinations. 
For non-alkylated and methyl substituted compounds, the GSH depletion 
percentages were low as compared to larger alkyl substituents across all 
halogen combinations. Non-alkylated compounds of Cl-Cl and Br-Br 
combinations were observed to have increased GSH depletion over methyl 
substituted ones. The compound with the highest GSH depletion was 
compound 24 (tert-butyl, Br-Br) and the lowest was compound 14 (n-propyl, 
F-F).  
 
5.3.3. Reactivity of AGs of the compounds towards Phe-Lys 
The compounds possess a carboxylic acid group and they are structurally 
similar to diclofenac. Thus, AGs can play a role in the toxicity caused by the 
compounds via metabolism. We generated AGs from the compounds using 
HLM and UDPGA as co-factor. Alamethicin was added as a pore-forming 
agent to aid in the penetration of the compounds into the membrane bound 
UGTs.  The biosynthesized AGs were then incubated with dipeptide, Phe-Lys, 
which traps the reactive AGs formed via acyl migration or transacylation. The 
AG reactivity was calculated as the relative amount of trapped AGs at 24 h 





Table 5-7 Reactivity of AGs of the twenty-four compounds toward Phe-Lys in 
a 24 h incubation. 
Compound R1 R2 R3 
AG Reactivity – 24 ha 
(%) 
1 H F Cl 5.36 ± 0.29 
2 H F F 0.29 ± 0.01 
3 (Diclofenac) H Cl Cl 8.67 ± 0.69 
4 H Br Br 7.02 ± 0.41 
5 (Lumiracoxib) Me F Cl 6.04 ± 0.56 
6 Me F F 0.44 ± 0.06 
7 Me Cl Cl 9.15 ± 0.96 
8 Me Br Br 6.28 ± 0.46 
9 Et F Cl 6.14 ± 0.67 
10 Et F F 0.56 ± 0.08 
11 Et Cl Cl 8.72 ± 1.25 
12 Et Br Br 5.50 ± 0.57 
13 n-Pr F Cl 4.96 ± 0.24 
14 n-Pr F F 0.77 ± 0.01 
15 n-Pr Cl Cl 4.60 ± 0.29 
16 n-Pr Br Br 3.16 ± 0.12 
17 i-Pr F Cl 5.47 ± 0.24 
18 i-Pr F F 0.78 ± 0.01 
19 i-Pr Cl Cl 5.38 ± 0.12 
20 i-Pr Br Br 3.66 ± 0.15 
21 t-Bu F Cl 3.72 ± 0.06 
22 t-Bu F F 0.74 ± 0.01 
23 t-Bu Cl Cl 3.86 ± 0.17 
24 t-Bu Br Br 2.74 ± 0.02 
a AG reactivity (%) was determined from duplicates and is expressed as mean 
± standard deviation. 
 
 
Figure 5-8 Comparison plot for AG reactivity between halogen substituents at 
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The reactivity of the AGs over 24 h were not as high as expected. The 
reactivity ranged from 0.29% to 9.15% (Table 5-7). The compound with the 
highest AG reactivity was compound 7 and the lowest was compound 2. The 
AG reactivity of the F-F compounds (2, 6, 10, 14, 18 and 22) was consistently 
very much lower than other halogen combinations (Figure 5-8). The reactivity 
of the AGs of the F-F compounds was consistently below 1%. Compounds 
that possess at least one chlorine atom had an elevated AG reactivity. The Cl-
Cl compounds possess the highest AG reactivity among each alkyl series. 




Figure 5-9 Comparison plot for AG reactivity between alkyl substituents at R1 
and grouped by R2 and R3 substituents. 
 
Surprisingly, the increase in alkyl size at R1 seemed to decrease the reactivity 
of the AGs. The n-propyl, iso-propyl and tert-butyl substituted compounds 
were shown to have decreased AG reactivity as compared to the smaller 
alkylated or non-alkylated compounds. The exception was F-F compounds 
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increased in size. The changes in reactivity contributed by methyl and ethyl 
were minimum as the AG reactivity values were not that much different as 
compared to non-alkylated compounds. 
 
5.3.4. Relationship between metabolic stability and metabolite reactivity 
To determine the role of metabolism in the toxicity of the compounds, we 
performed linear regressions to elucidate the relationship between metabolic 
stability and reactivity for both Phase I and Phase II metabolism. However, the 
trend was not correlated strongly quantitatively, especially for Phase I 
metabolism (Appendix 5-4). Thus, we carried out qualitative cross-
comparisons of the metabolic stability and reactivity of the compounds for 
both phases of metabolism. Figure 5-10 shows the cross-comparison for Phase 
I metabolism (separated into the two concentrations of compounds employed) 
and Figure 5-11 shows the cross-comparison for Phase II metabolism. 
 
From Figure 5-10, it was observed that there is no visible trend between Phase 
I metabolic stability and in vitro GSH depletion, which was in line with the 
linear regression performed (R2 = 0.0085 and R2 = 0.0008 for 20 µM and 10 
µM test concentration respectively). We expected to observe that compounds 
with high GSH depletion will have short metabolic t1/2 as we assumed that a 
faster rate of metabolism will result in higher chance of formation of reactive 
metabolites. However, we observed that short metabolic t1/2 did not 
correspond to high GSH depletion, indicating that metabolically unstable 
compounds do not necessarily equate to high reactivity of the metabolites 
formed. Compounds that followed our expectations were compounds 13, 15, 
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16, 20 and 23, which were observed to have relative short metabolic t1/2 
coupled with high GSH depletion. Compounds 7 to 11, 14, 18, 19 and 22, also 





Figure 5-10 (a) Comparison of Phase I average metabolic t1/2 and in vitro 
GSH depletion tested at 20 µM (6 h) and (b) comparison of Phase I average 
metabolic t1/2 and in vitro GSH depletion tested at 10 µM (6 h). 
 
The other compounds did not follow our expectations of long metabolic t1/2 
and low GSH depletion, vice versa. Compounds 12, 17 and 24 have relatively 
long metabolic t1/2, indicating they were not easily converted to metabolites by 




















































































high GSH depletion despite being metabolically stable. On the other hand, 
compounds 1 to 6 have relatively short metabolic t1/2 but had low GSH 
depletion instead of high GSH depletion. 
 
 
Figure 5-11 Comparison of Phase II average metabolic t1/2 and AG reactivity 
(24 h). 
 
For Phase II metabolism, a clearer trend can be seen between metabolic 
stability and AG reactivity. Similar to Phase I metabolism, we expected short 
metabolic t1/2 to correspond to high AG reactivity and vice versa. From Figure 
5-11, it can be observed that was somewhat a decreasing trend in AG 
reactivity associated with increase in metabolic t1/2. This was also observed in 
the linear regression performed where an inverse relationship was observed 
between AG reactivity and Phase II metabolic stability (Appendix 5-4). 
However, there were exceptions and abnormalities which lead to the poor 
linear regression obtained (R2 = 0.3802). Compound 10 has a relatively shorter 
t1/2 as compared to other F-F compounds, but has an AG reactivity similar to 
the more metabolically stable compounds. Compounds 5, 21 and 23 are 








































AGs were shown to be as reactive as compounds that are not as stable as them. 
Similarly, compounds 1, 3 and 15 have higher or similar AG reactivity as 
compounds that possess half of their metabolic t1/2.  
 
5.3.5. Relationship between metabolic stability and toxicity 
Similar to defining the relationship between metabolic stability and reactivity, 
we performed linear regression to clarify the relationship between metabolic 
stability and toxicity. We obtained poor linear regression models (Appendix 5-
5) and thus, we performed a qualitative cross-comparison between metabolic 
stability and toxicity to determine if metabolic stability affects the toxicity of 
the compound. Similar to the comparison between metabolic stability and 
metabolite reactivity in Section 5.3.4, we expected compounds with low LC50 
values to have less metabolic stability.  
 
 
Figure 5-12 Comparison of Phase I average metabolic t1/2 and in vitro toxicity 
in TAMH. 
 
From Figure 5-12, it can be seen that there is no visible trend between 







































the linear regression performed (R2 = 0.08310). Some compounds with low 
LC50 values were observed to have relatively high metabolic stability while 
some compounds with high LC50 values were observed to be relatively 
metabolically unstable. For example, compound 2, which has the highest LC50 
has a relatively short metabolic t1/2 of 10.9 minutes while compound 24, which 
has the lowest LC50 value has a moderately long metabolic t1/2 of 25.7 minutes. 
On the other hand, some compounds were within expectations, with low LC50 
values and short metabolic t1/2, vice versa, such as compounds 10, 15 and 16.   
 
 
Figure 5-13 Comparison of Phase II average metabolic t1/2 and in vitro 
toxicity in TAMH. 
 
For Phase II metabolism, we observed an increasing toxicity associated with 
increase in metabolic t1/2 (Figure 5-13). This was mirrored in the linear 
regression performed where a positive trend was observed between LC50 
values and Phase II metabolic stability (Appendix 5-5). Similar to Phase I 
metabolism, there were exceptions which resulted in the poor linear regression 
obtained (R2 = 0.3559). Compounds 4, 7 and 9 have relatively high LC50 










































Compounds 15 and 20 to 24 have low LC50 values but moderate to high 
metabolic stabilities. 
 
5.3.6. Relationship between reactivity and toxicity 
As previously mentioned in chapter 3, we postulated that toxicity of the 
compounds arises from the reactive metabolites formed via metabolism of the 
compounds. In this section, we initially performed a quantitative linear 
regression between metabolite reactivity and toxicity but poor models were 
obtained (Appendix 5-6). Thus, we performed a qualitative cross-comparison 
between metabolite reactivity and toxicity to investigate the relationship 
between the two. Figure 5-14 shows the cross-comparison between GSH 
depletion and toxicity in TAMH cells and Figure 5-15 shows the cross-
comparison between AG reactivity and toxicity. 
 
From Figure 5-14 we observed with decrease in LC50 values, GSH depletion 
increased for most compounds. This observation was in line with our 
expectations of low LC50 corresponding to high GSH depletion. The most 
toxic (compound 24) was the compound with the highest relative GSH 
depletion (tested at a lower concentration of 10 µM). There were exceptions 
such as compounds 8, 11, 14 and 18 which have moderately low LC50 values 
but the corresponding GSH depletion percentages were not as high as 
expected. Due to these exceptions, the correlation between GSH depletion and 







Figure 5-14 (a) Comparison of in vitro GSH depletion tested at 20 µM (6 h) 
and corresponding in vitro toxicity in TAMH and (b) comparison of in vitro 
















































































































On the other hand, we observed that for the cross-comparison for AG 
reactivity and LC50 values, there was no discernable trend (Figure 5-15). This 
was opposite of what we expected between AG reactivity and LC50 values. For 
F-F compounds with larger alkyl groups (n-propyl, iso-propyl and tert-butyl), 
compounds 14, 18 and 22 have low LC50 values but their AG reactivity values 
were significantly lower as compared to other compounds of close LC50 values. 
The most toxic compound, compound 24, was observed to have moderately 
low AG reactivity. Compounds 3, 7 and 11 possess toxicity values that fell 




5.4.1. Phase I and Phase II metabolic stability 
Microsomal incubation studies were carried out to investigate the Phase I and 
Phase II metabolic stability of the compounds separately. We chose to carry 
out microsomal metabolic stability assays instead of cell-based assays because 
microsomal assays are faster to carry out and simpler to interpret. Also, results 
will be reproducible when the same batches of microsomes are used. 
Comparing our experimental findings and literature findings on the metabolic 
t1/2 of diclofenac, we found that our experimental data was not in agreement 
with literature findings. The values obtained in our experiments were similar 
to that of previous literature values but it should be noted that a higher 
concentration of microsomes were used in our case. Thus, it would have been 
expected that our t1/2 value for diclofenac be shorter than literature findings. 
There are many factors accountable these discrepancies. One factor would be 
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the microsomes used in our study and in literature were from different 
companies or batches. Commercial microsomes have been shown to differ 
from company to company and from different batches (Jia and Liu, 2007). 
Companies prepare their microsomes differently and there is also subject-to-
subject differences from which the microsomes were obtained from. The type 
and amount of organic solvent used in the study will also have effects on the 
results obtained. It has been shown that type and amount of organic solvent 
used to dissolve the compounds have inhibitory or inductive effects on in vitro 
activities of metabolic enzymes (Easterbrook et al., 2001). The solvent used in 
our assays were acetonitrile (0.25% v/v) and have been shown to have the 
least inhibitory effect on P450s and UGTs activities (Easterbrook et al., 2001). 
The type and amount of solvents used in literature could have been different 
and resulted in the discrepancies seen between our findings and literature 
findings. Therefore, it is of importance to compare the different substituted 
compounds within the same experimental setup in order to obtain meaningful 
results. 
 
For Phase I metabolism, we are primarily looking at aromatic hydroxylation of 
the compounds by P450s as both diclofenac and lumiracoxib are extensively 
hydroxylated by CYP2C9 (Stierlin et al., 1979; Mangold et al., 2004). As seen 
in Figure 5-1, F-F compounds were observed to be more metabolically stable 
as compared to other halogen combinations when the size of the alkyl 
substituent at R1 was ethyl and larger. This observation was also seen when 
comparing between F-Cl and Cl-Cl compounds whereby F-Cl compounds 
were shown to be slightly more metabolically stable in comparison when alkyl 
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substituents at R1 increased in size to ethyl and beyond. This was within our 
expectations that fluorine substituted compound will show improved 
metabolic stability. Fluorine has been shown to improve metabolic stability 
and has been used extensively to improve the biological t1/2 in drug design. 
Indeed, a metabolic study done on halogen substituted benzenes have shown 
that the rate of hydroxylation increases from fluorobenzene to chlorobenzene 
and furthermore to bromobenzene (Burka et al., 1983). It was postulated that 
the presence of a fluorine atom adjacent to the site of the metabolic attack 
could increase or decrease the biotransformation rate depending on whether 
the metabolic attack is nucleophilic or electrophilic in nature and whether the 
inductive or resonance effects of the fluorine predominates (Park et al., 2001).  
Fluorine has been found to decrease the rate of reaction of electrophilic attacks 
on the π system of the substrate’s aromatic ring by the activated heme group in 
P450s (Cnubben et al., 1994; Koerts et al., 1998). This was due to decreased 
nucleophilicity of the aromatic ring by fluorine substituents (Koerts et al., 
1998). The site of hydroxylation on the halogenated ring of the compounds are 
meta in position to the halogen substituents. From table, the σm values for 
fluorine indicates that it is electron withdrawing to the site of hydroxylation. 
Coupled with higher electronegativity, fluorine would thus decrease 
nucleophilicity of the aromatic ring to a greater extent than chlorine or 
bromine. The higher the number of fluorine atoms substituted into the 
aromatic ring, the lower the rate of reaction of the aromatic ring with the heme 
group in P450 enzymes (Cnubben et al., 1994). This could possibly explain 
the increased metabolic t1/2 of F-F compounds in our study as compared to 
other halogen combinations when alkyl group size at R1 is ethyl or larger. 
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Table 5-8 Physicochemical parameters of halogen substituents employed in 
our study (Allred, 1961; Hansch and Leo, 1979; Batsanov, 2001) 
Parameter F Cl Br 
Hammett value σm 0.34 0.37 0.39 σp 0.06 0.23 0.23 
Hansch value, π 0.14 0.71 0.86 
Electronegativity 4.0 3.0 2.8 
Van der Waal radii, Å 1.65 2.05 2.10 
Taft size, Es -0.46 -0.97 -1.16 
 
Paradoxically, non-alkylated and methylated F-F compounds, metabolic 
stability was low, which was reverse of what is expected of fluorinated 
compounds. We expected bromine-substituted compounds to be less 
metabolically stable as compared to other halogen substituted compounds but 
we did not observe such a straightforward trend in our case. As mentioned 
earlier, F-F compounds were of high metabolic stability when certain alkyl 
substituents were present. Similar observations with other halogen 
combinations were seen. Metabolic stability of Br-Br compounds were 
relatively low in comparison to other halogen combinations when R1 was 
substituted with a propyl or tert-butyl group. On the other hand, when 
substituted with ethyl or smaller groups, the metabolic stability increased. 
Similarly for Cl-Cl and F-Cl compounds where certain alkyl group 
substitution resulted in decreased or increased metabolic stability as compared 
other halogen combinations. As seen from table, chlorine and bromine do not 
have very different Hammett values or electronegativity. Thus, it would be 
expected that their metabolic stability would not be that different. However, 
this was not the case and could likely be due to lipophilicity parameters and/ 





Other than the halogen substituents affecting the metabolic stability of the 
compounds, we noticed that the alkyl substituents at R1 had tremendous 
effects on the stability of the compounds. Interestingly, we expected tert-butyl 
substituted compounds to have low metabolic stabilities as compared to non-
alkylated or other alkylated compounds. Instead, we observed that ethyl 
substituted compounds were the most metabolically stable regardless of 
halogen substitutions. Our expectations stemmed from the fact that the Hansch 
value of tert-butyl (Table 5-9) is very high, indicating its significant 
contribution to the lipophilicity of the compounds. But as seen from Figure 5-
5 in section 5.3.1, lipophilicity and metabolic stability did not have any 
observable relationship across the compounds. This was not as expected as 
studies have found a positive relationship between lipophilicity and metabolic 
stability. Metabolism rates have been shown to increase with lipophilicity for 
both Phase I and Phase II (Siraki et al., 2005; Smith et al., 2006). This is 
because lipophilic compounds are more likely to interact with both P450s and 
UGTs (Little and Ryan, 1982; Lewis et al., 1995; Vashishtha et al., 2001). 
 
Table 5-9 Physicochemical parameters of alkyl substituents employed in our 
study (Hansch and Leo, 1979). 
Parameter H Me Et n-Pr i-Pr t-Bu 
Taft size, Es 0.00 -1.24 -1.31 -1.60 -1.71 -2.78 
Hansch value, π 0.00 0.56 1.02 1.55 1.53 1.98 
 
The lack of a relationship between lipophilicity and metabolic stability in our 
study could be due to the effect of the alkyl substituent on the steric 
configuration of the compound in the active site of the P450s. In order for 
hydroxylation to take place, the position to be hydroxylated on the aromatic 
ring needs to be in contact with the heme group in P450s. Investigative studies 
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on in silico docking of crystal structures of P450s found that in order for a 
molecule to be effectively hydroxylated, the point of hydroxylation needs to fit 
into the heme pocket and the molecule needs to be in an optimal configuration 
within the substrate binding pocket of the enzyme (Williams et al., 2000; 
Bathelt et al., 2002). Thus, the spatial configuration within the active site is 
important as just binding to the active site (high binding affinity due to high 
lipophilicity) does not indicate hydroxylation will occur via the heme group. 
Looking at the Taft size values (Es) of both halogen and alkyl substituents 
(Tables 5-8 and 5-9), we can observe a significant differences between each 
substituent. The steric effect contributed by each different substituent and their 
combination on the scaffold will result in different spatial configurations. The 
lack of relationship between Phase I metabolic stability and lipophilicity could 
possibly be related to the different spatial configurations that arise via 
different substituent combination on the scaffold. This could also explain why 
certain non-alkylated and methylated F-F compounds were found to have low 
metabolic stability yet their other alkylated counterparts were highly 
metabolically stable. 
 
For Phase II metabolism, we focused on glucuronidation of the carboxylic acid 
moiety on ring A of the compound, as it is the major metabolic fate for 
arylacids. Thus, it would seem intuitive that changes in substituents on the 
more distal ring B (R2 and R3) of the compound should not affect the Phase II 
metabolism of the compounds. This was not the case as fluorinated 
compounds, especially di-fluorinated compounds, of the same alkyl series 
have remarkably higher metabolic stability as compared to chlorinated or 
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brominated compounds. This could be due to the lipophilicity of the 
compounds, with di-fluorinated compounds having the lowest lipophilicity in 
each alkyl series. The role of glucuronidation in Phase II metabolism is to 
increase hydrophilicity of the lipophilic xenobiotic so as to aid in excretion. It 
is thus expected that more lipophilic compounds will be glucuronidated at a 
higher rate, leading to shorter metabolic t1/2. However, the relationship 
between lipophilicity and metabolic stability is not as straight-forward across 
the series and will be explained later on. 
 
Similar to Phase I metabolism, we observed no relationship between 
lipophilicity and Phase II metabolic stability across the series. It was found in 
literature that glucuronidation and lipophilicity follows a positive parabolic 
trend (Kim, 1991). This trend was not observed in our study due to the narrow 
range of log P(o/w) of the compounds in our series (approximately 3.5 to 6.0) 
as compared to the in silico range calculated in literature (-1.0 to 6.0). Other 
studies have also found a positive relationship between glucuronidation and 
lipophilicity and have attributed the relationship to the role of lipophilicity in 
affecting the compound’s ability to recognize the active site of the UGTs 
(Radominska-Pandya et al., 1999; Smith et al., 2003). In addition, UGTs are 
bound on the luminal face of the microsomal membrane, which requires the 
substrates to traverse the endoplasmic reticulum (Radominska-Pandya et al., 
1999). Lipophilic compounds will thus have higher penetration rate through 
the membrane. Such dynamics may not be mimicked from our study because 
we used alamethicin as a pore forming reagent to aid the compounds to 
transverse the membrane, which could have changed the relationship between 
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lipophilicity and Phase II metabolism. In addition, even with increased binding 
of the compound molecules to the active sites of UGTs due to increased 
lipophilicity, the configuration of the molecule may not be optimal and could 
have affected the lipophilicity-glucuronidation relationship 
 
5.4.2. Reactivity of metabolites generated via metabolism  
The toxicity of the compounds was postulated to arise from the formation of 
reactive metabolites. We investigated the reactivity of the possible metabolites 
formed by two ways. The first was to investigate the ability of the metabolites 
to conjugate to cellular GSH. In this study, we assumed that the depletion of 
cellular GSH by the compounds were mainly due to the formation of quinone 
imines and imine methides intermediates from Phase I metabolism. This 
assumption was based on studies showing that reactive metabolites of 
diclofenac such as quinone imines formed adducts with GSH in vivo and in 
vitro (Tang et al., 1999a; Tang et al., 1999b; Poon et al., 2001). However, we 
also accept the fact that Phase II metabolites may also cause some depletion of 
GSH. However, hard nucleophiles are preferred as binding targets for AGs. 
 
Here, we found the reactivity of the metabolites generated to be altered by 
changes in substituents. Hence, we examined the lability of hydroxylation at 
the 4’-position by P450s, its subsequent oxidation to electrophilic quinone 
imines in Phase I metabolism and the effect of halogen substituents on the 
aromatic ring (Figure 5-16). The electrophilicity of the quinone imines will be 
linked to their reactivity towards cellular nucleophiles such as GSH. A 
relationship between electrophilicity and toxicity of quinones has been 
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established. The study investigated the effect of different substituents on 
quinones on their reactivity towards GSH. GSH was used as a nucleophilic 
trapping agent. It was shown that increasing electrophilicity of a quinone by 
substituting more electron-withdrawing groups increased its reactivity towards 
GSH (Chan et al., 2008). Quinones and quinone imines are analogous and thus, 
this relationship would be seen in quinone imines too. Electron-withdrawing 
groups on the initial aminophenol will confer stronger electrophilic properties 
to the quinone imine as the electron density of the aromatic ring decreases. On 


























































Figure 5-16 Hydroxylation at 4’-position and subsequent oxidation to a 
quinone imine. 
 
The main substituents on the compounds that can affect the reactivity of the 
quinone imines formed via 4’-hydroxylation are fluorine, chlorine and 
bromine. The possible sites of adduct formation are 3’- and 5’-positions, 
which is para to the halogen substituents. Physicochemical properties of each 
halogen substituent will thus affect the reactivity of the sites of adduct 
formation. The Hammett values of fluorine, chlorine and bromine for para 
substituent, σp, are 0.06, 0.23 and 0.23 respectively (Table 5-8). From the 
given Hammett values, fluorine is the least electron-withdrawing substituent 
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(more negative Hammett value) even though fluorine is more electronegative 
than chlorine and bromine (Table 5-8). This is because the electron-donating 
mesomeric effect of fluorine dominates over the electron-withdrawing 
inductive effect (Neijenesch et al., 1991). The quinone imines of difluoro-
substituted compounds at R2 and R3 will be the weakest electrophile among 
the compounds. Weak electrophiles are less reactive towards nucleophiles. 
The quinone imines of difluoro-substituted compounds will thus be less likely 
to form covalent adducts with cellular nucleophiles. This effect is reflective of 
the cellular GSH depletion observed whereby F-F compounds were shown to 
have low percentage GSH depletion regardless of alkyl substitution at R1 
(Figure 5-6). 
 
Bromine is only slightly more electron-withdrawing than chlorine as a 
substituent. However, significant differences were observed between the GSH 
depletion of chlorinated and brominated compounds, with Br-Br compounds 
observed to have remarkably higher GSH depletion (Figure 5-6). Given the 
similarity in their electron-withdrawing properties of chlorine and bromine, 
the lipophilicity contributed by the halogens could have greater effects on 










































Figure 5-17 Formation of an imine methide when R1 is an alkyl group. 
 
Alkyl substituents on the R1 position can affect the cellular GSH depletion of 
the compounds too. The compounds possessing an alkyl group para to an 
amine group on an aromatic group have a possibility to be oxidized to imine 
methides (Figure 5-17). For example, lumiracoxib can be metabolized to an 
imine methide due to the presence of a methyl group (Kang et al., 2009). On 
the other hand, diclofenac does not form any imine methides. It is known that 
imine methides are more reactive than quinone imines due to their highly 
electrophilic nature, which arises from their decreased propensity to undergo 
one electron reductions (Thompson et al., 1993). This increased reactivity 
could be a reason for the increase in toxicity when alkyl groups are substituted 
at R1. Imine methides are analogous to quinone methides, thus, factors 
affecting the reactivity of quinone methides can be extrapolated to imine 
methides. One factor that affects the reactivity of imine methides is the type of 
substitutions on the exocyclic methylene group. Greater steric crowding due to 
larger substitutions at the exocyclic methylene group decreases the reactivity 
of the methylene group towards nucleophiles (Thompson et al., 1995). Thus, 
the reactivity of the methylene group towards nucleophiles decreases as the 
alkyl group size increases or branching occurs. The reactivity of the methylene 
group will thus be: methyl > ethyl > n-propyl > iso-propyl. tert-Butyl was 
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omitted from the list as it is unable to form any imine methides. Our overall 
trend showed that GSH depletion for propyl substituted compounds were 
technically higher than methyl and ethyl substituted compounds given propyl-
substituted compounds were tested a lower concentration (GSH depletion: iso-
propyl = n-propyl > ethyl > methyl). The exact reason for this anomalous 
trend is not clear. There could be two reasons as to why this trend was 
observed, namely the lipophilicity of the compounds and the binding 
selectivity of the imine methides formed. 
 
A study done on quinone methide formation of eugenol analogues showed that 
more lipophilic compounds generated more quinone methides (Thompson et 
al., 1995). Propyl-substituted compounds are more lipophilic as compared to 
the others, thus, more reactive imine methides could have been formed for 
propyl-substituted compounds. It was also observed in the study that quinone 
methides formed from methyl-substituted analogs were so reactive that such 
quinone methides have little ability to diffuse away from the site of formation 
to bind with critical cellular nucleophiles and they react readily with the 
surrounding solvent such as water (Thompson et al., 1995). On the other hand, 
propyl-substituted analogues formed quinone methides that were of 
intermediate reactivity and have the ability to diffuse away from the site of 
formation to bind to cellular nucleophiles (Thompson et al., 1995). This can 
be applied to the imine methides, whereby in this case, the methyl-substituted 
compounds at R1 formed highly reactive imine methides that have little ability 
to bind to critical cellular nucleophiles as they will non-selectively bind to 
surrounding nucleophiles such as water in the active site of the enzyme. 
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Overall, propyl-substituted compounds at the R1 position have the ability to 
form reactive imine methides that are of intermediate reactivity. These propyl-
substituted imine methides will have lesser tendency to bind to water and can 
diffuse away from the active site to bind to critical cellular nucleophiles. Thus, 
the GSH depletion observed with propyl-substituted compounds were higher 
than ethyl or methyl substituted compounds. All in all, the higher GSH 
depletion observed with propyl-substituted compounds could be due to their 
higher lipophilicity and the intermediate reactivity of their imine methides. 
 
As mentioned earlier, it should be noted with interest that tert-butyl-
substituted compounds do not form imine methides as tert-butyl group 
possesses no extractable hydrogen atom. However, when keeping the halogen-
substituents constant, the GSH depletion values of tert-butyl-substituted 
compounds were higher as compared to propyl-substituted compounds, 
especially for di-chlorinated and di-brominated compounds. tert-Butyl 
substituted compounds could form other reactive metabolites in larger 
quantities and of higher reactivity. In this case, the formation of imine 
methides may not be as important a factor in affecting the toxicity of the 
compounds synthesized. Therefore, we must consider alternative metabolites 


























































Figure 5-18 Hydroxylation at 5-position and subsequent oxidation to a 
quinone imine. 
 
It is also interesting to note that the non-alkylated compounds were shown to 
have comparable or higher GSH depletion as compared to methylated and in 
most cases, ethylated compounds (Figure 5-7). Hydroxylation can potentially 
occur at the 5-position on the arylacetic acid ring via P450s and subsequent 
oxidation to a quinone imine can occur (Figure). Thus, although lacking the 
ability to form imine methides, the formation of quinone imines on the 
arylacetic acid ring could contribute to the depletion of GSH via adduct 
formation.   
 
AGs formed via Phase II metabolism can bioactivate via two reactive 
pathways: (1) transacylation, whereby the aglycone moiety conjugates with a 
nucleophile, releasing the glucuronic acid moiety, and (2) acyl migration, 
whereby intramolecular rearrangement of the AGs result in ring opening and 
formation of reactive aldehydes. From what was observed, the halogen 
substituents at R2 and R3 had greater effects on the reactivity of the AGs as 
compared to the alkyl substituents at R1. Di-fluorinated compounds were very 
non-reactive while di-chlorinated compounds were the most reactive. On the 
other hand, the larger the alkyl group at R1, the less reactive the AGs became. 
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This is rather interesting as previous studies done on the reactivity of AGs 
have shown that bulky substituents on the α-carbon of the acetic acid group 
affects the reactivity of the AGs due to steric hindrance (Berry et al., 2009). In 
our study, the α-carbon was left un-substituted, thus, the steric hindrance on 
the α-carbon that affects AG reactivity does not apply.  Other studies have 
found that the reactivity of AGs formed from substituted benzoic acids 
depended on the Hammett values of the substituents, with electron-donating 
groups increasing the reactivity of the benzoic acid AGs (Vanderhoeven et al., 
2004a; Vanderhoeven et al., 2004b). However, it should be noted that our 
compounds are arylacetic acids with a more complex structure possessing 
more than one aromatic ring. In addition, the reactivity of arylacetic acid AGs 
is more complex and has been postulated to be affected by both steric and 
electronic factors (Benet et al., 1993; Wang et al., 2004; Berry et al., 2009). 
Thus, there is no single and straightforward explanation to the phenomenon 
seen in our study. The effect seen from the alkyl and halogen substituents 
could be due to the interplay of electronic and steric factors, acting against 
each other. However, more in-depth investigation needs to be carried out. We 
propose that further calculations of electronic and steric properties and 
possible QSAR models may help in the explanation of the results observed for 
AG reactivity of our compounds. 
 
5.4.3. Role of metabolic stability and metabolite reactivity in toxicity of the 
compounds 
We performed three-way cross-comparisons between metabolic stability, 
metabolite reactivity and the toxicity of the compounds in terms of in vitro 
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LC50 data. We observed no direct relationship between metabolic stability and 
toxicity for Phase I metabolism. This gives an indication that even with greater 
amount of metabolites formed; it may not mean that the metabolites formed 
are reactive or toxic in nature. A cross-comparison between GSH depletion 
and toxicity gave a positive relationship whereby high GSH depletion were 
shown to relate to high toxicity in many compounds. The results gave an 
indication that the formation of reactive metabolites and subsequent 
conjugation with GSH or oxidative stress causing depletion in cellular GSH 
resulted in the toxicity observed. GSH depletion is a measurement of toxicity 
in the cell and is a likely indicator of increased chance of binding of reactive 
metabolites to hepatic protiens. 
 
For compounds with high metabolic stability but yet high GSH depletion, it 
can be postulated that the amount of reactive metabolites formed, however 
small, was reactive enough to deplete cellular GSH and perhaps conjugate to 
other cellular nucleophiles at a relatively high rate to cause significant cell 
death. Similarly, for compounds with poor metabolic stability but low GSH 
depletion, it can be postulated that the large amount of metabolites formed 
were not very reactive in nature, thus resulting in lower cytotoxicity. Thus, 
metabolic stability may not be a good indicator of toxicity caused by 
metabolism as highly metabolically stable compounds can be equally or more 
toxic than metabolically unstable compounds. It is recommended that other 
assays that determine the actual reactivity of the compounds, for example, 




For Phase II metabolism, we could observe a positive relationship between 
metabolic stability and toxicity in general. But there were exceptions whereby 
compounds with high metabolic stability possess high toxicity. However, a 
cross-comparison between AG reactivity and toxicity gave no discernable 
relationship. This could be due to the toxicity of AGs contributing less than 
the toxicity of the Phase I reactive metabolites. On the other hand, the 
fluctuating AG reactivity could be due to different rates of transacylation and 
acyl migration of the AGs depending on the substituent combination on the 
scaffold. As the reactivity was measured in a controlled trapping environment, 
it may not clearly reflect on the transacylation or acyl migration rates in a 
whole cell. Thus, to better elucidate any possible relationships between AG 
reactivity and toxicity, a cell-based study should be carried out to observe the 
reactivity of AGs formed as the varying cellular nucleophiles and environment 
could have a profound effect on the transacylation and acyl migration rate on 
the AGs as compared to a buffered microsomal incubation used in our study.  
 
5.5. Conclusion 
The metabolic stabilities of the compounds with respect to Phase I and Phase 
II pathways were determined via microsomal incubations and LC-MS/MS 
analysis. The metabolic t1/2 of diclofenac for both phases of metabolism were 
not similar to that in literature, which we attributed to differences in 
microsomes batch and experimental procedures. For Phase I metabolism, F-F 
compounds were shown to be highly metabolically stable, especially when 
alkyl substituent at R1 was ethyl and larger. We attributed this to the decreased 
nucleophilicity of fluorinated compounds and subsequent decreased rate of 
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reaction with the heme group in P450s for Phase I metabolism. For Phase II 
metabolism, F-F compounds were observed to be the most metabolically 
stable regardless of the substituent at R1. The decreased lipophilicity of 
fluorine over chlorine and bromine for the same alkyl series was attributed to 
the increased metabolic stability observed. 
 
The metabolic stabilities of the compounds across the series (varying alkyl and 
halogen substituents) were not as we expected and were not correlated to 
lipophilicity as initial assumed by us. Several exceptions were observed such 
as high metabolic stability of F-F compounds with ethyl or larger alkyl 
substituent at R1 but low metabolic stability with methyl or no alkyl 
substituent at R1. We postulate that this could be due to unfavorable spatial 
configurations of the compounds within the active site of the P450s for Phase I 
metabolism. The substituent combination on all three investigated positions is 
important for spatial configuration given their different steric effect on the 
molecule. Thus, it is hard to draw a definite conclusion on structure-
metabolism relationship with the given experimental data. It is recommended 
that further in silico experiments could aid in determining if spatial 
configuration plays an important role.  
 
In addition to metabolic stability, we determined both the cellular GSH 
depletion and AG reactivity of the compounds. We found that GSH depletion 
increased across the series. We assumed that GSH depletion was mainly due 
to formation of quinone imines and imine methides via Phase I metabolism of 
the compounds. We postulated that the electrophilicity of the aromatic ring 
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affected by the halogen substituents due to electron donating and withdrawing 
effects could have affected these electrophilic reactive metabolites. The ease 
of formation of imine methides and the type of imine methides formed could 
be factors involved in affecting the toxicity of the compounds. However, the 
question on whether imine methides are truly contributors to toxicity remains 
as tert-butyl substituted compounds at R1 do not form imine methides yet are 
considerably toxic. Thus, there is a need to further study the type of reactive 
metabolites formed in order to determine which reactive metabolite is the 
major contributor to toxicity. 
 
AG reactivity of our compounds showed that the halogen substituents at R2 
and R3 affected the reactivity more than the alkyl substituents at R1. Literature 
findings have not yet been able to correlate complex AG structures to 
reactivity. We postulated that the effect seen from the halogen substituents 
could be electronic in nature and the effect from the alkyl groups at R1 could 
be steric in nature. Further investigation such as calculations of electronic and 
steric properties and QSAR modelling should be carried out to help in the 
explanation of the results observed for AG reactivity of our compounds. 
 
The cross-comparisons done between metabolic stability, metabolite reactivity 
and toxicity gave rise to interesting observations. For Phase I metabolism, we 
found no relationship between metabolic stability and toxicity. Thus, we 
conclude metabolic stability may not be a good indicator of toxicity caused by 
metabolism as highly metabolically stable compounds can be equally or more 
toxic than metabolically unstable compounds. On the other hand, we found 
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that metabolite reactivity and toxicity in general have a positive relationship. 
However, it is important to note that the correlation was not strong. We used 
GSH depletion as an indicator of metabolite reactivity but one should note that 
such metabolites could also bind to other cellular nucleophiles, resulting in 
cell death. 
 
A more complex relationship was seen for Phase II metabolism whereby 
metabolic stability correlated to toxicity positively while AG reactivity had no 
correlation to toxicity. Further cell-based AG reactivity assays should be 
carried out to try and elucidate out a clearer relationship between Phase II 




Chapter 6. Investigations of the Role of Metabolism in the Toxicity of the 
Synthesized Compounds: Structure Elucidation of Trapped Reactive 
Metabolites and Proposition of Possible Bioactivation Pathways 
 
6.1. Introduction 
In Chapter 5, we investigated Phase I and II metabolic stability of the 
compounds and the reactivity of the resulting metabolites. The results 
supported the hypothesis that toxicity of the compounds arose from formation 
of reactive metabolites. To crystallize this postulation, it is necessary to 
confirm the generation of reactive metabolites by identifying and proposing 
the structures of the possible metabolites formed. 
 
Our work is built upon the previous findings of Phase I reactive metabolites 
associated with the hepatotoxicity of diclofenac and lumiracoxib. Diclofenac 
has been found to form quinone imines and subsequent trapping of GSH on 
both rings (Shen et al., 1999; Tang et al., 1999b; Yu et al., 2005). On the other 
hand, lumiracoxib has also been found to form quinone imines from the 
aniline ring (Li et al., 2008; Kang et al., 2009). In addition, imine methides 
formed from the arylacetic acid ring have been documented (Kang et al., 
2009). Since our compounds are structurally similar, we expect to detect 
similarly trapped reactive metabolites, with the influence of the substituents on 
this propensity being the object of our study.  
 
In addition, the contribution of Phase II-mediated reactive metabolite 
formation cannot be undermined. We have shown in Chapter 5 that the AGs 
149 
 
formed from the compounds exhibit measurable reactivity towards a 
nucleophilic dipeptide consisting of phenylalanine and lysine. Diclofenac has 
also been documented to form AGs that can undergo transacylation or acyl 
migration, causing subsequent conjugation to cellular nucleophiles such as 
GSH and proteins (Kretzrommel and Boelsterli, 1994a; Grillo et al., 2003). 
Lumiracoxib has been found to form AGs in vivo and in vitro (Mangold et al., 
2004; Kang et al., 2009). However, little to no studies has been carried out to 
investigate the reactivity of the AGs of lumiracoxib nor to elucidate the 
structures of the adducted AGs. 
 
Therefore, this chapter is a deliberate effort to explore both Phase I and II 
metabolic pathways. The first part is the identification and subsequent 
structure proposition of the Phase I reactive metabolites. Emphasis is placed 
on investigating the effect of the varying substituents on the compounds and 
on the structures of the metabolites formed. The metabolites were generated 
via microsomal incubations and trapped with GSH. LC-MS/MS analysis was 
carried out to identify the structures of the trapped reactive metabolites. The 
second part involves the identification of the AGs of diclofenac, lumiracoxib 
and selected compounds trapped with Phe-Lys using LC-MS/MS analysis. 
This is to confirm the formation of AGs of lumiracoxib and selected 
compounds, and that like AGs of diclofenac, are able to undergo 
transacylation and acyl migrations to form reactive metabolites that contribute 





6.2 Experimental methods 
6.2.1. Microsomal incubation for Phase I reactive metabolites trapping with 
GSH 
Stock solutions of compounds were prepared in DMSO at concentrations of 50 
mM individually. The stock solutions were further dissolved in acetonitrile to 
a concentration of 5 mM. Each compound (50 µM) was incubated with 
shaking at 37°C for 1 h in a preparation consisting of 100 mM potassium 
phosphate buffer (pH 7.4), 1.0 mg/mL HLM, 1.3 mM NADP+, 3.3 mM 
glucose-6-phosphate, 0.4 U/mL glucose-6-phosphate dehydrogenase, 5 mM 
GSH, 3.3 mM magnesium chloride and 0.05 mM sodium citrate up to a total 
volume of 1 mL. The final organic solvent concentration was 0.4% v/v. 
Negative controls were prepared in absence of NADP+. The incubation 
mixture was quenched in 4X v/v ice cold acetonitrile. The mixture was 
vortexed for 30 s and centrifuged down at 13,000 rpm for 10 min at 4°C. The 
supernatant was transferred into a clean tube and evaporated under a stream of 
N2 at 30°C to dryness. The residue was reconstituted in 200 uL of 95/5 
water/acetonitrile (v/v) and centrifuged at 13,000 rpm for 10 min at 4°C. The 
supernatant was collected and injected into an LC-MS/MS for analysis (to be 
described in a subsequent section). 
 
6.2.2. Microsomal incubation for Phase II reactive metabolites trapping with 
Phe-Lys 
The incubation method from elsewhere was carried out with modifications as 
described below (Wang et al., 2004). Stock solutions of compounds in DMSO 
were prepared individually. HLM (1.0 mg/mL) and alamethicin (25 µg/mg 
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protein) in 100 mM potassium phosphate buffer were incubated in ice for 15 
min. After which, each compound (50 µM), 1 mM magnesium chloride and 4 
mM UDPGA were added up to a total volume of 120 µL and the mixture 
incubated with shaking at 37°C for 1.5 h. The final organic solvent 
concentration was 1.0% v/v. The microsomal incubation mixture from was 
centrifuged at 13,000 rpm and 4°C for 15 min. The supernatant (100 µL) was 
transferred to an equal volume of 20 mM Phe-Lys in 100 mM potassium 
phosphate buffer (pH 7.4). The mixture was incubated with shaking at 37°C 
for 24 h. An equal volume of acetonitrile was added to the incubation mixture, 
followed by vortexing for 1 min. The mixture was centrifuged at 13,000 rpm 
for 20 min at 4°C. The supernatant was collected and injected into LC-MS/MS 
for analysis. 
 
6.2.3. LC-MS/MS for identification of Phase I GSH trapped metabolites 
Samples generated in incubations experiments were analyzed using LC-
MS/MS. LC-MS/MS analysis was performed on an Agilent 1290 Infinity LC 
system connected to a AB Sciex Qtrap® 5500 (AB Sciex, Framingham, MA). 
The column used was a Waters AQUITY UPLC BEH C18 120Å, 1.7 µm, 2.1 
mm × 100 mm column (Waters Corporation, Milford, MA) and the flow rate 
used was 400 uL/min. The column temperature was set at 35°C. The mobile 
phase used was aqueous 0.1% formic acid, 5 mM ammonium formate and 
acetonitrile. Gradient elution was used to separate the trapped metabolites in 
the injection sample. Total run time was 20.5 min for each injected sample. 




Table 6-1 LC conditions for Phase I GSH trapped metabolites identification. 
Mobile Phase 
A: Aqueous 0.1% formic acid,  
     5 mM ammonium formate 
B: Acetonitrile 
Time (min) % B Flow (µL/min) 
0.0 5.0 400 
2.0 5.0 400 
16.0 90.0 400 
17.5 90.0 400 
19.0 5.0 400 
20.5 5.0 400 
 
Precursor ion followed by enhanced product ion (PI-EPI) analysis was carried 
out to identify the structures of GSH trapped metabolites in each sample. The 
PI scan of m/z 272 was run in negative mode at a scan range of m/z 300 to m/z 
1000 and a scan rate of 2000 Da/s. Information-dependent acquisition (IDA) 
was used to trigger the acquisition of EPI spectra for ions greater than 5000 
cps with exclusion of ions for 5 s after three occurrences for the two most 
intense peaks. The EPI scan was run in positive mode for daughter ions from 
m/z 100 to m/z 1000 at a scan rate of 10,000 Da/s and a LIT fill time of 35 ms. 
The LC effluent was introduced directly into the MS. Source operation 
parameters for the LC-MS/MS system are summarized in Table 6-2.  
 
Table 6-2 MS source parameters for Phase I GSH trapped metabolites 
identification. 
PI scan  EPI scan 
Source parameters  Source parameters 
Temperature (°C) 500  Temperature (°C) 500 
Curtain gas (psi) 25.0  Curtain gas (psi) 25.0 
Gas 1 (psi) 50.0  Gas 1 (psi) 50.0 
Gas 2 (psi) 60.0  Gas 2 (psi) 60.0 
Collision gas (psi) Medium  Collision gas (psi) High 
IonSpray voltage (V) -4500  IonSpray voltage 
(V) 
5500 
DP -75.0  DP 75.0 
EP -10.0  EP 7.0 
CE -30.0  CE 40.0 
CXP -12.0  CES 20.0 
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6.2.3.1. LC-MS/MS for identification of Phase II Phe-Lys trapped metabolites 
Samples generated in incubations experiments were analyzed using LC-
MS/MS. LC-MS/MS was performed on an Agilent 1290 Infinity LC system 
connected to a AB Sciex Qtrap® 5500. The column and flow rate used were 
identical to that of section 6.2.3. The column temperature was set at 35°C. The 
mobile phase used was constituted of aqueous 5 mM ammonium formate, pH 
5.0 and acetonitrile. Gradient elution was used to separate the trapped 
metabolites in the injection sample. Total run time was 15.0 min for each 
injected sample. The LC conditions are summarized in Table 6-3.  
 
Table 6-3 LC conditions for Phase II Phe-Lys trapped metabolites 
identification. 
Mobile Phase 
A: Aqueous 5 mM ammonium    
     formate, pH 5.0 
B: Acetonitrile 
Time (min) % B Flow (µL/min) 
0.0 10.0 400 
2.0 10.0 400 
10.0 90.0 400 
12.0 90.0 400 
13.0 10.0 400 
15.0 10.0 400 
 
Enhanced mass scan followed by enhanced product ion (EMS-EPI) analysis 
was carried out to identify the structures of Phe-Lys trapped metabolites in 
each sample. The EMS scan was run in negative mode at a scan range of m/z 
300 to m/z 1000 at a scan rate of 2000 Da/s. IDA was used to trigger the 
acquisition of EPI spectra for ions greater than 5000 cps for the two most 
intense peaks. The EPI scan was run in positive mode for daughter ions from 
m/z 100 to m/z 900 at a scan rate of 10,000 Da/s and a LIT fill time of 35 ms. 
154 
 
The LC effluent was introduced directly into the MS. Source operation 
parameters for the LC-MS/MS system are summarized in Table 6-4.  
 
Table 6-4 MS source parameters for Phase II Phe-Lys trapped metabolites 
identification. 
PI scan  EPI scan 
Source parameters  Source parameters 
Temperature (°C) 500  Temperature (°C) 500 
Curtain gas (psi) 25.0  Curtain gas (psi) 25.0 
Gas 1 (psi) 50.0  Gas 1 (psi) 50.0 
Gas 2 (psi) 60.0  Gas 2 (psi) 60.0 
Collision gas (psi) Medium  Collision gas (psi) High 
IonSpray voltage (V) -4500  IonSpray voltage 
(V) 
4500 
DP -75.0  DP 75.0 
EP -10.0  EP 10.0 
CE -30.0  CE 40.0 
CES 0.0  CES 12.0 
 
6.3. Results 
6.3.1. Structure elucidation of Phase I GSH trapped reactive metabolites for 
selected compounds 
The bio-synthesized GSH trapped reactive metabolites were analyzed using a 
PI-EPI scan using LC-MS/MS. The initial PI scan detects analytes with the 
propensity to form a product anion of m/z 272 which corresponds to the 
glutathionyl moiety (precursor of m/z 272). The detection of the product ion 
then triggers the acquisition of the EPI scan of the analytes via set IDA 
parameters. In order to confirm that the formation of the metabolites were due 
to Phase I metabolism, negative controls were prepared with omission of the 
required co-factor NADPH. As seen from Figures 6-1a and 6-1b, the total ion 
chromatogram (TIC) and extracted ion chromatogram (XIC) of the negative 
control of compound 3 (diclofenac) showed no visible peaks that corresponded 
to the possible trapped metabolites shown in Figures 6-1c and 6-1d. This 
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indicated that the peaks observed for the trapped metabolites were not 






Figure 6-1 TIC of negative PI scan of m/z 272 and the subsequent XIC trace 
of the trapped metabolites for compound 3 (diclofenac). (a) TIC of negative 
control; (b) XIC of negative control; (c) TIC of compound 3 sample and (d) 





























Figure 6-2 XIC trace of GSH trapped metabolites of (a) compound 5; (b) 



































Figure 6-3 XIC trace of GSH trapped metabolites of (a) compound 1; (b) 



































Figure 6-4 XIC trace of GSH trapped metabolites of (a) compound 21; (b) 
compound 23 and (c) compound 24. 
 
We chose twelve compounds for analysis of their possible reactive metabolites 
formed via Phase I metabolism. Compound 3 (diclofenac) was chosen as a 
validation compound to determine if the incubation and LC-MS/MS analysis 
method is usable. The methyl series (compounds 5 to 8) were chosen as a 
comparison set between different halogen substituents at R2 and R3. The F-Cl 























different alkyl substituents at R1. Figures 6-2 to 6-4 show the XIC of the 




Figure 6-5 EPI spectra for 3-RM2 (m/z 583). Proposed structure and 
fragmentation pathway of the structure is shown for 3-RM2. 
 
Figure 6-5 shows an example of the EPI spectra of a trapped metabolite of 
compound 3 (3-RM2). The EPI spectra list the possible daughter ion 
fragments from the parent ions analyzed. From this information, the structure 
of the parent ion can be proposed from the fragmentation pathway shown by 
the EPI spectra. The main fragments that were observed for each EPI spectra 
were the neutral loss of the glycine moiety (m/z 75) and the pyroglutamate 
moiety (m/z 129) from the conjugated GSH chain. 
 
To validate our analysis method used, we compared the proposed structures of 
diclofenac (compound 3) in our study with that of literature. 3-RM2 ([MH+] 
583) and 3-RM3s ([MH+] 617) are the major metabolites found in our study. 
3-RM2 corresponds to the hydroxylation at the 4’-position on the aniline ring 



























dechlorinated carbon. 3-RM3s have two structures; 3-RM3a was proposed to 
be hydroxylation at the 4’-position on the aniline ring followed by GSH 
conjugation on the ring and 3-RM3b was proposed to be hydroxylation at the 
5-position on phenylacetic acid ring followed by GSH conjugation on the ring. 
These trapped metabolites have been extensively investigated and identified in 
several microsomal incubation studies, indicating that the analysis method 
employed in our study is valid for detection of GSH trapped metabolites of our 
compounds (Tang et al., 1999a; Poon et al., 2001; Yu et al., 2005; Zheng et al., 
2007; Wen et al., 2008). 
 
In chapter 5, we investigated the reactivity of the compounds towards cellular 
GSH after exposure to Phase I metabolism and found that the compounds 
exhibited some reactivity towards GSH. This work followed-up on that to 
confirm adduct formation of such reactive species by exogenous GSH and to 
propose the chemical structures based on signature MS/MS spectra. Tables 6-5 
to 6-16 show the proposed structure and fragmentation pathways of the 
trapped metabolites of the all the compounds analyzed from the EPI spectra 
scans obtained. 
 
In addition to common metabolites found in literature for diclofenac, we have 
detected the formation of benzyl-S-GSH metabolite of diclofenac (3-RM1) in 
our study. This was a novel GSH conjugated metabolite of diclofenac detected 
in studies involving in vivo and in vitro analysis and proposed to be formed via 
decarboxylation of the carboxylic acid moiety of ring A (Grillo et al., 2008; 
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Teffera et al., 2008). Here, we discovered that this benzyl-S-GSH metabolite 
formation is ubiquitous across all compounds analyzed in our study. 
 
Di-hydroxylated diclofenac metabolites were found to be formed in vivo in 
human (Stierlin et al., 1979) and a di-hydroxylated, dechlorinated GSH 
trapped diclofenac metabolite formed via in vitro microsomal incubations was 
identified in a separate study (Wen et al., 2008). However, we detected a GSH 
trapped di-hydroxylated diclofenac metabolites (3-RM4s) that did not undergo 
dechlorination. The peak corresponding to the 3-RM4s on the XIC of 
compound 3 was observed to be very small (Figure 6-1d). A further search 
through literature showed no studies that have identified this GSH trapped di-
hydroxylated metabolite. 
 
Comparing across different halogen substituents at R2 and R3 on the formation 
of reactive metabolites for the methylated compounds, we observed some 
interesting findings. Firstly, the major metabolite formed for each halogen 
combination was the mono-hydroxylated, dehalogenated GSH adduct (Figures 
6-1 to 6-4). Defluorination, dechlorination and debromination has been found 
to be able to occur in halogenated aromatic compounds during Phase I 
metabolism (Park et al., 2001; Hakk and Letcher, 2003; Isin and Guengerich, 
2007). For the symmetrical F-F, Cl-Cl and Br-Br compounds (6, 7 and 8), the 
dehalogenation involves either one of the halogen substituent. When an 
asymmetrical halogenated ring (F-Cl) is involved (e.g. compound 5, 
lumiracoxib), we observed that defluorination took priority over 
dechlorination. This was in line with literature findings whereby compound 5 
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(lumiracoxib) was found to form the mono-hydroxylated and defluorinated 
GSH adduct instead of the dechlorinated GSH adduct (Li et al., 2008; Kang et 
al., 2009). That said, a mono-hydroxylated and dechlorinated GSH adduct (5-
RM2) was observed for compound 5 but the amount of this metabolite formed 
was very small as compared to the defluorinated GSH adduct (5-RM3) as seen 
from Figure 6-2a. 5-RM2 has not been found in prior studies. A study found 
instead that for dechlorination to occur, defluorination needs to have taken 
place, resulting in the formation of an adduct with double conjugated GSH 
(Kang et al., 2009). The preference towards defluorination was observed for 
all the F-Cl compounds analyzed in this study (compounds 1, 5, 9, 13, 17 and 
21). 
 
Comparing across the alkyl series for F-Cl compounds, we observed that the 
major metabolite formed was the mono-hydroxylated, defluorinated GSH 
adduct regardless of the alkyl substituent at R1. With methyl, ethyl, n-propyl 
and iso-propyl substituted compounds, a direct GSH adduct with the alkyl 
group at R1 was formed. This is in line with literature findings whereby 
lumiracoxib was observed to form such an adduct (Kang et al., 2009) and 
quinone methides with methyl, ethyl and propyl substituents were observed to 
form GSH adducts (Thompson et al., 1995). We confirmed that the tert-butyl 
substituted compounds (21, 23 and 24) were observed to be unable to form a 
direct GSH adduct with the tert-butyl group at R1. This was as expected as 




Given that tert-butyl substituted compounds could not form imine methides 
and yet was the most toxic compounds of the series, we decided to investigate 
the two most toxic compounds, 23 and 24. From the LC-MS/MS analysis data, 
we observed that for compound 23, the type of metabolites formed were 
similar to other compounds. The only exception was the detection of a direct 
GSH adduct formed through the removal of a chlorine substituent (23-RM2) 
(Table 6-15). This indicated that compound 23, in its non-hydroxylated state 
has the ability to form adducts with GSH. On the other hand, for the most 
toxic compound (24), we observed no such direct GSH adduct formation. 
Instead, we observed that the formation of the mono-hydroxylated, 
debrominated GSH adduct was very much in dominance over the other two 
















Table 6-5 Proposed structures and fragmentation pathways for GSH-trapped 
metabolites of compound 1. 

























































































































Table 6-6 Proposed structures and fragmentation pathways for GSH-trapped 
metabolites of compound 3 (diclofenac). 

















































































































Table 6-6 (Cont.) Proposed structures and fragmentation pathways for GSH-
trapped metabolites of compound 3 (diclofenac). 










































































Table 6-7 Proposed structures and fragmentation pathways for GSH-trapped 
metabolites of compound 5 (lumiracoxib). 






























































































































Table 6-7 (Cont.) Proposed structures and fragmentation pathways for GSH-
trapped metabolites of compound 5 (lumiracoxib). 





































































Table 6-8 Proposed structures and fragmentation pathways for GSH-trapped 
metabolites of compound 6. 






































































































Table 6-9 Proposed structures and fragmentation pathways for GSH-trapped 
metabolites of compound 7. 



























































































































Table 6-10 Proposed structures and fragmentation pathways for GSH-trapped 
metabolites of compound 8. 





























































































































Table 6-11 Proposed structures and fragmentation pathways for GSH-trapped 
metabolites of compound 9. 


























































































































Table 6-12 Proposed structures and fragmentation pathways for GSH-trapped 
metabolites of compound 13. 








































































































































Table 6-13 Proposed structures and fragmentation pathways for GSH-trapped 
metabolites of compound 17. 
































































































































Table 6-14 Proposed structures and fragmentation pathways for GSH-trapped 
metabolites of compound 21. 


























































































336 m/z 657 639-H2O
564-H2O
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Table 6-15 Proposed structures and fragmentation pathways for GSH-trapped 
metabolites of compound 23. 
































































































































Table 6-16 Proposed structures and fragmentation pathways for GSH-trapped 
metabolites of compound 24. 



































































































6.3.2. Structure elucidation of Phase II Phe-Lys trapped reactive metabolites 
for selected compounds 
The bio-synthesized Phe-Lys trapped reactive metabolites from Phase II 
metabolism were analyzed using an EMS-EPI scan using LC-MS/MS. The 
initial EMS scan detects for analytes and the acquisition of the EPI scan was 
triggered via set IDA parameters when a peak is detected from the EMS scan. 
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As seen from Figure 6-6a, the TIC of compound 3 (diclofenac) shows several 
peaks, of which three corresponded to the Phe-Lys trapped AGs formed from 
compound 3 as seen from the XIC trace (Figure 6-6b). Two peaks were 
observed for 3-rAG1 due to the formation of isomeric derivatives. 
 
Further EPI spectra showed that the reactivity of the AGs towards Phe-Lys 
arose from both acyl migration (3-rAG1) and transacylation (3-rAG2) (Figures 
6-6c and 6-6d). This was in line with literature findings whereby AGs of 
diclofenac were found to undergo acyl migration and subsequently conjugate 
to cellular nucleophiles with retention of the glucuronic acid moiety 
(Kretzrommel and Boelsterli, 1994a; Wang et al., 2004). Also, AGs of 
diclofenac were found to undergo direct transacylation whereby the glucuronic 
acid moiety was lost and replaced by a cellular nucleophile (Grillo et al., 
2003). The mechanisms of transacylation and acyl migration will be further 
explained in the section 6.4.2. We also observed that the peak corresponding 
to transacylation in the XIC trace was very much smaller than the peak 












Figure 6-6 (a) TIC of negative EMS full scan of compound 3 (diclofenac) 
reactive AGs trapped with Phe-Lys; (b) XIC of negative EMS full scan, 
showing the peaks corresponding to the two reactive AGs trapped with Phe-
Lys; (c) Positive EPI spectra of 3-rAG1 that underwent acyl migration and the 
fragmentation pathway involved and (d) Positive EPI spectra of 3-rAG2 that 

































































To confirm that AGs of lumiracoxib, like diclofenac can undergo acyl 
migration and transacylation, we carried out the EMS-EPI scan on Phe-Lys 
trapped lumiracoxib AGs samples. As seen from Figure 6-7a, we found three 
peaks that corresponded to the trapped AGs of lumiracoxib (compound 5), two 
of which corresponded to isomeric derivatives of 5-rAG1 and one of which 
corresponded to 5-rAG2. Similar to diclofenac, we found Phe-Lys derivatives 
that underwent acyl migration (5-rAG1) and transacylation (5-rAG2). Further 
EPI spectra scans gave the fragmentation pathway of the derivatives, which 
clearly indicated that 5-rAG1 retained the glucuronic acid moiety and 5-rAG2 
lost the glucuronic acid moiety. Thus, we have proposed the structure of 
reactive AGs of lumiracoxib and have shown that like diclofenac, it can form 
conjugates with cellular nucleophiles via acyl migration or transacylation. 
Also observed for diclofenac, we found that the peak corresponding to 
transacylation in the XIC trace for lumiracoxib was very much smaller than 
















Figure 6-7 (a) TIC of negative EMS full scan of compound 5 (lumiracoxib) 
reactive AGs trapped with Phe-Lys; (b) XIC of negative EMS full scan, 
showing the peaks corresponding to the two reactive AGs trapped with Phe-
Lys; (c) Positive EPI spectra of 5-rAG1 that underwent acyl migration and the 
fragmentation pathway involved and (d) Positive EPI spectra of 5-rAG2 that 
underwent transacylation and the fragmentation pathway involved. 
 
Five compounds of the F-Cl series (1, 9, 13, 17 and 21) were selected to 

























































transacylation, congruent to the phenomenon seen with diclofenac. Similar to 
diclofenac and lumiracoxib, we found that all five compounds can undergo 
acyl migration and transacylation with subsequent adduct formation with Phe-
Lys (Table 6-17). Similar to both diclofenac and lumiracoxib, we observed 
that the peak corresponding to transacylation in the XIC trace was very much 
smaller than the peak corresponding to acyl migration (Appendix 6-1). From 
data obtained from this sub-set of compounds, we propose that all the AGs of 
the compounds in our series can undergo the same acyl migration and 
transacylation transformations, contributing to the formation of reactive 
metabolites. 
 
Table 6-17 Proposed structures and fragmentation pathways for Phe-Lys-
trapped metabolites of five selected compounds. 




























































Table 6-17 (Cont.) Proposed structures and fragmentation pathways for Phe-
Lys-trapped metabolites of five selected compounds. 



































































































































Table 6-17 (Cont.) Proposed structures and fragmentation pathways for Phe-
Lys-trapped metabolites of five selected compounds. 



































































6.4.1. Structure elucidation and possible bioactivation pathways of Phase I 
GSH trapped reactive metabolites for selected compounds 
The LC-MS/MS analyses for the structure elucidation of the twelve selected 
compounds have confirmed the formation of several reactive metabolites, 
consistent with the role expected in the depletion of cellular GSH and 
subsequent toxicity expressed by the compounds. Collectively, the compounds 
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have generated several distinct reactive metabolites that are also associated 










































































Figure 6-8 Possible pathways for dehalogenation of quinone imines formed 
with subsequent conjugation of GSH via (a) direct attack on chlorinated atom 
or (b) ipso GSH addition. 
 
The most common reactive metabolite detected for all the compounds was the 
mono-hydroxylated and dehalogenated GSH adduct. Like fluorine and 
chlorine substituents which can undergo dechlorination and defluorination in 
previous studies for diclofenac and lumiracoxib, bromine substituents can also 
undergo debromination in our series of compounds (Yu et al., 2005; Kang et 
al., 2009). This metabolite had been proposed to be formed via the quinone 
imine intermediate derived from the aniline ring (Yu et al., 2005). The GSH 
molecule attacks the halogenated carbon on the quinone imine followed by 
removal of the halogen ion (Figure 6-8a). Another study proposed that 
formation of such dehalogenated GSH adduct could be via an ipso GSH 
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addition to a halogenated quinone imine at the ortho position (Figure 6-8b) 
(Zhang et al., 2011). Thus, we postulate that generic dehalogenation, including 
debromination, for the series of compounds could be due to either pathway 
proposed in literature.  
 
We made an interesting observation with F-Cl compounds, where 
defluorination prevailed over dechlorination during GSH adduct formation. 
While unexpected, this observation was also made by studies done on 
lumiracoxib whereby defluorination occurred instead of or before 
dechlorination (Li et al., 2008; Kang et al., 2009). Li et al. (2008) postulated 
that the preference towards defluorination could be due the small size of 
fluorine allowing easier access of the GSH to attack the site and stronger 
electron-withdrawing effect of fluorine rendering the fluorinated carbon a 
preferred target for attack by nucleophilic GSH. For some compounds such as 
lumiracoxib (compound 5) and compound 21, we detected a mono-
hydroxylated, dechlorinated GSH adduct (5-RM2 and 21-RM4). This type of 
adduct had not been previously found for compounds with such chemical 
scaffold. A possible reason could be that the amount of the mono-
hydroxylated, dechlorinated adducts detected was very small as shown by the 
extremely low peak height in the XICs (Figures 6-1d and 6-4a) and could had 
gone un-detected in previous studies.  
 
There were no previous studies done on the metabolism of brominated 2-
phenylaminophenylacetic acid derived compounds. We have mentioned that 
metabolic debromination was observed with our brominated compounds. 
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Metabolic debromination have been extensively studied in brominated flame 
retardants (Hakk and Letcher, 2003). It is less commonly studied in 
pharmaceutical drugs due to the fact that brominated drugs are uncommon 
(Hernandes et al., 2010). From what was observed from our results, 
debromination, like defluorination and dechlorination serves as a mechanistic 
pathway to adduct formation. The higher toxicity observed with brominated 
compounds over other halogenated compounds could likely be due to other 
factors that affect the reactivity of the metabolites (Chapter 3 and Chapter 5). 
 
Mono-hydroxylated GSH adduct were detected for each compound in addition 
to their dehalogenated counterpart. However, this adduct was not as significant 
as their dehalogenated counterpart. Similar to the mono-hydroxylated, 
dehalogenated GSH adducts, it had been proposed that the formation of such 
adducts was via the formation of a quinone imine and subsequent conjugation 
of GSH to an un-substituted carbon on the aromatic ring (Figure 6-9) (Tang et 
al., 1999b; Li et al., 2008). For hydroxylation to occur on Ring A, the 
substituent at R1 can only be hydrogen as that is the point of hydroxylation. 
Thus, no mono-hydroxylated, GSH conjugated adducts on Ring A will be 
observed for compounds possessing an alkyl group on Ring A as shown in the 




















































Figure 6-9 Possible pathways for GSH adduct formation from quinone imines 
formed from the phenylacetic acid (Ring A) or the aniline ring (Ring B). 
 
For the compounds substituted with methyl, ethyl, n-propyl and iso-propyl at 
R1 in our study, we detected the formation of a direct GSH adduct to the alkyl 
group of the compounds (5-RM4, 6-RM3, 7-RM4, 8-RM3, 9-RM3, 13-RM4, 
17-RM4). This direct GSH adduct was also detected for lumiracoxib (5-RM4) 
in literature and was proposed to be formed via an imine methide (Figure 6-10) 
(Kang et al., 2009). Imine methides can be formed as long as extractable 
hydrogens are available on the alkyl group involved. Thus, tert-butyl 
substituted compounds do not have the ability to form imine methides. This is 
confirmed by the absence of the direct GSH adducts observed with tert-butyl 























Figure 6-10 Possible pathways for GSH adduct formation from imine 
methides formed from alkyl groups with an extractable hydrogen (R1 = methyl, 
ethyl, n-propyl and iso-propyl). 
 
A GSH adduct formed via decarboxylation of the carboxylic acid group and 
subsequent conjugation with GSH was detected for the all the compounds 
assayed. This GSH adduct was previously found in literature and was 
proposed to be formed via oxidative decarboxylation and formation of an 
ortho-imine methide (Figure 6-11) (Grillo et al., 2008; Teffera et al., 2008). 
Grillo et al. (2008) found that the P450 responsible for the oxidative 
decarboxylation was CYP3A4. Previously, lumiracoxib was proposed to 
metabolized only by CYP2C9 (Mangold et al., 2004). We found that 
lumiracoxib has the propensity to form this decarboxylated GSH adduct (5-
RM1), thus, indicating that perhaps lumiracoxib can be metabolized by 
CYP3A4 via the oxidative decarboxylation pathway. This applies to our other 
compounds too as the decarboxylated GSH adduct was observed for all the 
























Figure 6-11 Possible pathways for GSH adduct formation from ortho-imine 
methides formed oxidative decarboxylation. 
190 
 
It is of interest to note that the two most toxic compounds could not form 
imine methides. As a result, it is reasonable to propose that although the 
formation of imine methides may contribute to the toxicity of the compounds, 
it may not be a major determinant. On the other hand, Compound 23 was 
found to be able to form direct GSH adducts via dechlorination without prior 
hydroxylation on the aromatic ring (23-RM2), as an alternative metabolic 
pathway towards nucleophile adduction. However, the peak corresponding to 
this GSH adduct is extremely small and its role as a major contributing factor 
to the toxicity of the compound remains questionable (Figure 6-4b). A 
possible mechanism for the formation of such a metabolite could be an ipso 
GSH addition to a dihalogenated aniline ring (Ring B) (Figure 6-12). This 
mechanism was proposed for dihalogenated anilines at the ortho- and para-
positions but could likely be applied to double ortho-halogenated anilines 






























































Figure 6-12 Possible pathway for formation of 23-RM2 from dechlorination 
followed by direct GSH conjugation via an ipso GSH addition mechanism. 
 
For both compounds 23 and 24, the major GSH adduct observed was the 
mono-hydroxylated, dehalogenated adduct (23-RM3 and 24-RM1), especially 
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in the case of compound 24 where the other GSH adducts detected were very 
much lower than 24-RM1. This GSH adduct could be more harmful than other 
adducts as the reactive metabolite precursor seems to be more reactive than 
other metabolites with its abundant formation.  Given that 24-RM1 is an 
abundant metabolite of compound 24, it is no surprise compound 24 is highly 
toxic. Overall, we observed that common adducts were formed for each 
compound. The different substituents on them affect the quantity of each type 
of adduct formed when qualitatively comparing the peaks in each XIC trace. 
However, there seems to be no deducible trend on the effect of individual 
substituents on the structures of adducts formed as cross-compound 
comparison cannot be carried out. In order to investigate further, studies to 
quantify each GSH adduct formed for each compound would be needed for 
cross-compound comparison to elucidate the effect of substituents on the type 
and amount of adduct formed. 
 
6.4.2. Structure elucidation and possible bioactivation pathways of Phase II 
Phe-Lys trapped reactive metabolites for selected compounds 
AGs have been extensively studied and were found to be reactive when acyl 
migration or transacylation occurs and subsequent glycation of cellular 
nucleophiles such as proteins and DNA. Transacylation involves an 
intermolecular exchange of the glucuronic acid moiety for a cellular 
nucleophile such as GSH or protein (Faed, 1984; Stachulski et al., 2006). The 
adduct forms consist of the parent aglycone and the conjugated nucleophile 
with the loss of the glucuronic acid moiety (Figure 6-13). Acyl migration 
occurs when the parent aglycone moiety migrate from the 1-position to the 2- 
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or 3-position to form 2-O-β or 3-O-β-AG followed by ring opening and 
formation of an aldehyde at the anomeric carbon (Faed, 1984; Langguth and 
Benet, 1992). Glycation of the amine group on cellular nucleophiles to the 
reactive aldehyde can form an imine known as a Schiff Base (Figure 6-13) 























































Figure 6-13 Pathways involved in formation of AG adducts for the 
synthesized compounds. Transacylation involves replacement of the 
glucuronic acid moiety with a nucleophile. Acyl migration involves 
intramolecular rearrangement of aglycone. Here, a 3-O-β-glucuronide is 
shown and subsequent ring opening to form an aldehyde and glycation to form 
a Schiff base. 2-O-β-glucuronides and 4-O-β-glucuronides are able to undergo 
ring opening to form reactive aldehydes. 
 
The AGs of diclofenac have been shown to be reactive towards cellular 
protein and GSH via both acyl migration and transacylation and have been 
proposed to be a contributor to the hepatotoxicity associated with diclofenac 
(Kretzrommel and Boelsterli, 1993; Kretzrommel and Boelsterli, 1994a; Grillo 
et al., 2003). We have shown in our study that our analysis method could 
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detect the trapped AGs that had undergone acyl migration and transacylation. 
Lumiracoxib have been shown to form AGs in vivo, albeit as a minor 
metabolite and in vitro (Mangold et al., 2004; Kang et al., 2009). However, no 
studies have investigated the reactivity of AGs of lumiracoxib either via acyl 
migration or transacylation. In Chapter 5, we have shown that the AGs 
biosynthesized from lumiracoxib have a degree of reactivity that is slightly 
lower as compared to diclofenac. Further LC-MS/MS analysis of the Phe-Lys 
trapped AGs of lumiracoxib showed that the AGs can undergo acyl migration 
(5-rAG1) and transacylation (5-rAG2) as shown by the proposed 
fragmentation pathways seen in Figures 6-7c and 6-7d. Thus, we propose that 
like diclofenac, the AGs of lumiracoxib may contribute to the hepatotoxicity 
associated with the drug due to the reactivity seen with its AGs and the ability 
to form acyl migrated and transacylated glycation adducts. 
 
Similar to diclofenac and lumiracoxib, we observed acyl migration and 
transacylation occurring for the AGs of five selected compounds (1, 9, 13, 17 
and 21) in our series of compounds. This reflects a high possibility that the 
compounds in our series can form AGs which can further undergo acyl 
migration and transacylation. This may play a role in the toxicity observed 
with the compounds. This is supported by the AG reactivity results shown in 
Chapter 5 whereby we found that all the AGs of all the compounds in our 
series had certain degrees of reactivity towards the trapping agent, Phe-Lys. 
Judging from the reactive AGs identified and proposed, the substituents at R1, 
R2 and R3 had no effect on the structures of the trapped AGs but instead had 




Comparing the peaks corresponding to the different trapped AGs for each 
compound, the peak corresponding to transacylation was consistently smaller 
than that of acyl migration for all of the assayed compounds. This difference 
in peak heights could be due acyl migration being the major pathway in which 
AGs bioactivates. However, we also cannot rule out that this difference could 
be due to the different reactivity of the acyl migrated AGs and AGs 
undergoing transacylation towards the trapping agent used.  
 
6.5. Conclusion 
The bioactivation of the synthesized compounds via Phase I and Phase II 
metabolism were associated with the toxicity observed in Chapter 5. In order 
to further confirm that bioactivated reactive metabolites were responsible for 
the toxicity of the compounds and to investigate the possible structures of the 
reactive metabolites, we carried out LC-MS/MS analysis for structure 
elucidation on twelve selected compounds. GSH trapped metabolites were 
detected for each compound analyzed, which indicates that the presence of 
trapped metabolites supports a role for formation of reactive metabolites in the 
toxicity observed with the synthesized compounds. 
 
We found that for Phase I metabolism, the major reactive metabolite was the 
mono-hydroxylated, dehalogenated metabolite for all the compounds tested. 
For F-Cl compounds, there was a preference for defluorination over 
dechlorination. The reactivity of the hydroxylated metabolites was proposed to 
arise from the formation of quinone imines, which are electrophilic in nature 
195 
 
and is susceptible towards attack by cellular nucleophiles such as GSH or 
protein. The compounds that possess an alkyl substituent at R1 (methyl, ethyl, 
n-propyl, iso-propyl) were able to directly conjugate to GSH at the alkyl 
substituent. The formation of these GSH adducts at the alkyl group was 
proposed to be due to the formation of imine methides. tert-Butyl substituted 
compounds were unable to form such a GSH adduct due to the absence of an 
extractable hydrogen at the site of attack. 
 
In addition to hydroxylated, dehalogenated and direct GSH adducts of our 
compounds, we also detected benzyl-S-GSH adducts for all the compounds. 
Benzyl-S-GSH adducts were proposed to be formed via oxidative 
decarboxylation by CYP3A4. This adduct was previously detected for 
diclofenac but was not detected for lumiracoxib. Thus, lumiracoxib benzyl-S-
GSH adduct is a novel metabolite detected in our study. With the detection of 
this GSH adduct, we propose that lumiracoxib and our synthesized compounds, 
like diclofenac, can be metabolized by both CYP2C9 and CYP3A4. A 
summary of all the possible Phase I metabolites proposed for our synthesized 















































































Figure 6-14 Possible reactive metabolites and their GSH conjugates proposed 
for our synthesized compounds. It should be noted that individual compounds 
have their own signature reactive metabolites and not every reactive 
metabolites illustrated will be found for a single compound. 
 
 
We have confirmed that lumiracoxib, like diclofenac, can form adducts with 
amine groups on proteins via acyl migration and transacylation from the 
fragmentation spectras of the Phe-Lys trapped AGs. Although AGs of 
lumiracoxib have been found to a minor metabolite in vivo, the ability of the 
AGs to bind to cellular nucleophiles can contribute to the hepatotoxicity 
associated with the drug. In addition, from the proposed pathways of Phase II 
reactive metabolites of five selected compounds, we propose that all the 
compounds in our series can form AGs that have the ability to undergo acyl 
migration and transacylation, which in turn could play a role in the toxicity 




All in all, we have shown that our compounds can form reactive metabolites 
via both Phase I and Phase II metabolism in vitro. Together with the Phase I 
and Phase II metabolite reactivity results in Chapter 5, we conclude that the 
formation of reactive metabolites may have a role in toxicity observed with 
our compounds. From what was observed from our reactive metabolite 
trapping results, the most common pathway for formation of reactive 
metabolites for Phase I metabolism was hydroxylation with dehalogenation. 
For Phase II metabolism, the most common pathway was acyl migration. 
However, we should carry out absolute quantification of the individual trapped 
metabolites in order to confirm on the importance of the pathways involved 
and to carry out cross-compound comparisons in order to determine the effect 
of substituents on the type and amount of adducts formed. On the other hand, 
we cannot conclude on which phase of metabolism contributes more to the 
toxicity of the compounds as both phases of metabolism were measured 
separately from each other. In order to investigate whether Phase I and Phase 
II metabolism has a more critical role, both phases of metabolism should be 
carried out for the compounds concurrently and the reactive metabolites 





Chapter 7. Conclusion and Future Work 
 
The aim of the thesis is to investigate the effects of substituent on toxicity and 
pharmacological properties, specifically using the 2-phenylaminophenylacetic 
acid scaffold that brought about drugs like diclofenac and lumiracoxib. 
Although there have been several individual studies on the toxicity and 
pharmacology of said drugs, there have been few to no studies to compare the 
toxicity on its own or with pharmacological properties of such structurally 
similar drugs. Several studies have shown the undeniable link between 
bioactivation and hepatotoxicity of diclofenac and lumiracoxib. However, the 
relative contribution of the diverse mechanisms described thus far, and the 
influence of key substituents that may perturb this process remains elusive. 
Thus, we hypothesized that the varying substituents on the 2-
phenylaminophenylacetic acid scaffold will affect bioactivation and 
subsequently, toxicity to a significant degree. We also hypothesized that the 
substituents will affect the intricate link between toxicity and pharmacological 
properties. 
 
In order to investigate our hypotheses, we designed and synthesized twenty-
four 2-phenylaminophenylacetic acid analogs that were structurally similar to 
diclofenac and lumiracoxib with varying substituents at three positions on the 
said chemical backbone (Chapter 2). The in vitro toxicity of the synthesized 
compounds were determined on two liver cell-lines in Chapter 3 with 
differentiating metabolic capibilities using MTT assay in order to determine 
their toxicity and subsequently, the effect of substituents on the toxicity 
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expressed by the compounds on liver cells and the possible role of metabolism 
in toxicity of the compounds. The cytotoxicity profile of the compounds 
showed that metabolism could be play an important role in the toxicity of the 
compounds, given that LC50 values were lower in the more metabolically 
capable cell line (TAMH) as compared to the less metabolically capable cell 
line (HuH-7). Substituents on both phenyl rings were observed to affect the 
toxicity of the compounds significantly. It was observed that increasing the 
alkyl group size at R1 resulted in an increase in toxicity (indicated by a 
decrease in LC50 values). Increasing the halogen group size at R2 and R3 also 
increased the toxicity. Taken together, fluoro-substituted compounds are the 
least toxic while bromo-substituted compounds are the most toxic. Further 
comparative structure-toxicity relationships were carried out via a QSTR 
model. A linear relationship between lipophilicity and toxicity was elucidated, 
with increase in lipophilicity contributing to toxicity. However, with only the 
cytotoxicity data, we cannot attribute metabolism to reactive metabolites as 
the major cause. 
 
The initial data from Chapter 3 enabled us to postulate a possible role of 
metabolism and bioactivation in the toxicity observed by the compounds. With 
that in mind, we decided carry out more in-depth investigations of the role of 
metabolism and bioactivation in the toxicity observed for the compounds in 
Chapter 5. In vitro bioactivation assays such as metabolic stabilities, GSH 
depletion assay and AG reactivity determination were thus performed. From 
observations made from our QSTR models in Chapter 3, we initially expected 
that lipophilicity, toxicity of the compounds and Phase I and Phase II 
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metabolic stability to exhibit an inverse relationship. However, the metabolic 
stability of the compounds across the series (varying alkyl and halogen 
substituents) was not correlated to lipophilicity. We postulate that this could 
be due to unfavourable spatial configurations of the compounds within the 
active site of the P450s for Phase I metabolism. The usage of alamethicin as a 
pore forming reagent to aid penetration the compounds across cell membranes 
could have changed the relationship between lipophilicity and Phase II 
metabolism. A cross-comparison between toxicity and metabolic stability 
showed that no relationship between metabolic stability and toxicity was 
observed for Phase I metabolism. On the other hand, for Phase II metabolism, 
metabolic stability correlated to toxicity positively. This gives an indication 
that metabolic stability of a compound may not be a predictor of bioactivation 
even though metabolism itself is a pre-requisite. Instead, the reactivity of the 
metabolites generated in the process could possibly play a more important role 
in the manifestation of toxicity for the compounds. 
 
In addition to metabolic stability, we determined both the cellular GSH 
depletion and AG reactivity of the compounds. We found that GSH depletion 
increased across the series. On the other hand, AG reactivity decreased across 
the series. The effect of substituents on GSH depletion and AG reactivity was 
clearly observed from our experimental data. Larger substituents (either alkyl 
or halogen) generally increased the GSH depletion of the compound, with 
some exceptions. This was as what we expected, which was GSH depletion 
increasing with increase in size of the compounds. On the other hand, the 
reverse was seen for AG reactivity, which was not as expected. Difluorinated 
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compounds were observed to have absolutely low AG reactivity regardless of 
which alkyl substituent were present on the scaffold. A cross-comparison 
between metabolite reactivity and toxicity gave rise to a proportional 
relationship between GSH depletion and toxicity. However, the correlation 
was not strong due to exceptions. This supports the possible role of 
bioactivation in the toxicity exhibited by our compounds towards liver cells. 
On the other hand, AG reactivity was found to correlate to toxicity inversely, 
albeit to a slight degree. A possible explanation could be that the toxicity of 
the compounds may be less dependent on Phase II metabolism. We postulate 
that the effect of substituents on AG reactivity from the halogen substituents 
could be electronic in nature and the effect from the alkyl groups at R1 could 
be steric in nature. 
 
We have thus far shown that bioactivation may play an important role in the 
toxicity of the compounds and that substituents on the compounds in turn 
could affect the bioactivation process and subsequently, the toxicity of the 
compounds. In Chapter 6, we looked further into the possible pathways and 
structures of the Phase I and Phase II reactive metabolites of the compounds 
that could potentially contribute to the toxicity of the compounds. One reason 
for carrying out the identification was to confirm the formation of reactive 
metabolites via their trapped counterparts. GSH trapped (Phase I) and Phe-Lys 
trapped (Phase II) metabolites were detected for each compound analyzed, 
which indicated that the formation of reactive metabolites do have a role in 




The proposed reactive metabolites for both Phase I and Phase II metabolism 
are summarized in Figure 7-1. Mono-hydroxylated metabolites for all the 
compounds tested were found to be able to undergo dehalogenation during 
GSH adduct formation, including brominated compounds of this chemical 
scaffold that were not previously studied. For F-Cl unsymmetrical compounds, 
there was a preference for defluorination over dechlorination. The compounds 
that possess an alkyl substituent at R1 (methyl, ethyl, n-propyl, iso-propyl) 
were able to directly conjugate to GSH at the alkyl substituent via formation 
of imine methides. tert-Butyl substituted compounds were unable to form such 
an GSH adduct due to the absence of an extractable hydrogen at the site of 
attack. This is rather interesting as tert-butyl compounds were shown to be the 
most toxic of all the alkyl substituted compounds. This could indicate that the 
formation of imine methide may not be a major bioactivation pathway. 
Benzyl-S-GSH adducts were detected for all the compounds formed and its 
formation was proposed to be via oxidative decarboxylation. Lumiracoxib 
benzyl-S-GSH adduct is a novel metabolite not previously detected in 
bioactivation studies of lumiracoxib. From the data obtained, we observed that 
the varying substituents do affect the structures and amount of reactive 
metabolites formed. However, due to the limitations of the study done on 
Phase I metabolism, we are unable to firmly conclude any trends or effects of 

































































































































Figure 7-1 Possible reactive metabolites and their trapped conjugates 
proposed for our synthesized compounds for both Phase I and Phase II 
metabolism. For Phase I metabolism, it should be noted that individual 
compounds have their own signature reactive metabolites and not every 
reactive metabolites illustrated will be found for a single compound. For Phase 
II metabolism, every compound will potentially form only the transacylated or 
acyl migrated- glycated adduct. 
 
 
For Phase II metabolism, our compounds were shown to be able to undergo 
either transacylation and/ or acyl migration and subsequent adduct formation 
with Phe-Lys. This vindicates the AG reactivity data from Chapter 5, 
indicating that the metabolite reactivity observed was due to transacylation 
and/or acyl migration. Judging from the reactive AGs identified and proposed, 
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the substituents at R1, R2 and R3 had no effect on the structures of the trapped 
AGs but instead had some effects on the reactivity of the AGs as shown in 
Chapter 5. 
 
In addition to toxicity, the pharmacological aspect of the compounds in terms 
of their inhibitory effects on COX-1 and COX-2 was determined using whole 
cell assay in Chapter 4. In terms of absolute activity, diclofenac (compound 3) 
was found to be the most potent in both COX isoforms. In general, the 
addition of an alkyl group at R1 on ring A of the compound and the increase in 
size of the alkyl group were observed to decrease potency. The halogen 
substituents at R2 and R3 on ring B were found to affect the activity in addition 
to the alkyl group at R1, with improvement to potency via the presence of a 
chlorine substituent. In terms of selectivity, lumiracoxib (compound 5) was 
found to be the most selective of all the compounds. The selectivity arises 
from the addition of the methyl or ethyl group at R1. However, further increase 
in alkyl chain length decreased selectivity in general. An increase in selectivity 
was observed to occur with a decrease in absolute potency for certain cases. 
Thus, it can be concluded that the right combination of substituents at R1, R2 
and R3 are required for good selectivity and potency. 
 
A safety index was generated to link toxicity to pharmacology and to show the 
effect of substituents on the toxicity-pharmacology relationship. Diclofenac 
(compound 3) was found to be the safest among all the compounds and is not 
selective to COX-2. Lumiracoxib (compounds 5), which is selective towards 
COX-2 had a 3.8 times lower safety index as compared to diclofenac. From 
this, we can conclude that selectivity (due to changes in substituents) may 
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come at the expense of compound safety (increased toxicity) in the case of 
diclofenac and lumiracoxib. 
 
Taken together, the findings of this thesis supported the hypothesis that 
varying substituents on the 2-phenylaminophenylacetic acid scaffold will alter 
bioactivation and subsequently, toxicity to a significant degree. Although the 
metabolic stability of the compounds provided no indication that the extent of 
metabolism influenced toxicity of the compounds, further metabolite reactivity 
studies and reactive metabolite identification allowed us to conclude that the 
formation of reactive metabolites via metabolism may have a major role in the 
toxic observed with our compounds. However, other toxicity pathways cannot 
be excluded and could also play an important role in the toxicity observed 
with the compounds. In addition, the link between toxicity and pharmacology 
was elucidated in this thesis for our series of compounds, providing a better 
understanding in the balance between toxicity and activity and presents the 
possibility to associate the two biological outcomes. 
 
The present work has raised questions and issues that could be pursued in 
future investigations. Firstly, we postulated that the effect of substituents on 
AG reactivity from the halogen substituents could be due electronic in nature 
and the effect from the alkyl groups at R1 could be due steric in nature. Further 
investigation such as calculations of electronic and steric properties and QSAR 
modelling should be carried out to help in the explanation of the results 
observed for AG reactivity of our compounds. Secondly, we could not 
conclude on the trends and effects of the substituents on structures and amount 
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of reactive metabolites formed for Phase I metabolism. Absolute 
quantification of the individual trapped metabolites could be carried out in 
order to confirm on the importance of the pathways involved and to carry out 
cross-compound comparisons in order to determine the effect of substituents 
on the type and amount of adducts formed. Thirdly, while we have 
characterize the involvement of both Phase I and II metabolism to toxicity, we 
were unable to determine their relative contribution as both phases of 
metabolism were measured separately from each other. In order to investigate 
whether Phase I and Phase II metabolism has a more critical role, both phases 
of metabolism should be carried out for the compounds concurrently and the 
reactive metabolites formed individually quantitated. Fourthly, further 
synthesis of compounds with other types of substituents such as –CF3 or a 
halogen at R1, alkyl groups a R2 and R3 and substituents at other positions 
such as key sites for metabolism will enable a broader and more complete 
insight on the effect of substituents on structure-toxicity-bioactivation 
relationships and on the structure-toxicity-activity relationships. Last but not 
least, other toxicity pathways such as direct toxicity of the parent compound 
should be further investigated. 
 
In conclusion, the results presented in this thesis have contributed to a better 
understanding on the structure-toxicity-bioactivation relationships and on the 
structure-toxicity-activity relationships for 2-phenylaminophenylacetic acid 
derived compounds. Several more questions were raised with regards to the 
initial investigative questions, allowing more room for improvement and 
further investigations. Overall, the rigors of this process have led to the 
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development of a set of approaches that bears witness to the differential 
influence of substituents on both toxicity and pharmacological activity. Such 






Acemoglu, M., Allmendinger, T., Calienni, J., Cercus, J., Loiseleur, O., 
Sedelmeier, G.H., Xu, D., 2004. Synthesis of new N-aryl oxindoles as 
intermediates for pharmacologically active compounds. Tetrahedron 
60, 11571-11586. 
 
Agundez, J.A., Lucena, M.I., Martinez, C., Andrade, R.J., Blanca, M., Ayuso, 
P., Garcia-Martin, E., 2011. Assessment of nonsteroidal anti-
inflammatory drug-induced hepatotoxicity. Expert Opinion on Drug 
Metabolism & Toxicology 7, 817-828. 
 
Allred, A.L., 1961. Electronegativity values from thermochemical data. 
Journal of Inorganic and Nuclear Chemistry 17, 215-221. 
 
Attia, S.M., 2010. Deleterious Effects of Reactive Metabolites. Oxidative 
Medicine and Cellular Longevity 3, 238-253. 
 
Bannwarth, B., Berenbaum, F., 2007. Lumiracoxib in the management of 
osteoarthritis and acute pain. Expert Opinion on Pharmacotherapy 8, 
1551-1564. 
 
Barbato, F., LaRotonda, M.I., Quaglia, F., 1997. Interactions of nonsteroidal 
antiinflammatory drugs with phospholipids: Comparison between 
octanol/buffer partition coefficients and chromatographic indexes on 
immobilized artificial membranes. Journal of Pharmaceutical Sciences 
86, 225-229. 
 
Barnard, S., Kelly, D.F., Storr, R.C., Park, B.K., 1993. The effect of fluorine 
substitution on the hepatotoxicity and metabolism of paracetemol in 
the mouse. Biochemical Pharmacology 46, 841-849. 
 
Bathelt, C., Schmid, R.D., Pleiss, J., 2002. Regioselectivity of CYP2B6: 
homology modeling, molecular dynamics simulation, docking. Journal 
of Molecular Modeling 8, 327-335. 
 
Batsanov, S.S., 2001. Van der Waals Radii of Elements. Inorganic Materials 
37, 871-885. 
 
Benet, L.Z., Spahnlangguth, H., Iwakawa, S., Volland, C., Mizuma, T., Mayer, 
S., Mutschler, E., Lin, E.T., 1993. Predictability of the covalent 
binding of acidic drugs in man. Life Sciences 53, PL141-PL146. 
 
Berg, J., Christoph, T., Widerna, M., Bodenteich, A., 1997. Isoenzyme-
specific cyclooxygenase inhibitors: A whole cell assay system using 
the human erythroleukemic cell line HEL and the human monocytic 
cell line Mono Mac 6. Journal of Pharmacological and Toxicological 




Berry, N.G., Iddon, L., Iqbal, M., Meng, X.L., Jayapal, P., Johnson, C.H., 
Nicholson, J.K., Lindon, J.C., Harding, J.R., Wilson, I.D., Stachulski, 
A.V., 2009. Synthesis, transacylation kinetics and computational 
chemistry of a set of arylacetic acid 1 beta-O-acyl glucuronides. 
Organic & Biomolecular Chemistry 7, 2525-2533. 
 
Bessems, J.G.M., Gaisser, H.D., Koppele, J.M.T., VanBennekom, W.P., 
Commandeur, J.N.M., Vermeulen, N.P.E., 1995. 3,5-disubstituted 
analogues of paracetamol. Synthesis, analgesic activity and 
cytotoxicity. Chemico-Biological Interactions 98, 237-250. 
 
Bessone, F., 2010. Non-steroidal anti-inflammatory drugs: What is the actual 
risk of liver damage? World Journal of Gastroenterology 16, 5651-
5661. 
 
Blobaum, A.L., Marnett, L.J., 2007. Molecular determinants for the selective 
inhibition of cyclooxygenase-2 by lumiracoxib. Journal of Biological 
Chemistry 282, 16379-16390. 
 
Boelsterli, U.A., 2003. Diclofenac-induced liver injury: a paradigm of 
idiosyncratic drug toxicity. Toxicology and Applied Pharmacology 192, 
307-322. 
 
Bolton, J.L., Trush, M.A., Penning, T.M., Dryhurst, G., Monks, T.J., 2000. 
Role of quinones in toxicology. Chemical Research in Toxicology 13, 
135-160. 
 
Bruggemann, R., Bartel, H.G., 1999. A theoretical concept to rank 
environmentally significant chemicals. Journal of Chemical 
Information and Computer Sciences 39, 211-217. 
 
Bruggemann, R., Bucherl, C., Pudenz, S., Steinberg, C.E.W., 1999. 
Application of the concept of partial order on comparative evaluation 
of environmental chemicals. Acta Hydrochimica Et Hydrobiologica 27, 
170-178. 
 
Burka, L.T., Plucinski, T.M., Macdonald, T.L., 1983. Mechanisms of 
hydroxylation by cytochrome-P450 – Metabolism of 
monohalobenzenes by phenobarbital-induced microsomes. 
Proceedings of the National Academy of Sciences of the United States 
of America-Biological Sciences 80, 6680-6684. 
 
Carlsen, L., 2008. Assessment of Chemicals Applying Partial Order Ranking 
Techniques. Combinatorial Chemistry & High Throughput Screening 
11, 794-805. 
 
Chakraborti, A.K., Garg, S.K., Kumar, R., Motiwala, H.F., Jadhavar, P.S., 
2010. Progress in COX-2 Inhibitors: A Journey So Far. Current 
Medicinal Chemistry 17, 1563-1593. 
210 
 
Chan, K., Jensen, N., O'Brien, P.J., 2008. Structure–activity relationships for 
thiol reactivity and rat or human hepatocyte toxicity induced by 
substituted p-benzoquinone compounds. Journal of Applied 
Toxicology 28, 608-620. 
 
Chan, K., Jensen, N.S., Silber, P.A., O'Brien, P.J., 2007. Structure-activity 
relationships for halobenzene induced cytotoxicity in rat and human 
hepatoctyes. Chemico-Biological Interactions 165, 165-174. 
 
Cnubben, N.H.P., Peelen, S., Borst, J.W., Vervoort, J., Veeger, C., Rietjens, I., 
1994. Molecular orbital-based quantitative structure-activity 
relationship for the cytochrome P450-catalyzed 4-hydroxylation of 
halogenated anilines. Chemical Research in Toxicology 7, 590-598. 
 
Coe, K.J., Jia, Y., Ho, H.K., Rademacher, P., Bammler, T.K., Beyer, R.P., 
Farin, F.M., Woodke, L., Plymate, S.R., Fausto, N., Nelson, S.D., 2007. 
Comparison of the cytotoxicity of the nitroaromatic drug flutamide to 
its cyano analogue in the hepatocyte cell line TAMH: Evidence for 
complex I inhibition and mitochondrial dysfunction using 
toxicogenomic screening. Chemical Research in Toxicology 20, 1277-
1290. 
 
Cronin, M.T.D., Schultz, T.W., 1996. Structure-toxicity relationships for 
phenols to Tetrahymena pyriformis. Chemosphere 32, 1453-1468. 
 
Davies, N.M., Skjodt, N.M., 2000. Choosing the Right Nonsteroidal Anti-
Inflammatory Drug for the Right Patient: A Pharmacokinetic Approach. 
Clinical Pharmacokinetics 38, 377-392. 
 
Ding, A., Ojingwa, J.C., McDonagh, A.F., Burlingame, A.L., Benet, L.Z., 
1993. Evidence for covalent binding of acyl glucuronides to serum-
albumin via an imine mechanism as revealed by tandem mass-
spectroscopy. Proceedings of the National Academy of Sciences of the 
United States of America 90, 3797-3801. 
 
Easterbrook, J., Lu, C., Sakai, Y., Li, A.P., 2001. Effects of organic solvents 
on the activities of cytochrome P450 isoforms, UDP-dependent 
glucuronyl transferase, and phenol sulfotransferase in human 
hepatocytes. Drug Metabolism and Disposition 29, 141-144. 
 
Faed, E.M., 1984. Properties of Acyl Glucuronides: Implications for Studies 
of the Pharmacokinetics and Metabolism of Acidic Drugs. Drug 
Metabolism Reviews 15, 1213-1249. 
 
FitzGerald, G.A., Patrono, C., 2001. The Coxibs, Selective Inhibitors of 
Cyclooxygenase-2. New England Journal of Medicine 345, 433-442. 
 
Fratello, G., Marchini, S., Zucco, F., Sapora, O., Stammati, A., 1997. 
Cytotoxicity of halogenated benzenes and its relationship with logP. 
Toxicology in Vitro 11, 673-677. 
211 
 
Gan, T.J., 2010. Diclofenac: an update on its mechanism of action and safety 
profile. Current Medical Research and Opinion 26, 1715-1731. 
 
Ganey, P.E., Kauffman, F.C., Thurman, R.G., 1988. Oxygen-dependent 
hepatotoxicity due to doxorubicin – Role of reducing equivalent supply 
in perfused rat-liver. Molecular Pharmacology 34, 695-701. 
 
Giri, S., Nieber, K., Bader, A., 2010. Hepatotoxicity and hepatic metabolism 
of available drugs: current problems and possible solutions in 
preclinical stages. Expert Opinion on Drug Metabolism & Toxicology 
6, 895-917. 
 
Grillo, M.P., Knutson, C.G., Sanders, P.E., Waldon, D.J., Hua, F.M., Ware, 
J.A., 2003. Studies on the chemical reactivity of diclofenac acyl 
glucuronide with glutathione: Identification of diclofenac-S-acyl-
glutathione in rat bile. Drug Metabolism and Disposition 31, 1327-
1336. 
 
Grillo, M.P., Ma, J., Teffera, Y., Waldon, D.J., 2008. A novel bioactivation 
pathway for 2- 2-(2,6-dichlorophenyl)aminophenyl ethanoic acid 
(diclofenac) initiated by cytochrome P450-mediated oxidative 
decarboxylation. Drug Metabolism and Disposition 36, 1740-1744. 
 
Grosser, T., 2006. The pharmacology of selective inhibition of COX-2. 
Thrombosis and Haemostasis 96, 393-400. 
 
Guo, L., Dial, S., Shi, L.M., Branham, W., Liu, J., Fang, J.L., Green, B., Deng, 
H., Kaput, J., Ning, B.T., 2011. Similarities and Differences in the 
Expression of Drug-Metabolizing Enzymes between Human Hepatic 
Cell Lines and Primary Human Hepatocytes. Drug Metabolism and 
Disposition 39, 528-538. 
 
Hacker, M., 2009. Adverse Drug Reactions. In Hacker, M., Messer, W., 
Bachmann, K., (Eds.), Pharmacology: principles and practice. 
Academic Press/Elsevier, Boston, pp. 327-352. 
 
Hakk, H., Letcher, R.J., 2003. Metabolism in the toxicokinetics and fate of 
brominated flame retardants - a review. Environment International 29, 
801-828. 
 
Halfon, E., Reggiani, M.G., 1986. ON RANKING CHEMICALS FOR 
ENVIRONMENTAL-HAZARD. Environmental Science & 
Technology 20, 1173-1179. 
 
Hansch, C., Leo, A., 1979. Substituent Constants for Correlation Analysis in 
Chemistry and Biology. Wiley, New York. 
 
Hernandes, M.Z., Cavalcanti, S.M.T., Moreira, D.R.M., de Azevedo, W.F., 
Leite, A.C.L., 2010. Halogen Atoms in the Modern Medicinal 
212 
 
Chemistry: Hints for the Drug Design. Current Drug Targets 11, 303-
314. 
 
Ionescu, C., Caira, M.R., 2005a. Pathways of Biotransformation - Phase I 
Reactions. In Ionescu, C., Caira, M.R., (Eds.), Drug Metabolism: 
Current Concepts. Springer, Dordrecht, pp. 41-128. 
 
Ionescu, C., Caira, M.R., 2005b. Pathways of Biotransformation - Phase II 
Reactions. In Ionescu, C., Caira, M.R., (Eds.), Drug Metabolism: 
Current Concepts. Springer, Dordrecht, pp. 129-170. 
 
Isin, E.M., Guengerich, F.P., 2007. Complex reactions catalyzed by 
cytochrome P450 enzymes. Biochimica Et Biophysica Acta-General 
Subjects 1770, 314-329. 
 
Jia, L., Liu, X.D., 2007. The conduct of drug metabolism studies considered 
good practice (II): In vitro experiments. Current Drug Metabolism 8, 
822-829. 
 
Kang, P., Dalvie, D., Smith, E., Renner, M., 2009. Bioactivation of 
Lumiracoxib by Peroxidases and Human Liver Microsomes: 
Identification of Multiple Quinone Imine Intermediates and GSH 
Adducts. Chemical Research in Toxicology 22, 106-117. 
 
Kenny, J.R., Maggs, J.L., Meng, X.L., Sinnott, D., Clarke, S.E., Park, B.K., 
Stachulski, A.V., 2004. Syntheses and characterization of the acyl 
glucuronide and hydroxy metabolites of diclofenac. Journal of 
Medicinal Chemistry 47, 2816-2825. 
 
Khojasteh, C., Wong, H., Hop, C.E.C.A., 2010. Drug Metabolizing Enzymes, 
The Drug Metabolism and Pharmacokinetics Quick Guide. Springer, 
London, pp. 17-46. 
 
Kim, K.H., 1991. Quantitative structure-activity relationships of the 
metabolism of drugs by uridine-diphosphate glucuronosyltransferase. 
Journal of Pharmaceutical Sciences 80, 966-970. 
 
Koerts, J., Soffers, A., Vervoort, J., De Jager, A., Rietjens, I., 1998. 
Occurrence of the NIH shift upon the cytochrome P450-catalyzed in 
vivo and in vitro aromatic ring hydroxylation of fluorobenzenes. 
Chemical Research in Toxicology 11, 503-512. 
 
Kretzrommel, A., Boelsterli, U.A., 1993. Diclofenac covalent protein-binding 
is dependent on acyl glucuronide formation and is inversely related to 
P450-mediated acute cell injury in cultured rat hepatocytes. 
Toxicology and Applied Pharmacology 120, 155-161. 
 
Kretzrommel, A., Boelsterli, U.A., 1994a. Mechanism of covalent adduct 
formation of diclofenac to rat hepatic-microsomal proteins – Retention 
213 
 
of the glucuronic-acid moiety in the adduct. Drug Metabolism and 
Disposition 22, 956-961. 
 
Kretzrommel, A., Boelsterli, U.A., 1994b. Selective protein adducts to 
membrane-proteins in cultured rat hepatocytes exposed to diclofenac – 
Radiochemical and immunochemical analysis. Molecular 
Pharmacology 45, 237-244. 
 
Langguth, H.S., Benet, L.Z., 1992. Acyl Glucuronides Revisited: Is the 
Glucuronidation Proces a Toxification as Well as a Detoxification 
Mechanism? Drug Metabolism Reviews 24, 5-47. 
 
Lee, K.S., Oh, S.J., Kim, H.M., Lee, K.H., Kim, S.K., 2011. Assessment of 
Reactive Metabolites in Drug-Induced Liver Injury. Archives of 
Pharmacal Research 34, 1879-1886. 
 
Lee, W.M., 2003. Medical progress: Drug-induced hepatotoxicity. New 
England Journal of Medicine 349, 474-485. 
 
Leemann, T., Transon, C., Dayer, P., 1993. Cytochrome-P450TB (CYP2C) – 
A major monooxygenase catalyzing diclofenac 4’-hydroxylation in 
human liver. Life Sciences 52, 29-34. 
 
Lerche, D., Bruggemann, R., Sorensen, P., Carlsen, L., Nielsen, O.J., 2002. A 
comparison of partial order technique with three methods of multi-
criteria analysis for ranking of chemical substances. Journal of 
Chemical Information and Computer Sciences 42, 1086-1098. 
 
Leung, L., Kalgutkar, A.S., Obach, R.S., 2011. Metabolic activation in drug-
induced injury. Drug Metabolism Reviews, 1-16. 
 
Lewis, D.F.V., Ioannides, C., Parke, D.V., 1995. A quantitative structure-
activity relationship study on a series of 10 parasubstituted toluenes 
binding to cytochrome P4502B4 (CYP2B4), and their hydroxylation 
rates. Biochemical Pharmacology 50, 619-625. 
 
Li, J.J., 2009. Name Reactions:A Collection of Detailed Reaction Mechanisms 
and Synthetic Applications. Springer-Verlag Berlin Heidelberg, 
Germany. 
 
Li, Y., Slatter, J.G., Zhang, Z.P., Doss, G.A., Braun, M.P., Stearns, R.A., Dean, 
D.C., Baillie, T.A., Tang, W., 2008. In vitro metabolic activation of 
lumiracoxib in rat and human liver preparations. Drug Metabolism and 
Disposition 36, 469-473. 
 
Lipinski, C.A., 2000. Drug-like properties and the causes of poor solubility 
and poor permeability. Journal of Pharmacological and Toxicological 




Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., 2001. 
Experimental and computational approaches to estimate solubility and 
permeability in drug discovery and development settings. Advanced 
Drug Delivery Reviews 46, 3-26. 
 
Little, P.J., Ryan, A.J., 1982. Inhibitors of hepatic mixed-function oxidases .4. 
Effects of benzimidazole and related-compounds on aryl-hydrocarbon 
hydroxylase-activity from phenobarbitone and 3-methylcholanthrene 
induced rats. Journal of Medicinal Chemistry 25, 622-626. 
 
Mangold, J.B., Gu, H., Rodriguez, L.C., Bonner, J., Dickson, J., Rordorf, C., 
2004. Pharmacokinetics and metabolism of lumiracoxib in healthy 
male subjects. Drug Metabolism and Disposition 32, 566-571. 
 
Masferrer, J.L., Zweifel, B.S., Seibert, K., Needleman, P., 1990. Selective 
regulation of cellular cyclooxygenase by dexamethasone and 
endotoxin in mice. Journal of Clinical Investigation 86, 1375-1379. 
 
McDonald, M.G., Rettie, A.E., 2007. Sequential metabolism and bioactivation 
of the hepatotoxin benzbromarone: Formation of glutathione adducts 
from a catechol intermediate. Chemical Research in Toxicology 20, 
1833-1842. 
 
McLaughlin, L.A., Dickmann, L.J., Wolf, C.R., Henderson, C.J., 2008. 
Functional expression and comparative characterization of nine murine 
cytochromes P450 by fluorescent inhibition screening. Drug 
Metabolism and Disposition 36, 1322-1331. 
 
Mitchell, J.A., Akarasereenont, P., Thiemermann, C., Flower, R.J., Vane, J.R., 
1993. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors 
of constitutive and inducible cyclooxygenase. Proceedings of the 
National Academy of Sciences of the United States of America 90, 
11693-11697. 
 
Monks, T.J., Hinson, J.A., Gillette, J.R., 1982. Bromobenzene and para-
bromophenol toxicity and covalent binding invivo. Life Sciences 30, 
841-848. 
 
Monks, T.J., Jones, D.C., 2002. The Metabolism and Toxicity of Quinones, 
Quinonimines, Quinone Methides, and Quinone-Thioethers. Current 
Drug Metabolism 3, 425-438. 
 
Moser, P., Sallmann, A., Wiesenberg, I., 1990. Synthesis and quantitative 
structure-activity-relationships of diclofenac analogs. Journal of 
Medicinal Chemistry 33, 2358-2368. 
 
Neijenesch, H.A., Deruiter, R., Ridderikhoff, E.J., Vandenende, J.O., 
Laarhoven, L.J., Vanputten, L.J.W., Cornelisse, J., 1991.  
Intramolecular meta photocycloaddition of 6-arylhex-2-enes .2. Journal 
of Photochemistry and Photobiology a-Chemistry 60, 325-343. 
215 
 
Nelson, S.D., 2001. Structure toxicity relationships - How useful are they in 
predicting toxicities of new drugs? Biological Reactive Intermediates 
Vi: Chemical and Biological Mechanisms in Susceptibility to and 
Prevention of Environmental Diseases 500, 33-43. 
 
Obach, R.S., 1999. Prediction of human clearance of twenty-nine drugs from 
hepatic microsomal intrinsic clearance data: An examination of in vitro 
half-life approach and nonspecific binding to microsomes. Drug 
Metabolism and Disposition 27, 1350-1359. 
 
Oneill, P.M., Harrison, A.C., Storr, R.C., Hawley, S.R., Ward, S.A., Park, 
B.K., 1994. The effect of fluorine substitution on the metabolism and 
antimalarial activity of amodiaquine. Journal of Medicinal Chemistry 
37, 1362-1370. 
 
Park, B.K., Kitteringham, N.R., O'Neill, P.M., 2001. Metabolism of fluorine-
containing drugs. Annual Review of Pharmacology and Toxicology 41, 
443-470. 
 
Patel, R.N., Attur, M.G., Dave, M.N., Patel, I.V., Stuchin, S.A., Abramson, 
S.B., Amin, A.R., 1999. A Novel Mechanism of Action of Chemically 
Modified Tetracyclines: Inhibition of COX-2-Mediated Prostaglandin 
E2 Production. The Journal of Immunology 163, 3459-3467. 
 
Perloft, E.S., Crocker, R.M., Dandeneau, A.A., Morgan, L., Crespi, C.L., 
Stresser, D.M., 2006. Validation of a Phase I and Phase II Metabolic 
Stability Assay in Subcellular Fractions, Woburn, MA, United States 
of America, pp. 
 
Pierce, R.H., Franklin, C.C., Campbell, J.S., Tonge, R.P., Chen, W.C., Fausto, 
N., Nelson, S.D., Bruschi, S.A., 2002. Cell culture model for 
acetaminophen-induced hepatocyte death in vivo. Biochemical 
Pharmacology 64, 413-424. 
 
Plumb, J.A., Milroy, R., Kaye, S.B., 1989. Effects of the pH Dependence of 3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide-
Formazan Absorption on Chemosensitivity Determined by a Novel 
Tetrazolium-based Assay. Cancer Research 49, 4435-4440. 
 
Poon, G.K., Chen, Q., Teffera, Y., Ngui, J.S., Griffin, P.R., Braun, M.P., Doss, 
G.A., Freeden, C., Stearns, R.A., Evans, D.C., Baillie, T.A., Tang, W., 
2001. Bioactivation of diclofenac via benzoquinone imine 
intermediates-identification of urinary mercapturic acid derivatives in 
rats and humans. Drug Metabolism and Disposition 29, 1608-1613. 
 
Prasanna, S., Manivannan, E., Chaturvedi, S.C., 2005. QSAR studies on 
structurally similar 2-(4-methanesulfonylphenyl)pyran-4-ones as 
selective COX-2 inhibitors: a Hansch approach. Bioorganic & 
Medicinal Chemistry Letters 15, 313-320. 
216 
 
Prins, B., Dartee, W.P., Verboom, W., Reinhoudt, D.N., Koster, A.S., 1994. 
Quantitative structure-activity relationships for the acute cytotoxicity 
of 13(bis)aziridinyl-benzoquinones – Relation to cellular ATP 
depletion. Archives of Toxicology 68, 255-260. 
 
Radominska-Pandya, A., Czernik, P.J., Little, J.M., Battaglia, E., Mackenzie, 
P.I., 1999. Structura; and functional studies of UDP-
glucuronosyltransferases1*. Drug Metabolism Reviews 31, 817-899. 
 
Regan, S.L., Maggs, J.L., Hammond, T.G., Lambert, C., Williams, D.P., Park, 
B.K., 2010. Acyl Glucuronides: The Good, The Bad and The Ugly. 
Biopharmaceutics & Drug Disposition 31, 367-395. 
 
Rice, G.C., Bump, E.A., Shrieve, D.C., Lee, W., Kovacs, M., 1986. 
Quantitative-analysis of cellular glutathione by flow-cytometry 
utilizing monochlorobimane – Some applications to radiation and 
drug-resistance invitro and invivo. Cancer Research 46, 6105-6110. 
 
Rowlinson, S.W., Kiefer, J.R., Prusakiewicz, J.J., Pawlitz, J.L., Kozak, K.R., 
Kalgutkar, A.S., Stallings, W.C., Kurumbail, R.G., Marnett, L.J., 2003. 
A novel mechanism of cyclooxygenase-2 inhibition involving 
interactions with Ser-530 and Tyr-385. Journal of Biological 
Chemistry 278, 45763-45769. 
 
Russo, M.W., Galanko, J.A., Shrestha, R., Fried, M.W., Watkins, P., 2004. 
Liver transplantation for acute liver failure from drug induced liver 
injury in the United States. Liver Transplantation 10, 1018-1023. 
 
Sangster, 2006. LOGKOW Database, Montreal, Quebec, Canada, pp. 
 
Schultz, T.W., Cajinaquezada, M., Wesley, S.K., 1989. Structure toxicity 
relationships for mono alkyl-substituted or halogen-substituted anilines. 
Bulletin of Environmental Contamination and Toxicology 43, 564-569. 
 
Selassie, C.D., 2003. History of Quantitative Structure-Activity Relationship. 
In Abraham, D.J., (Ed.), Burger's Medicinal Chemistry and Drug 
Discovery. John Wiley & Sons, Inc., New York, pp. 1-48. 
 
Shen, S.J., Marchick, M.R., Davis, M.R., Doss, G.A., Pohl, L.R., 1999. 
Metabolic activation of diclofenac by human cytochrome P450 3A4: 
Role of 5-hydroxydiclofenac. Chemical Research in Toxicology 12, 
214-222. 
 
Siraki, A.G., Chevaldina, T., O'Brien, P.J., 2005. Application of quantitative 
structure-toxicity relationships for acute NSAID cytotoxicity in rat 
hepatocytes. Chemico-Biological Interactions 151, 177-191. 
 
Sivertsson, L., Ek, M., Darnell, M., Edebert, I., Ingelman-Sundberg, M., Neve, 
E.P.A., 2010. CYP3A4 Catalytic Activity Is Induced in Confluent 
217 
 
Huh7 Hepatoma Cells. Drug Metabolism and Disposition 38, 995-
1002. 
 
Smith, D.A., Waterbeemd, H.v.d., Walker, D.K., 2006. Pharmcacokinetics and 
Metabolism in Drug Design. WILEY-VCH Verlag GmbH & Co. 
KGaA, Weinheim. 
 
Smith, P.A., Sorich, M.J., McKinnon, R.A., Miners, J.O., 2003. In silico 
insights: Chemical and structural characteristics associated with 
uridine diphosphate-glucuronosyltransferase substrate selectivity. 
Clinical and Experimental Pharmacology and Physiology 30, 836-840. 
 
Smith, P.C., Benet, L.Z., McDonagh, A.F., 1990. Covalent binding of 
zomepirac glucuronide to proteins – Evidence for a Schiff-base 
mechanism. Drug Metabolism and Disposition 18, 639-644. 
 
Srivastava, A., Maggs, J.L., Antoine, D.J., Williams, D.P., Smith, D.A., Park, 
B.K., 2010. Role of Reactive Metabolites in Drug-Induced 
Hepatotoxicity. In Uetrecht, J., (Ed.), Adverse Drug Reactions. 
Springer‐Verlag Berlin Heidelberg, London, pp. 165-194. 
 
Stachulski, A.V., Harding, J.R., Lindon, J.C., Maggs, J.L., Park, B.K., Wilson, 
I.D., 2006. Acyl glucuronides: Biological activity, chemical reactivity, 
and chemical synthesis. Journal of Medicinal Chemistry 49, 6931-6945. 
 
Stepan, A.F., Walker, D.P., Bauman, J., Price, D.A., Baillie, T.A., Kalgutkar, 
A.S., Aleo, M.D., 2011. Structural Alert/Reactive Metabolite Concept 
as Applied in Medicinal Chemistry to Mitigate the Risk of 
Idiosyncratic Drug Toxicity: A Perspective Based on the Critical 
Examination of Trends in the Top 200 Drugs Marketed in the United 
States. Chemical Research in Toxicology 24, 1345-1410. 
 
Stierlin, H., Faigle, J.W., Sallmann, A., Kung, W., Richter, W.J., Kriemler, 
H.P., Alt, K.O., Winkler, T., 1979. Biotransformation of diclofenac 
sodium (Voltaren) in animals and in man .1. Isolation and 
identification of principal metabolites. Xenobiotica 9, 601-610. 
 
Stirnimann, G., Kessebohm, K., Lauterburg, B., 2010. Liver injury caused by 
drugs: an update. Swiss Medical Weekly 140, 18-24. 
 
Tang, W., 2003. The metabolism of diclofenac - Enzymology and toxicology 
perspectives. Current Drug Metabolism 4, 319-329. 
 
Tang, W., Stearns, R.A., Bandiera, S.M., Zhang, Y., Raab, C., Braun, M.P., 
Dean, D.C., Pang, J.M., Leung, K.H., Doss, G.A., Strauss, J.R., Kwei, 
G.Y., Rushmore, T.H., Chiu, S.H.L., Baillie, T.A., 1999a. Studies on 
cytochrome P-450-mediated bioactivation of diclofenac in rats and in 
human hepatocytes: Identification of glutathione conjugated 
metabolites. Drug Metabolism and Disposition 27, 365-372. 
218 
 
Tang, W., Stearns, R.A., Wang, R.W., Chiu, S.H.L., Baillie, T.A., 1999b. 
Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the 
metabolic activation of diclofenac. Chemical Research in Toxicology 
12, 192-199. 
 
Teffera, Y., Waldon, D.J., Colletti, A.E., Albrecht, B.K., Zhao, Z., 2008. 
Identification of a Novel Glutathione Conjugate of Diclofenac by 
LTQOrbitrap. Drug Metabolism Letters 2, 35-40. 
 
Thompson, D.C., Perera, K., Krol, E.S., Bolton, J.L., 1995. o-Methoxy-4-
alkylphenols that form quinone methides of intermediate reactivity are 
the most toxic in rat liver slices. Chemical Research in Toxicology 8, 
323-327. 
 
Thompson, D.C., Thompson, J.A., Sugumaran, M., Moldeus, P., 1993. 
Biological and toxicological consequences of quinone methide 
formation. Chemico-Biological Interactions 86, 129-162. 
 
Tran, T., Lee, W., 2013. DILI: New Insights into Diagnosis and Management. 
Current Hepatitis Reports 12, 53-58. 
 
Trott, O., Olson, A.J., 2010. Software News and Update AutoDock Vina: 
Improving the Speed and Accuracy of Docking with a New Scoring 
Function, Efficient Optimization, and Multithreading. Journal of 
Computational Chemistry 31, 455-461. 
 
United-Nations, 2005a. Consolidated List of products whose consumption 
and/or sale have been banned, withdrawn, severly restricted or not 
approved by governments. In Nations, U., (Ed.), Pharmaceuticals: 
restrictions in use and availability. United Nations Publications, New 
York, pp. 
 
United-Nations, 2005b. Consolidated List of products whose consumption 
and/or sale have been banned, withdrawn, severly restricted or not 
approved by governments. In Nations, U., (Ed.), Pharmaceuticals: 
restrictions in use and availability. United Nations Publication, New 
York, pp. 
 
Vanderhoeven, S.J., Lindon, J.C., Troke, J., Tranter, G.E., Wilson, I.D., 
Nicholson, J.K., 2004a. NMR and QSAR studies on the transacylation 
reactivity of model 1β-O-acyl glucuronides. I: design, synthesis and 
degradation rate measurement. Xenobiotica 34, 73-85. 
 
Vanderhoeven, S.J., Troke, J., Tranter, G.E., Wilson, I.D., Nicholson, J.K., 
Lindon, J.C., 2004b. Nuclear magnetic resonance (NMR) and 
quantitative structure–activity relationship (QSAR) studies on the 
transacylation reactivity of model 1β-O-acyl glucuronides. II: QSAR 
modelling of the reaction using both computational and experimental 
NMR parameters. Xenobiotica 34, 889-900. 
219 
 
Vashishtha, S.C., Hawes, E.M., McKay, G., McCann, D.J., 2001. Quaternary 
ammonium-linked glucuronidation of 1-substituted imidazoles: Studies 
of human UDP-glucuronosyltransferases involved and substrate 
specificities. Drug Metabolism and Disposition 29, 1290-1295. 
 
Vasquezvivar, J., Augusto, O., 1992. Hydroxylated metabolites of the 
antimalarial drug primaquine – Oxidation and redox cycling. Journal of 
Biological Chemistry 267, 6848-6854. 
 
Vogel, A.I., 1989. A Textbook of Practical Organic Chemistry. Longman 
Scientific & Technical, London. 
 
Vonkeman, H.E., van de Laar, M., 2010. Nonsteroidal Anti-Inflammatory 
Drugs: Adverse Effects and Their Prevention. Seminars in Arthritis 
and Rheumatism 39, 294-312. 
 
Wang, J.Y., Davis, M., Li, F.B., Azam, F., Scatina, J., Talaat, R., 2004. A 
novel approach for predicting acyl glucuromide reactivity via Schiff 
base formatiom. Development of rapidly formed peptide adducts for 
LC/MS/MS measurements. Chemical Research in Toxicology 17, 
1206-1216. 
 
Warne, M.A., Osborn, D., Lindon, J.C., Nicholson, J.K., 1999. Quantitative 
structure-toxicity relationships for halogenated substituted-benzenes to 
Vibrio fischeri, using atom-based semi-empirical molecular-orbital 
descriptors. Chemosphere 38, 3357-3382. 
 
Wen, B., Ma, L., Nelson, S.D., Zhu, M., 2008. High-througput screening and 
characterization of reative metabolites using polarity switching of 
hybrid triplequadrapole linear ion trap mass spectrometry. Analytical 
Chemistry 80, 1788-1799. 
 
Wilcken, R., Zimmermann, M.O., Lange, A., Joerger, A.C., Boeckler, F.M., 
2013. Principles and Applications of Halogen Bonding in Medicinal 
Chemistry and Chemical Biology. Journal of Medicinal Chemistry 56, 
1363-1388. 
 
Wilkerson, W.W., Copeland, R.A., Covington, M., Trzaskos, J.M., 1995. 
Antiinflammatory 4,5-diarylpyrroles .2. Activity as a function of 
cyclooxygenase-2 inhibition. Journal of Medicinal Chemistry 38, 
3895-3901. 
 
Williams, D.P., Kitteringham, N.R., Naisbitt, D.J., Pirmohamed, M., Smith, 
D.A., Park, B.K., 2002. Are Chemically Reactive Metabolites 
Responsible for Adverse Reactions to Drugs? Current Drug 
Metabolism 3, 351-366. 
 
Williams, J.A., Hyland, R., Jones, B.C., Smith, D.A., Hurst, S., Goosen, T.C., 
Peterkin, V., Koup, J.R., Ball, S.E., 2004. Drug-drug interactions for 
UDP-glucuronosyltransferase substrates: A pharmacokinetic 
220 
 
explanation for typically observed low exposure (AUC(i)/AUC) ratios. 
Drug Metabolism and Disposition 32, 1201-1208. 
 
Williams, P.A., Cosme, J., Sridhar, V., Johnson, E.F., McRee, D.E., 2000. 
Mammalian microsomal cytochrome P450 monooxygenase: Structural 
adaptations for membrane binding and functional diversity. Molecular 
Cell 5, 121-131. 
 
Wold, S., Eriksson, L., Clementi, S., 1995. Statistical Validation of QSAR 
Results. In Waterbeemd, H.v.d., (Ed.), Chemometric Methods in 
Molecular Design. Wiley-VCH Verlag GmbH, Weinheim, Germany, 
pp. 
 
Wolfe, J.P., Buchwald, S.L., 2000. Scope and limitations of the Pd/BINAP-
catalyzed amination of aryl bromides. Journal of Organic Chemistry 65, 
1144-1157. 
 
Wu, J.C., Merlino, G., Cveklova, K., Mosinger, B., Fausto, N., 1994. 
Autonomous growth in serum-free medium and production of 
hepatocellular carcinomas by differentiated hepatocyte lines that 
overexpress transforming growth-factor-alpha. Cancer Research 54, 
5964-5973. 
 
Yu, L.J., Chen, Y., DeNinno, M.P., O'Connell, T.N., Hop, C., 2005. 
Identification of a novel glutathione adduct of diclofenac, 4 '-hydroxy-
2 '-glutathion-deschloro-diclofenac, upon incubation with human liver 
microsomes. Drug Metabolism and Disposition 33, 484-488. 
 
Zhang, C.H., Kenny, J.R., Le, H., Deese, A., Ford, K.A., Lightning, L.K., Fan, 
P.W., Driscoll, J.P., Halladay, J.S., Hop, C., Khojasteh, S.C., 2011. 
Novel Mechanism for Dehalogenation and Glutathione Conjugation of 
Dihalogenated Anilines in Human Liver Microsomes: Evidence for 
ipso Glutathione Addition. Chemical Research in Toxicology 24, 
1668-1677. 
 
Zheng, J., Ma, L., Xin, B.M., Olah, T., Humphreys, W.G., Zhu, M.S., 2007. 
Screening and identification of GSH-trapped reactive metabolites 
using hybrid triple quadruple linear ion trap mass spectrometry. 
Chemical Research in Toxicology 20, 757-766. 
 
Zhou, S.F., Liu, J.P., Chowbay, B., 2009. Polymorphism of human 
cytochrome P450 enzymes and its clinical impact. Drug Metabolism 








Appendix 2-1: Complete structures of all twenty-four synthesized compounds 






















































































































































Appendix 2-2: Characterization of synthesized compounds (1 – 24) and 
imtermediates (25 – 72) 
 
{2-[(2-Chloro-6-fluorophenyl)amino]phenyl}acetic acid (1) 
Off-white powder. Yield: 64.5%. M.p.: 150.3 – 151.4 ºC. 1H NMR (300 MHz, 
DMSO-d6) δ 7.36 (d, J = 7.9 Hz, 1H), 7.28 – 7.06 (m, 5H), 6.86 (t, J = 7.3 Hz, 
1H), 6.47 (d, J = 7.6 Hz, 1H), 3.68 (s, 2H); 13C NMR (75 MHz, DMSO-d6) δ 
173.59 (s, 1C), 156.12 (d, JC-F = 247.5 Hz, 1C), 142.59 (s, 1C), 130.95 (s, 1C), 
128.58 (d, JC-F = 14.0 Hz, 1C), 128.24 (d, JC-F = 4.0 Hz, 1C), 127.69 (s, 1C), 
125.95 (s, 1C), 124.22 (d, JC-F = 8.7 Hz, 1C), 124.02 (s, 1C), 121.04 (s, 1C), 
116.13 (s, 1C), 115.43 (d, JC-F = 20 Hz, 1C), 37.93 (s, 1C); MS-ESI: [M+H]+: 
280.0, 282.0 m/z.  
 
{2-[(2,6-Difluorophenyl)amino]phenyl}acetic acid (2) 
White powder. Yield: 61.3%. M.p.: 131.8 – 132.8 ºC. 1H NMR (300 MHz, 
DMSO-d6) δ 7.20 – 7.11 (m, 5H), 7.10 (t, J = 7.4 Hz, 1H), 6.85 (t, J = 7.3 Hz, 
1H), 6.54 (d, J = 7.9 Hz, 1H), 3.69 (s, 2H); 13C NMR (75 MHz, DMSO-d6) δ 
173.39 (s, 1C), 156.12 (d, JC-F = 245.5 Hz, 1C), 156.04 (d, JC-F = 245.2 Hz, 
1C), 142.60 (s, 1C), 130.82 (s, 1C), 127.59 (s, 1C), 123.63 (s, 1C), 123.17 (t, 
JC-F = 9.7 Hz, 1C), 120.54 (s, 1C), 119.76 (t, JC-F = 15.4 Hz, 1C), 115.51 (s, 
1C), 112.21 (d, JC-F = 16.1 Hz, 1C), 112.12 (d, JC-F = 16.2 Hz, 1C), 37.49 (s, 
1C); MS-ESI [M+H]+: 264.0 m/z.  
 
{2-[(2,6-Dichlorophenyl)amino]phenyl}acetic acid (3) 
White powder. M.p.: 155.8 – 157.4 ºC. 1H NMR (300 MHz, CDCl3) δ 7.34 (d, 
J = 8.1 Hz, 2H), 7.25 (d, J = 6.7 Hz, 1H), 7.15 (t, J = 7.7 Hz, 1H), 6.98 (t, J = 
8.1 Hz, 1H), 6.96 (t, J = 6.7 Hz, 1H), 6.80 (s, 1H), 6.56 (d, J = 8.0 Hz, 1H), 
3.86 (s, 2H); 13C NMR (75 MHz, CDCl3) δ 178.10 (s, 1C), 142.65 (s, 1C), 
137.73 (s, 1C), 130.97 (s, 1C), 129.43 (s, 2C), 128.87 (s, 2C), 128.26 (s, 1C), 
124.07 (s, 1C), 123.63 (s, 1C), 122.20 (s, 1C), 118.43 (s, 1C), 38.23 (s, 1C); 






{2-[(2,6-Dibromophenyl)amino]phenyl}acetic acid (4) 
White powder. Yield: 25.6%. M.p.: 152.4 – 153.6 ºC. 1H NMR (300 MHz, 
CDCl3) δ ppm 7.35 (d, J = 8.0 Hz, 2H), 7.25 (d, J = 4.7 Hz, 1H), 7.13 (t, J = 
7.6 Hz, 1H), 6.97 (t, J = 7.4 Hz, 1H), 6.85 (t, J = 8.0 Hz, 1H), 6.70 (s, 1H), 
6.52 (d, J = 7.9 Hz, 1H), 3.85 (s, 2H); 13C NMR (75 MHz, CDCl3) δ 178.17 (s, 
1C), 142.91 (s, 1C), 140.16 (s, 1C), 132.85 (s, 2C), 131.04 (s, 1C), 128.35 (s, 
1C), 125.51 (s, 1C), 123.91 (s, 1C), 122.24 (s, 1C), 119.94 (s, 2C), 118.59 (s, 
1C), 38.28 (s, 1C); MS-ESI [M+H]+: 383.8, 385.8, 387.8 m/z. HRMS-ESI [M-
H]-: Calcd 381.9084 m/z Found 381.9070 m/z. 
 
{2-[(2-Chloro-6-fluorophenyl)amino]-5-methylphenyl}acetic acid (5) 
Pale yellow powder. Yield: 89.2%. M.p.: 137.5 – 139.5 ºC. 1H NMR (300 
MHz, DMSO-d6) δ 7.34 (d, J = 7.8 Hz, 1H), 7.21 (dd, J = 9.0 Hz, JH-F = 9.8 
Hz, 1H), 7.14-6.98 (m, 3H), 6.91 (d, J = 7.7 Hz, 1H), 6.43 (d, J = 6.6 Hz, 1H), 
3.65 (s, 2H), 2.21 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 173.38 (s, 1C), 
155.50 (d, JC-F = 247.1 Hz, 1C), 139.86 (s, 1C), 131.24 (s, 1C), 130.01 (s, 1C), 
128.95 (d, JC-F = 13.8 Hz, 1C), 127.87 (s, 1C), 127.28 (d, JC-F = 4.1 Hz, 1C), 
125.68 (s, 1C), 124.29 (s, 1C), 123.28 (d, JC-F = 8.7 Hz, 1C), 116.69 (s, 1C), 
115.24 (d, JC-F = 20.1 Hz, 1C), 37.69 (s, 1C), 20.07 (s, 1C); [M+H]+: 293.9, 
295.8 m/z. 
 
{2-[(2,6-Difluorophenyl)amino]-5-methylphenyl}acetic acid (6) 
Off-white crystals. Yield: 74.5%. M.p.: 136.4 – 137.4 ºC. 1H NMR (300 MHz, 
DMSO-d6) δ 7.16-7.01 (m, 4H), 6.99 (s, 1H), 6.91 (d, J = 8.2 Hz, 1H), 6.49 (d, 
J = 8.1 Hz, 1H), 3.65 (s, 2H), 2.20 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 
173.39 (s, 1C), 155.61 (d, JC-F = 245.0 Hz, 1C), 155.53 (d, JC-F = 245.0, 1C), 
139.96 (s, 1C), 131.23 (s, 1C), 129.64 (s, 1C), 127.90 (s, 1C), 124.10 (s, 1C), 
122.25 (t, JC-F = 9.6 Hz, 1C), 120.33 (t, JC-F = 15.1 Hz, 1C), 116.26 (s, 1H), 
112.10 (d, JC-F = 16.0 Hz, 1C), 112.00 (d, JC-F = 16.3 Hz, 1C), 37.48 (s, 1C), 
20.07 (s, 1C); MS-ESI [M+H]+: 278.0 m/z. 
 
{2-[(2,6-Dichlorophenyl)amino]-5-methylphenyl}acetic acid (7) 
Off-white fluffy crystals. Yield: 82.6%. M.p.: 146.6 – 148.2 ºC. 1H NMR (300 
MHz, DMSO-d6) δ 7.49 (d, J = 8.0 Hz, 2H), 7.19-7.01 (m, 3H), 6.87 (d, J = 
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8.0 Hz, 1H), 6.23 (d, J = 8.1 Hz, 1H), 3.66 (s, 2H), 2.20 (s, 3H); 13C NMR (75 
MHz, DMSO-d6) δ 173.37 (s, 1C), 140.06 (s, 1C), 137.50 (s, 1C), 131.36 (s, 
1C), 129.96 (s, 1C), 129.19 (s, 2C), 129.11 (s, 2C), 127.86 (s, 1C), 124.90 (s, 
1C), 124.37 (s, 1C), 116.67 (s, 1C), 37.76 (s, 1C), 20.09 (s, 1C); [M+H]+: 
309.9, 312.0, 314.0 m/z. 
 
{2-[(2,6-Dibromophenyl)amino]-5-methylphenyl}acetic acid (8) 
Pale yellow crystals. Yield: 42.3%. M.p.: 133.0 – 135.0 ºC. 1H NMR (300 
MHz, DMSO-d6) δ 7.69 (d, J = 8.0 Hz, 2H), 7.07-6.96 (m, 2H), 6.92 (s, 1H), 
6.86 (d, J = 8.0 Hz, 1H), 6.17 (d, J = 8.1 Hz, 1H), 3.65 (s, 2H), 2.20 (s, 3H); 
13C NMR (75 MHz, DMSO-d6) δ 173.00 (s, 1C), 140.08 (s, 1C), 139.61 (s, 
1C), 132.68 (s, 2C), 131.11 (s, 1C), 129.56 (s, 1C), 127.64 (s, 1C), 126.20 (s, 
1C), 124.16 (s, 1C), 120.03 (s, 2C), 116.36 (s, 1C), 37.53 (s, 1C), 19.82 (s, 
1C); MS-ESI [M+H]+: 397.8, 399.6, 401.7 m/z. HRMS-ESI [M-H]-: Calcd 
395.9240 m/z Found 395.9231 m/z. 
 
{2-[(2-Chloro-6-fluorophenyl)amino]-5-ethylphenyl}acetic acid (9) 
White fluffy crystals. Yield: 52.8%. M.p.: 141.0 – 142.0 ºC. 1H NMR (400 
MHz, DMSO-d6) δ 7.35 (dt, J = 8.1 Hz, 1.2 Hz, JH-F = 1.2 Hz, 1H), 7.23 (ddd, 
J = 8.3 Hz, 1.3 Hz, JH-F = 9.7 Hz, 1H), 7.03 – 6.89 (m 3H), 6.94 (dd, J = 8.2 
Hz, 2.0 Hz, 1H) , 6.44 (dd, J = 8.1 Hz, JH-F = 3.0 Hz, 1H), 3.66 (s, 2H), 2.51 
(q, J = 7.6 Hz, 2H), 1.13 (t, J = 7.6 Hz, 3H); 13C NMR (101 MHz, DMSO-d6) 
δ 173.50 (s, 1C), 155.59 (d, JC-F = 247.3 Hz, 1C), 140.12 (s, 1C), 136.58 (s, 
1C), 130.14 (s, 1C), 128.94 (d, JC-F = 13.7 Hz, 1C), 127.40 (d, JC-F = 4.3 Hz, 
1C), 126.75 (s, 1C), 125.76 (d, JC-F = 3.0 Hz, 1C), 124.24 (s, 1C), 123.45 (d, 
JC-F = 8.9 Hz, 1C), 116.67 (s, 1C), 115.30 (d, JC-F = 20.1 Hz, 1C), 37.85 (s, 
1C), 27.33 (s, 1C), 15.69 (s, 1C); MS-ESI [M+H]+: 307.9, 309.9 m/z. 
 
{2-[(2,6-Difluorophenyl)amino]-5-ethylphenyl}acetic acid (10) 
White powder. Yield: 32.4%. M.p.: 120.4 – 121.8 ºC. 1H NMR (400 MHz, 
CDCl3) δ 7.03 (ddd, J = 8.2 Hz, 2.1 Hz, JH-F = 10.3 Hz, 2H), 6.94-6.91 (m, 
3H), 6.74 (dt, J = 8.2 Hz, 2.3 Hz, JH-F = 2.3 Hz, 1H), 3.79 (s, 2H), 2.59 (q, J = 
7.6 Hz, 2H), 1.22 (t, J = 7.6 Hz, 3H); 13C NMR (101 MHz, DMSO-d6) δ 
173.51 (s, 1C), 155.71 (d, JC-F = 244.93 Hz, 1C), 155.65 (d, JC-F = 244.9 Hz, 
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1C), 140.24 (s, 1C), 136.22 (s, 1C), 130.13 (s, 1C), 126.77 (s, 1C), 124.03 (s, 
1C), 122.45 (t, JC-F = 9.5 Hz, 1C), 120.30 (t, JC-F = 15.2 Hz, 1C), 116.20 (s, 
1C), 112.21 (d, JC-F = 6.3 Hz, 1C), 112.04 (d, JC-F = 6.1 Hz, 1C), 37.64 (s, 1C), 
27.34 (s, 1C), 15.75 (s, 1C); MS-ESI [M+H]+: 292.0 m/z. 
  
{2-[(2,6-Dichlorophenyl)amino]-5-ethylphenyl}acetic acid (11) 
White fluffy crystals. Yield: 68.8%. M.p.: 123.5 – 125.1 ºC. 1H NMR (400 
MHz, DMSO-d6) δ 7.49 (d, J = 8.1 Hz, 2H), 7.14 (t, J = 8.0 Hz, 1H), 7.06 (s, 
1H), 7.05 (s, 1H), 6.91 (d, J = 8.1 Hz, 1H), 6.24 (d, J = 8.1 Hz, 1H), 3.67 (s, 
2H), 2.50 (q, J = 7.7 Hz, 2H), 1.13 (t, J = 7.6 Hz, 3H); 13C NMR (101 MHz, 
DMSO-d6) δ 173.47 (s, 1C), 140.33 (s, 1C), 137.52 (s, 1C), 136.50 (s, 1C), 
130.25 (s, 1C), 129.33 (s, 2C), 129.17 (s, 2C), 126.72 (s, 1C), 125.07 (s, 1C), 
124.33 (s, 1C), 116.64 (s, 1C), 37.92 (s, 1C), 27.33 (s, 1C), 15.64 (s, 1C); MS-
ESI [M+H]+: 324.0, 326.1, 327.0  m/z. 
 
{2-[(2,6-Dibromophenyl)amino]-5-ethylphenyl}acetic acid (12) 
Off-white crystals. Yield: 39.3%. M.p.: 118.9 – 121.1 ºC. 1H NMR (400 MHz, 
CDCl3) δ 7.69 (d, J = 8.0 Hz, 2H), 7.05 (s, 1H), 7.01 (t, J = 8.0 Hz, 1H), 6.92 
(s, 1H), 6.70 (d, J = 8.1 Hz, 1H), 6.18 (d, J = 8.1 Hz, 1H), 3.67 (s, 2H), 2.5 (q, 
J = 7.6 Hz, 2H), 1.13 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, DMSO-d6) δ 
173.36 (s, 1C), 140.61 (s, 1C), 139.90 (s, 1C), 136.31 (s, 1C), 133.00 (s, 2C), 
130.24 (s, 1C), 126.74 (s, 1C), 126.60 (s, 1C), 124.37 (s, 1C), 120.42 (s, 2C), 
116.58 (s, 1C), 37.94 (s, 1C), 27.31 (s, 1C), 15.60 (s, 1C); MS-ESI [M+H]+: 
411.7, 413.7, 415.7 m/z. HRMS-ESI [M-H]-: Calcd 409.9397 m/z Found 
409.9393 m/z. 
 
{2-[(2-Chloro-6-fluorophenyl)amino]-5-propylphenyl}acetic acid (13) 
White fluffy crystals. Yield: 39.4%. M.p.: 123.9 – 125.8 ºC. 1H NMR (400 
MHz, DMSO-d6) δ 7.34 (d, J = 8.1 Hz), 7.22 (ddd, J = 8.4 Hz, 1.3 Hz, JH-F = 
9.6 Hz, 1H), 7.11 – 7.07 (m, 2H), 7.01 (s, 1H), 6.91 (dd, J = 8.2 Hz, 1.7 Hz, 
1H), 6.43 (dd, J = 8.1 Hz, JH-F = 2.9 Hz, 1H), 3.65 (s, 2H), 2.45 (t, J = 7.4 Hz, 
2H), 1.53 (sext, J = 7.4 Hz, 2H), 0.87 (t, J = 7.3 Hz, 3H); 13C NMR (101 MHz, 
DMSO-d6) δ 173.56 (s, 1C), 155.61 (d, JC-F = 247.3 Hz, 1C), 140.17 (s, 1C), 
135.04 (s, 1C), 130.73 (s, 1C), 128.97 (d, JC-F = 13.7 Hz, 1C) , 127.40 (d, JC-F 
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= 6.0 Hz, 1C), 127.38 (s, 1C), 125.80 (d, JC-F = 3.0 Hz, 1C), 124.22 (s, 1C), 
123.48 (d, JC-F = 8.8 Hz, 1C), 116.65 (s, 1C), 115.34 (d, JC-F = 20.2 Hz, 1C), 
37.89 (s, 1C), 36.50 (s, 1C), 24.22 (s, 1C), 13.70 (s, 1C); MS-ESI [M+H]+: 
321.9, 323.9 m/z. HRMS-ESI [M-H]-: Calcd 320.0859 m/z Found 320.0852 
m/z. 
 
{2-[(2,6-Difluorophenyl)amino]-5-propylphenyl}acetic acid (14) 
White powder. Yield: 37.9%. M.p.: 120.4 – 121.3 ºC. 1H NMR (400 MHz, 
CDCl3) δ 7.14 – 7.04 (m, 4H), 7.0 (s, 1H), 6.92 (dd, J = 8.2 Hz, 2.0 Hz, 1H), 
6.49 (dt, J = 8.1, 21.9 Hz, JH-F = 1.9 Hz, 1H), 3.65 (s, 2H), 2.45 (t, J = 7.6 Hz, 
2H), 1.53 (sext, J = 7.6 Hz, 2H), 0.87 (t, J = 7.3 Hz, 3H); 13C NMR (101 MHz, 
DMSO-d6) δ 173.48 (s, 1C), 155.71 (d, JC-F = 245.0 Hz, 1C), 155.64 (d, JC-F = 
245.0, 1C), 140.24 (s, 1C), 134.57 (s, 1C), 130.66 (s, 1C), 127.33 (s, 1C), 
123.92 (s, 1C), 122.45 (t, JC-F = 9.5 Hz, 1C), 120.27 (t, JC-F = 15.2 Hz, 1C), 
116.07 (s, 1C), 112.20 (d, JC-F = 6.2 Hz, 1C), 112.03 (d, JC-F = 6.1 Hz, 1C), 
37.61 (s, 1C), 36.46 (s, 1C), 24.20 (s, 1C), 13.66 (s, 1C); MS-ESI [M+H]+: 
306.0 m/z. HRMS-ESI [M-H]-: Calcd 304.1155 m/z Found 304.1147 m/z. 
 
{2-[(2,6-Dichlorophenyl)amino]-5-propylphenyl}acetic acid (15) 
White fluffy crystals. Yield: 52.1%. M.p.: 119.2 – 121.0 ºC. 1H NMR (400 
MHz, DMSO-d6) δ 7.49 (d, J = 8.1 Hz, 2H), 7.14 (d, J = 8.1 Hz, 1H), 7.09 (s, 
1H), 7.03 (s, 1H), 6.89 (dd, J = 8.1 Hz, 1.6 Hz, 1H), 6.24 (d, J = 8.1 Hz, 1H), 
3.67 (s, 2H), 2.45 (t, J = 7.6 Hz, 2H), 1.54 (sext, J = 7.5 Hz, 2H), 0.88 (t, J = 
7.3 Hz, 3H); 13C NMR (101 MHz, DMSO-d6) δ 173.36 (s, 1C), 140.25 (s, 1C), 
137.46 (s, 1C), 134.78 (s, 1C), 130.67 (s, 1C), 129.20 (s, 2C), 129.07 (s, 2C), 
127.17 (s, 1C), 124.89 (s, 1C), 124.21 (s, 1C), 116.52 (s, 1C), 37.81 (s, 1C), 
36.41 (s, 1C), 24.07 (s, 1C), 13.61 (s, 1C); MS-ESI [M+H]+: 337.9, 339.9, 
341.7 m/z. HRMS-ESI [M-H]-: Calcd 336.0564 m/z Found 336.0558 m/z. 
 
{2-[(2,6-Dibromophenyl)amino]-5-propylphenyl}acetic acid (16) 
Off-white powder. Yield: 39.9%. M.p.: 119.2 – 121.5 ºC. 1H NMR (400 MHz, 
DMSO-d6) δ 7.69 (d, J = 8.0 Hz, 2H), 7.03 (s, 1H), 7.01 (t, J = 8.0 Hz, 1H), 
6.94 (s, 1H), 6.89 (dd, J = 8.0 Hz, 1.8 Hz, 1H), 6.18 (d, J = 8.1 Hz, 1H), 3.66 
(s, 2H), 2.45 (t, J = 7.4 Hz, 2H), 1.54 (sext, J = 7.5 Hz, 2H), 0.88 (t, J = 7.3 
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Hz, 3H); 13C NMR (101 MHz, DMSO-d6) δ 173.47 (s, 1C), 140.76 (s, 1C), 
140.07 (s, 1C), 134.87 (s, 1C), 133.13(s, 1C), 130.90 (s, 2C), 127.44 (s, 1C), 
126.66 (s, 1C), 124.50 (s, 1C), 120.51 (s, 2C), 116.71 (s, 1C), 38.05 (s, 1C), 
36.63 (s, 1C), 24.26 (s, 1C), 13.84 (s, 1C); MS-ESI [M+H]+: 425.7, 427.7, 




Off-white powder. Yield: 35.1%. M.p.: 130.3 – 131.6 ºC. 1H NMR (400 MHz, 
DMSO-d6) δ 7.35 (d, J = 8.1 Hz, 1H), 7.23 (ddd, J = 8.3 Hz, 1.2 Hz, JH-F = 
10.1 Hz, 1H), 7.12-7.07 (m, 3H), 6.97 (dd, J = 8.2, 1.9 Hz, 1H), 6.45 (dd, J = 
8.2, JH-F = 3.0 Hz, 1H), 3.67 (s, 2H), 2.79 (sept, J = 6.9 Hz, 1H), 1.16 (d, J = 
6.9 Hz, 6H); 13C NMR (101 MHz, DMSO-d6) δ 173.50 (s, 1C), 155.56 (d, JC-F 
= 247.35 Hz, 1C), 141.17 (s, 1C), 140.16 (s, 1C), 128.88 (d, JC-F = 13.8 Hz, 
1C), 128.68 (s, 1C), 127.39 (d, JC-F = 4.3 Hz, 1C), 125.70 (d, JC-F = 2.9 Hz, 
1C), 125.19 (s, 1C), 124.06 (s, 1C), 123.42 (d, JC-F = 8.8 Hz, 1C), 116.44 (s, 
1C), 115.27 (d, JC-F = 20.1 Hz, 1C), 37.92 (s, 1C), 32.61 (s, 1C) , 23.99 (s, 2C); 
MS-ESI [M+H]+: 321.9, 323.9 m/z. HRMS-ESI [M-H]-: Calcd 320.0859 m/z 
Found 320.0851 m/z. 
 
{2-[(2,6-Difluorophenyl)amino]-5-(propan-2-yl)phenyl}acetic acid (18) 
Off-white powder. Yield: 38.6%. M.p.: 117.1 – 119.2 ºC. 1H NMR (400 MHz, 
DMSO-d6) δ 7.13-7.05 (m, 5H), 6.98 (dd, J = 8.2, 1.6 Hz, 1H), 6.51 (d, J = 
8.2 Hz, 1H), 3.67 (s, 2H), 2.79 (sept, J = 6.9 Hz, 1H), 1.16 (d, J = 6.9 Hz, 6H); 
13C NMR (101 MHz, DMSO-d6) δ 173.42 (s, 1C), 155.65 (d, JC-F = 244.96 Hz, 
1C), 155.59 (d, JC-F = 244.96 Hz, 1C), 140.74 (s, 1C), 140.23 (s, 1C), 128.60 
(s, 1C), 125.13 (s, 1C), 123.79 (s, 1C), 122.37 (t, JC-F = 9.5 Hz, 1C), 120.17 (t, 
JC-F = 15.2 Hz, 1C), 115.94 (s, 1C), 112.10 (d, JC-F = 6.3 Hz, 1C), 111.93 (d, 
JC-F = 6.1 Hz, 1C), 37.65 (s, 1C), 32.55 (s, 1C), 23.96 (s, 2C); MS-ESI 







{2-[(2,6-Dichlorophenyl)amino]-5-(propan-2-yl)phenyl}acetic acid (19) 
White fluffy crystals. Yield: 59.6%. M.p.: 134.8 – 136.7 ºC. 1H NMR (400 
MHz, DMSO-d6) δ 7.50 (d, J = 8.1 Hz, 2H), 7.14 (t, J = 8.0 Hz, 1H), 7.09 (s, 
2H), 6.94 (dd, J = 8.2 Hz, 2.1 Hz, 1H), 6.25 (d, J = 8.2 Hz, 1H), 3.68 (s, 2H), 
2.79 (sept, J = 6.9 Hz, 1H), 1.16 (d, J = 6.9 Hz, 6H); 13C NMR (101 MHz, 
DMSO-d6) δ 173.37 (s, 1C), 140.97 (s, 1C), 140.30 (s, 1C), 137.40 (s, 1C), 
129.29 (s, 2C), 129.04 (s, 2C), 128.69 (s, 1C), 125.08 (s, 1C), 124.96 (s, 1C), 
124.06 (s, 1C), 116.39 (s, 1C), 37.91 (s, 1C), 32.52 (s, 1C), 23.91 (s, 2C); MS-
ESI [M+H]+: 337.8, 339.9, 340.7 m/z. HRMS-ESI [M-H]-: Calcd 336.0564 
m/z Found 336.0566 m/z. 
 
{2-[(2,6-Dibromophenyl)amino]-5-(propan-2-yl)phenyl}acetic acid (20) 
White fluffy crystals. Yield: 45.2%. M.p.: 127.8 – 130.0 ºC. 1H NMR (400 
MHz, DMSO-d6) δ 7.69 (d, J = 8.0 Hz, 2H), 7.09 (s, 1H), 7.02 (t, J = 8.0 Hz, 
1H), 6.94 (s, 1H), 6.93 (dd, J = 8.0 Hz, 2.0 Hz, 1H), 6.19 (d, J = 8.2 Hz, 1H), 
3.67 (s, 2H), 2.78 (sept, J = 7.2 Hz, 1H), 1.16 (d, J = 6.9 Hz, 6H); 13C NMR 
(101 MHz, DMSO-d6) δ 173.33 (s, 1C), 140.87 (s, 1C), 140.64 (s, 1C), 139.84 
(s, 1C), 132.93 (s, 2C), 128.74 (s, 1C), 126.56 (s, 1C), 125.19 (s, 1C), 124.17 
(s, 1C), 120.44 (s, 2C), 116.41 (s, 1C), 37.99 (s, 1C), 32.54 (s, 1C), 23.95 (s, 
2C); MS-ESI [M+H]+: 425.7, 427.6, 429.7 m/z. HRMS-ESI [M-H]-: Calcd 
423.9553 m/z Found 423.9555 m/z. 
 
{5-tert-Butyl-2-[(2-chloro-6-fluorophenyl)amino]phenyl}acetic acid (21) 
White crystals. Yield: 31.4%. M.p.: 131.3 – 133.2 ºC. 1H NMR (400 MHz, 
DMSO-d6) δ 7.36 (d, J = 8.1 Hz, 1H), 7.27-7.21 (m, 2H), 7.15-7.08 (m, 3H), 
6.45 (dd, J = 8.4, JH-F = 2.9 Hz, 1H), 3.69 (s, 2H), 1.24 (s, 9H); 13C NMR (101 
MHz, DMSO-d6) δ 173.51 (s, 1C), 155.55 (d, JC-F = 247.35, 1C), 143.35 (s, 
1C), 139.81 (s, 1C), 128.78 (d, JC-F = 13.8 Hz, 1C), 127.51 (s, 1C), 127.42 (d, 
JC-F = 4.3 Hz, 1C), 125.65 (d, JC-F = 3.0 Hz, 1C), 124.15 (s, 1C), 123.56 (s, 
1C), 123.43 (d, JC-F = 8.9 Hz, 1C), 116.04 (s, 1C), 115.21 (d, JC-F = 20.2 Hz, 
1C), 38.04 (s, 1C), 33.69 (s, 1C), 31.11 (s, 3C); MS-ESI [M+H]+: 335.9, 337.9 





{5-tert-Butyl-2-[(2,6-difluorophenyl)amino]phenyl}acetic acid (22) 
White crystals. Yield: 50.3%. M.p.: 121.9 – 123.9 ºC. 1H NMR (400 MHz, 
DMSO-d6) δ 7.20 (s, 1H), 7.14-7.09 (m, 4H), 7.08 (s, 1H), 6.50 (dt, J = 8.4 Hz, 
JH-F = 1.9 Hz, 1H), 3.69 (s, 2H), 1.24 (s, 9H); 13C NMR (101 MHz, DMSO-d6) 
δ 173.49 (s, 1C), 155.70 (d, JC-F = 245.1 Hz, 1C), 155.64 (d, JC-F = 245.0 Hz, 
1C), 142.97 (s, 1C), 139.92 (s, 1C), 127.47 (s, 1C), 124.16 (s, 1C), 123.33 (s, 
1C), 122.47 (t, JC-F = 9.5 Hz, 1C), 120.11 (t, JC-F = 15.2 Hz, 1C), 115.54 (s, 
1C), 112.11 (d, JC-F = 6.2 Hz, 1C), 111.9 (d, JC-F = 6.2 Hz, 1C), 37.82 (s, 1C), 
33.66 (s, 1C), 31.22 (s, 3C); MS-ESI [M+H]+: 319.9 m/z. HRMS-ESI [M-H]-: 
Calcd 318.1311 m/z Found 318.1302 m/z. 
 
{5-tert-Butyl-2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid (23) 
White fluffy crystals. Yield: 43.6%. M.p.: 134.9 – 136.7 ºC. 1H NMR (400 
MHz, DMSO-d6) δ 7.50 (d, J = 8.1 Hz, 2H), 7.23 (s, 1H), 7.15 (t, J = 8.1 Hz, 
1H), 7.09 (s, 1H), 7.08 (dd, J = 8.3 Hz, 2.2 Hz, 1H), 6.24 (d, J = 8.4 Hz, 1H), 
3.69 (s, 2H), 1.23 (s, 9H); 13C NMR (101 MHz, DMSO-d6) δ 173.48 (s, 1C), 
143.23 (s, 1C), 140.03 (s, 1C), 137.38 (s, 1C), 129.41 (s, 2C), 129.06 (s, 2C), 
127.61 (s, 1C), 125.07 (s, 1C), 124.10 (s, 1C), 123.61 (s, 1C), 116.00 (s, 1C), 
38.10 (s, 1C), 33.69 (s, 1C), 31.22 (s, 3C); MS-ESI [M+H]+: 351.9, 353.8, 
354.9 m/z. HRMS-ESI [M-H]-: Calcd 350.0720 m/z Found 350.0715 m/z. 
 
{5-tert-Butyl-2-[(2,6-dibromophenyl)amino]phenyl}acetic acid (24) 
White crystals. Yield: 25.7%. M.p.: 138.7 – 140.5 ºC. 1H NMR (400 MHz, 
DMSO-d6) δ 7.70 (d, J = 8.0 Hz, 2H), 7.23 (s, 1H), 7.08 (dd, J = 8.4, 2.2 Hz, 
1H), 7.03 (t, J = 8.0 Hz, 1H), 6.94 (s, 1H), 6.18 (d, J = 8.4 Hz, 1H), 3.69 (s, 
2H), 1.24 (s, 9H); 13C NMR (101 MHz, DMSO-d6) δ 173.38, 143.11, 140.33, 
139.81, 132.92, 127.63, 126.65, 124.18, 123.67, 120.56, 116.01, 38.13, 33.70, 
31.24; MS-ESI [M+H]+: 439.7, 441.7, 443.6 m/z. HRMS-ESI [M-H]-: Calcd 
437.9710 m/z Found 437.9710 m/z. 
 
2-(2-Iodophenyl)-N,N-dimethylacetamide (25) 
Colorless oil. Yield: 95.0%. 1H NMR (300 MHz, CDCl3) δ 7.84 (d, J = 7.8 Hz, 
1H), 7.31 (t, J = 7.6 Hz, 1H), 7.26 (t, J = 7.1 Hz, 1H), 6.94 (td, J = 7.9 Hz, 1.8 





Orange crystals. Yield: 90.5%. 1H NMR (300 MHz, CDCl3) δ 7.22 (d, J = 7.9 
Hz, 1H), 7.18-7.08 (m, 2H), 7.05-6.85 (m, 3H), 6.69 (dd, J = 7.8, JH-F = 2.9 
Hz, 1H), 3.84 (s, 2H), 3.21 (s, 3H), 3.00 (s, 3H). 
 
2-{2-[(2,6-Difluorophenyl)amino]phenyl}-N,N-dimethylacetamide (27) 
Orange crystals. Yield: 81.3%. 1H NMR (300 MHz, CDCl3) δ 7.13 (m, 2H), 




Purple crystals. Yield: 97.6%. 1H NMR (300 MHz, CDCl3) δ 7.56 (d, J = 8.0 
Hz, 2H), 7.16 (d, J = 7.4 Hz, 1H), 7.08 (t, J = 7.7 Hz, 1H), 6.92 (t, J = 7.2 Hz, 
1H), 6.84 (t, J = 8.0, 1H), 6.47 (d, J = 7.9 Hz, 1H), 3.85 (s, 2H), 3.20 (s, 3H), 
3.00 (s, 3H). 
 
2-Bromo-N-(2-chloro-6-fluorophenyl)-N-(4-methylphenyl)acetamide (49) 
Yellow residue. Yield: 74.5%. 1H NMR (300 MHz, CDCl3) δ 7.48 (d, J = 7.7 
Hz, 1H), 7.36 – 7.04 (m, 6H), 3.91 – 3.80 (m, 2H), 2.35 (d, J = 14.4 Hz, 3H). 
 
2-Bromo-N-(2,6-difluorophenyl)-N-(4-methylphenyl)acetamide (50) 
Red oil. Yield: 99.5%. 1H NMR (300 MHz, CDCl3) δ 7.41 (d, J = 7.8 Hz, 1H), 
7.28 – 7.18 (m, 3H), 6.93 (t, J = 8.1 Hz, 1H), 3.85 (d, J = 6.9 Hz, 2H), 2.35 (d, 
J = 13.5 Hz, 3H). 
 
2-Bromo-N-(2,6-dichlorophenyl)-N-(4-methylphenyl)acetamide (51) 
Synthesis carried out as stated in general method. Purification carried out by 
recrystallization from ethanol. White crystals. Yield: 73.9%. 1H NMR (300 
MHz, CDCl3) δ 7.67 – 7.08 (m, 7H), 4.00 (s, 1H), 3.80 (s, 1H), 2.34 (d, J = 







Synthesis carried out as stated in general method. Purification carried out by 
chromatography (eluting with EtOAc:hexane, 1:9 to 1:4). Pale orange crystals. 
Yield: 59.8%. 1H NMR (300 MHz, CDCl3) δ 7.72 – 7.69 (m, 3H), 7.28 – 7.04 
(m, 4H), 4.06 (s, 1H), 3.81 (s, 1H), 2.34 (d, J = 15.0 Hz, 3H). 
 
1-(2-Chloro-6-fluorophenyl)-5-methyl-1,3-dihydro-2H-indol-2-one (53) 
Pale yellow crystals. Yield: 37.3%. 1H NMR (300 MHz, CDCl3) δ 7.42 (ddd, J 
= 8.4 Hz, 6.1 Hz, JH-F = 14.7 Hz, 1H), 7.18-7.00 (m, 4H), 6.46 (d, J = 7.9 Hz, 
1H), 3.72 (s, 2H), 2.35 (s, 3H). 
 
1-(2,6-Difluorophenyl)-5-methyl-1,3-dihydro-2H-indol-2-one (54) 
Bright yellow crystals. Yield: 74.5%. 1H NMR (300 MHz, CDCl3) δ 7.48-7.34 
(m, 2H), 7.25-7.13 (m, 2H), 7.01 (d, J = 7.9 Hz, 1H), 6.37 (d, J = 8.0 Hz, 1H), 
3.74 (s, 2H), 2.35 (s, 3H). 
 
1-(2,6-Dichlorophenyl)-5-methyl-1,3-dihydro-2H-indol-2-one (55) 
Yellow crystals. Yield: 53.9%. 1H NMR (300 MHz, CDCl3) δ 7.50 (d, J = 8.0 
Hz, 2H), 7.38 (d, J = 7.5 Hz, 1H), 7.17 (s, 1H), 7.01 (d, J = 7.6 Hz, 1H), 6.30 
(d, J = 7.8 Hz, 1H), 3.74 (s, 2H), 2.35 (s, 3H). 
 
1-(2,6-Dibromophenyl)-5-methyl-1,3-dihydro-2H-indol-2-one (56) 
Synthesis carried out as stated in general method. Purification carried out by 
chromatography (eluting with DCM:hexane, 7:3 to 4:1). Light brown crystals. 
1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 8.1 Hz, 2H), 7.22 (t, J = 8.1 Hz, 
1H), 7.17 (s, 1H), 7.01 (d, J = 7.9 Hz, 1H), 6.29 (d, J = 8.0 Hz, 1H), 3.73 (s, 
2H), 2.35 (s, 3H). 
 
1-(2-Chloro-6-fluorophenyl)-5-ethyl-1H-indole-2,3-dione (57) 
Orange-red residue. Yield: 61.5%. 1H NMR (300 MHz, CDCl3) δ 7.58 (s, 1H), 
7.49-7.36 (m, 4H), 7.26-7.20 (m, 1H), 6.48 (d, J = 8.1 Hz, 1H), 2.66 (q, J = 






Orange-red residue. Yield: 60.7%. 1H NMR (300 MHz, CDCl3) δ 7.56 (s, 1H), 
7.47 (tt, J = 8.5, JH-F = 6.1 Hz, 1H), 7.40 (dd, J = 8.1 Hz, JH-F = 1.8 Hz, 1H), 
7.13 (dd, J = 7.7 Hz, JH-F = 8.0 Hz, 2H), 6.58 (d, J = 8.1 Hz, 1H), 2.66 (q, J = 
7.6 Hz, 2H), 1.24 (t, J = 7.6 Hz, 3H). 
 
1-(2,6-Dichlorophenyl)-5-ethyl-1H-indole-2,3-dione (59) 
Orange-red residue. Yield: 65.3%. 1H NMR (300 MHz, CDCl3) δ 7.61-7.50 
(m, 3H), 7.45-7.36 (m, 2H), 6.41 (d, J = 8.1 Hz, 1H), 2.66 (q, J = 7.6 Hz, 2H), 
1.25 (t, J = 7.6 Hz, 3H). 
 
1-(2,6-Dibromophenyl)-5-ethyl-1H-indole-2,3-dione (60) 
Orange-yellow residue. Yield: 63.0%. 1H NMR (400 MHz, CDCl3) δ 7.72 (d, 
J = 8.1 Hz, 2H), 7.58 (s, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.26 (t, J = 8.1 Hz, 




Orange-red residue. Yield: 67.1%. 1H NMR (400 MHz, CDCl3) δ 7.54 (s, 1H), 
7.48-7.40 (m, 2H), 7.36 (dd, J = 8.1, JH-F = 1.6 Hz, 1H), 7.23 (td, J = 8.6 Hz, 
JH-F = 1.6 Hz, 1H), 6.48 (d, J = 8.1 Hz, 1H), 2.59 (t, J = 7.6 Hz, 2H), 1.64 
(sext, J = 7.6 Hz, 2H), 0.95 (t, J = 7.3 Hz, 3H). 
 
1-(2,6-Difluorophenyl)-5-propyl-1H-indole-2,3-dione (62) 
Orange-red residue. Yield: 70.6%. 1H NMR (400 MHz, CDCl3) δ 7.54 (s, 1H), 
7.48 (tt, J = 8.6, JH-F = 6.1 Hz, 1H), 7.38 (dd, J = 8.1, JH-F = 1.8 Hz, 1H), 7.13 
(dd, J = 7.7 Hz, JH-F = 8.5 Hz, 2H), 6.57 (d, J = 8.1 Hz, 1H), 2.59 (t, J = 7.6 
Hz, 2H), 1.64 (sext, J = 7.7 Hz, 2H), 0.95 (t, J = 7.3 Hz, 3H). 
 
1-(2,6-Dichlorophenyl)-5-propyl-1H-indole-2,3-dione (63) 
Orange-red residue. Yield: 62.5%. 1H NMR (400 MHz, CDCl3) δ 7.54 (s, 1H), 
7.51 (d, J = 7.7 Hz, 2H), 7.41 (t, J = 7.4 Hz, 1H), 7.35 (dd, J = 8.1, 1.3 Hz, 
1H), 6.40 (d, J = 8.1 Hz, 1H), 2.58 (t, J = 7.6 Hz, 2H), 1.63 (sext, J = 7.5 Hz, 





Orange-red residue. Yield: 53.5%. 1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 
8.1 Hz, 2H), 7.55 (s, 1H), 7.35 (dd, J = 8.1, 1.8 Hz, 1H), 7.26 (t, J = 8.1 Hz, 
1H), 6.39 (d, J = 8.1 Hz, 1H), 2.59 (t, J = 7.6 Hz, 2H), 1.65 (sext, J = 7.6 Hz, 
2H), 0.95 (t, J = 7.3 Hz, 3H). 
 
1-(2-Dhloro-6-fluorophenyl)-5-(propan-2-yl)-1H-indole-2,3-dione (65) 
Orange-red residue. Yield: 83.2%. 1H NMR (400 MHz, CDCl3) δ 7.60 (s, 1H), 
7.46-7.39 (m, 3H), 7.22 (td, J = 8.5, JH-F = 1.5 Hz, 1H), 6.48 (d, J = 8.2 Hz, 
1H), 2.91 (sept, J = 6.9 Hz, 1H), 1.24 (d, J = 6.9 Hz, 6H). 
 
1-(2,6-Difluorophenyl)-5-(propan-2-yl)-1H-indole-2,3-dione (66) 
Orange-red residue. Yield: 93.0%. 1H NMR (400 MHz, CDCl3) δ 7.60 (s, 1H), 
7.51-7.45 (m, 1H), 7.43 (J = 8.2 Hz, JH-F = 1.9 Hz, 1H), 7.12 (dd, J = 7.5 Hz, 
JH-F = 8.8 Hz, 2H), 6.58 (d, J = 8.2 Hz, 1H), 2.91 (sept, J = 6.9 Hz, 1H), 1.24 
(dd, J = 6.9, 1.6 Hz, 6H). 
 
1-(2,6-Dichlorophenyl)-5-(propan-2-yl)-1H-indole-2,3-dione (67) 
Orange-red residue. Yield: 87.7%. 1H NMR (400 MHz, CDCl3) δ 7.62 (s, 1H), 
7.53 (d, J = 7.8 Hz, 2H), 7.42 (t, J = 7.6 Hz, 1H), 7.40 (d, J = 8.8 Hz, 1H), 
6.41 (d, J = 8.1 Hz, 1H), 2.92 (sept, J = 6.9 Hz, 1H), 1.26 (d, J = 6.9 Hz, 6H). 
 
1-(2,6-Dibromophenyl)-5-(propan-2-yl)-1H-indole-2,3-dione (68) 
Orange-red residue. Yield: 47.6%. 1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 
8.1 Hz, 2H), 7.62 (s, 1H), 7.40 (dd, J = 8.3, 1.7 Hz, 1H), 7.26 (t, J = 8.1 Hz, 




Orange-red residue. Yield: 41.4%. 1H NMR (400 MHz, CDCl3) δ 7.67 (s, 1H), 
7.49 (dd, J = 8.3, JH-F = 2.1 Hz, 1H), 7.38-7.29 (m, 2H), 7.12 (td, J = 8.2 Hz, 





Orange-red residue. Yield: 54.0%. 1H NMR (400 MHz, CDCl3) δ ppm 7.76 (s, 
1H), 7.61 (dd, J = 8.4, JH-F = 2.1 Hz, 1H), 7.47 (tt, J = 8.5, JH-F = 6.1 Hz, 1H), 
7.12 dd, J = 7.7 Hz, JH-F = 8.4 Hz, 2H), 6.60 (d, J = 8.4 Hz, 1H), 1.31 (s, 9H). 
 
5-tert-Butyl-1-(2,6-dichlorophenyl)-1H-indole-2,3-dione (71) 
Orange-red residue. Yield: 44.1%. 1H NMR (400 MHz, CDCl3) δ ppm 7.62 (s, 
1H), 7.43 (dd, J = 8.3, 2.1 Hz, 1H), 7.36 (d, J = 8.0 Hz, 2H), 7.26 (t, J = 8.1 
Hz, 1H), 6.28 (d, J = 8.3 Hz, 1H), 1.17 (s, 9H). 
 
5-tert-Butyl-1-(2,6-dibromophenyl)-1H-indole-2,3-dione (72) 
Orange-red residue. Yield: 29.4%. 1H NMR (400 MHz, CDCl3) δ ppm 7.79 (s, 
1H), 7.73 (d, J = 8.1 Hz, 2H), 7.58 (dd, J = 8.3, 2.1 Hz, 1H), 7.27 (t, J = 8.1 





Appendix 2-3: Purities of compounds 1 – 24 as determined by HPLC at 280 
nm (two gradients) 
 




Gradient A Gradient B 
Retention 
Time  (min) Area (%) 
Retention 
Time  (min) Area (%) 
1 7.527 100.0 9.616 98.5 
2 7.188 100.0 9.213 100.0 
3 7.895 100.0 10.030 100.0 
4 8.101 100.0 10.167 100.0 
5 8.013 97.1 8.298 97.1 
6 7.683 98.4 8.000 98.2 
7 8.410 98.5 8.631 97.4 
8 8.616 100.0 8.793 100.0 
9 6.901 100.0 8.655 100.0 
10 6.608 100.0 8.380 100.0 
11 7.270 100.0 8.941 100.0 
12 7.453 100.0 9.070 98.2 
13 7.382 100.0 8.969 98.3 
14 7.083 100.0 8.732 100.0 
15 7.757 100.0 9.223 98.8 
16 7.943 99.2 9.340 98.3 
17 7.234 100.0 8.867 100.0 
18 6.931 100.0 8.628 100.0 
19 7.568 100.0 9.117 100.0 
20 7.746 100.0 9.236 100.0 
21 7.468 100.0 9.043 100.0 
22 7.187 100.0 8.822 100.0 
23 7.858 100.0 9.274 100.0 




Appendix 3-1a: Partial ranking (Hasse diagram) of the twenty-four 
compounds in TAMH cells 
 
 
The numbers in the circles are the compound numbers. The numbers in the left 
margin are the levels that the compounds are assigned to according to partial 








Appendix 3-1b: Partial ranking (Hasse diagram) of the twenty-four 
compounds in HuH-7 cells 
 
 
The numbers in the circles are the compound numbers. The numbers in the left 
margin are the levels that the compounds are assigned to according to partial 





Appendix 3-2a: QSTR regression statistics for TAMH cells 
 
QSAR regression model obtained for the TAMH cell line was: 
−log(TAMH IC50) = 0.801  logP(o/w) − 0.568 
 








ANOVA for TAMH 
  df SS MS F 
Significance 
F 
Regression 1 8.01002055 8.01002055 1161.02214 1.56048E-20
Residual 22 0.15178044 0.00689911
Total 23 8.16180099       
  
Statistical significance of coefficients and intercepts of QSTR equation for 
TAMH 
  Coefficients Standard Error t Stat P-value 
Intercept 0.567965311 0.11820142 4.805063365 8.45554E-05 




Appendix 3-2b: QSTR regression statistics for HuH-7 
QSAR regression model obtained for the HUH-7 cell line was: 
-log(HUH-7 IC50) = 14.485  FASA_H − 8.913 
 








ANOVA for HuH-7 
  df SS MS F Significance F 
Regression 1 1.13544131 1.13544131 106.635733 6.70708E-10 
Residual 22 0.234252704 0.01064785
Total 23 1.369694015       
 
Statistical significance of coefficients and intercepts of QSTR equation for 
HuH-7 
  Coefficients Standard Error t Stat P-value 
Intercept -8.912674809 1.204923456 -7.396880494 2.11449E-07 





Appendix 4-1: Recipes for Western-Blot buffers and gels 
Cell lysis buffer 
Reagents Volume (mL) Final Concentration 
1M Hydroxyethyl 
piperazineethanesulfonic acid 
(HEPES), pH 7.5 
10 50 mM 
5M Sodium Chloride 6 150 mM 
0.5M Ethylenediaminetetraacetic 
acid (EDTA) 0.4 1 mM 
100% Glycerol 20 10% 
100% Triton-X 2 1% 
0.2M Sodium pyrophosphate 10 10 mM 
Deionized water 151.6 - 
 
Complete lysis buffer 
Reagents Volume (mL) 
Cell lysis buffer 950 
0.5 M Sodium fluoride 20 
100 mM Sodium orthovanadate 20 
100 mM Phenylmethylsulfonyl fluoride (PMSF) 10 
200 µg/mL Aprotinin 0.5 
 
6X Laemmli SDS protein sample buffer 
Reagents Amount 
4X Tris-Cl/SDS (pH 6.8) 7 mL 
Glycerol 3.8 g 
SDS 1 g 




Sodium chloride 40 g 
Potassium chloride 1 g 
Na2HPO4·7H2O 13.6 g 
KH2PO4 1.2 g 
Tween-20 2.5 mL 
Deionized water Make up to 1 L 
 
10X Wet transfer buffer, pH 8.3 
Reagents Amount 
Tris-base 60.6 g 
Glycine 288 g 




5X Running buffer 
Reagents Amount 
Tris-base 15.1 g 
Glycine 72 g 
10% SDS 50 mL 
Deionized water Make up to 1 L 
 
5% SDS-PAGE stacking gel 
Reagents Amount (mL) 
30% Acrylamide 0.335 
4X Tris-Cl/SDS, pH 6.8 0.625 
Deionized water 1.525 
10% (w/v) APS 0.02 
TEMED 0.004 
 
10% SDS-PAGE resolving gel 
Reagents Amount (mL) 
30% Acrylamide 3.30 
4X Tris-Cl/SDS, pH 6.8 2.50 
Deionized water 4.20 





Appendix 4-2: Docking poses of all twenty-four compounds in COX-1 and 
COX-2 
 
Orange = docked molecule; blue = existing ligand. 





























































Appendix 4-3: Log D(o/w) value calculated using online ACD/I-Lab 
prediction engine 





























Appendix 5-1: Precursor and product ions utilized for MRM analysis in 
determination of Phase I and Phase II metabolic stability. 
 
Compounds 1 to 12 
Compound Precursor ion, m/z (Q1) 




1 278.2 234.1 2.89 197.9 
2 262.1 218.0 2.77 197.9 
3 294.1 250.0 3.04 213.8 
4 383.8 339.9 3.12 257.8 
5 291.8 247.8 3.08 211.8 
6 276.2 231.8 2.95 211.9 
7 307.9 263.9 3.24 228.0 
8 397.8 353.9 3.31 274.1 
9 306.0 261.9 3.25 210.7 
10 290.0 246.0 3.12 225.9 
11 321.8 278.1 3.40 242.1 















Compounds 13 to 24 
Compound Precursor ion, m/z (Q1) 




13 320.1 275.9 3.43 210.9 
14 303.9 259.8 3.30 240.2 
15 335.9 291.9 3.58 227.1 
16 425.6 381.9 3.65 301.9 
17 320.1 275.9 3.38 223.9 
18 303.8 260.3 3.26 240.1 
19 335.9 291.9 3.53 256.2 
20 425.6 381.9 3.60 301.9 
21 334.0 290.0 3.48 237.8 
22 318.0 274.0 3.36 254.1 
23 350.0 306.1 3.62 270.0 










Appendix 5-2: List of masses used for SIM analysis. Selection was based on 
nominal mass and tailored for negative ESI mode. 
 
Compound Mass of AG (Da)  Compound
Mass of AG-Phe-Lys 
(Da) 
1 454  1 729 
2 438  2 713 
3 470  3 745 
4 558  4 833 
5 468  5 743 
6 452  6 727 
7 484  7 759 
8 572  8 847 
9 482  9 757 
10 466  10 741 
11 498  11 773 
12 586  12 861 
13 496  13 771 
14 480  14 755 
15 512  15 787 
16 600  16 875 
17 496  17 771 
18 480  18 755 
19 512  19 787 
20 600  20 875 
21 510  21 785 
22 494  22 769 
23 526  23 801 




Appendix 5-3: Representative mass spectrum and linear regression model for 
determination of Phase I and Phase II metabolic stability. 
 
MRM spectrum of compound 8 and indomethacin (internal standard) 
 
 
Linear regression model of relative ratio of peak area of compound 8 to 
internal standard against time. 
 
Calcualtion of t1/2 from linear regression model equations 
Log 50% 
1.7 
1 2 3 
t1/2 (as calculated from regression equation) 40.7 38.6 39.4 
Average t1/2 (min) 39.6 
Standard deviation 1.1 





































Appendix 5-4: Linear regression models for metabolite reactivity and 
metabolic stability relationships for Phase I and Phase II metabolism. 
 
GSH Depletion vs Phase I Metabolic Stability



















AG Reactivity vs Phase II Metabolic Stability




























Appendix 5-5: Linear regression models for toxicity and metabolic stability 
relationships for Phase I and Phase II metabolism 
 
TAMH LC50 vs Phase I Metabolic Stability



















TAMH LC50 vs Phase II Metabolic Stability






















Appendix 5-6: Linear regression models for toxicity and metabolite reactivity 
relationships for Phase I and Phase II metabolism 
 
TAMH LC50 vs GSH Depletion



















TAMH LC50 vs AG reactivity




















Appendix 6-1: Phase II reactive metabolite trapping - XIC traces of selected 
compounds 
 
 
 
 
 
 
 
1‐rAG1 XIC of –EMS Compound 1 
XIC of –EMS 
Compound 9 
XIC of –EMS 
Compound 13 
XIC of –EMS 
Compound 17 
XIC of –EMS 
Compound 21 
1‐rAG2
9‐rAG1
9‐rAG2
13‐rAG1
13‐rAG2
17‐rAG1
17‐rAG2
21‐rAG2
21‐rAG1
